{"title": "Isaac Y. Kim", "author": "Isaac Y Kim", "url": "https://www.yalemedicine.org/specialists/isaac-kim", "hostname": "yalemedicine.org", "description": "Isaac Yi Kim, MD, PhD, MBA, chair of the Department of Urology at Yale School of Medicine, specializes in the treatment and management of prostate cancer with the goal of helping patients navigate and better understand their disease. Although he cares for all men with localized disease, his clinical and research focus is in men with high-risk disease, recurrence after radiation, and metastatic prostate cancer to lymph nodes, bones, lungs, and abdominal organs.Dr. Kim is an expert in minimally invasive robotic surgery and has performed more than 2,100 robot-assisted radical prostatectomies, which are surgeries to remove the entire prostate gland. In addition, he has established a same-day radical prostatectomy program by using the latest-generation da Vinci robot to remove a diseased prostate through a single, one-inch incision in the abdomen. This results in less pain\u2014and pain medication\u2014for the patient, who usually goes home the same day of the surgery. He was inspired to become a prostate surgeon during his medical training, when he decided he wanted to help men he saw struggling with complications such as impotence and incontinence, which often develop after prostate cancer surgery. Those post-surgery problems are less common with expert robotic surgeons, he says. \"I see what an impact and a difference the surgical robot has made in helping our patients and allaying their fears.\" As a professor at Yale School of Medicine, Dr. Kim is also a surgeon-scientist who is studying the mechanism of prostate cancer treatment resistance. He is the principal investigator in clinical trials focused on advanced and metastatic prostate cancer, providing surgery in men with Stage IV prostate cancer. He says the traditional paradigm shows that when cancer cells have escaped the organ of origin, it's too late to help. But his early data is showing that removing the prostate may enhance the effectiveness of chemotherapy and hormonal therapies for men with late-stage disease. Dr. Kim says working at Yale Medicine is rewarding because of the rich history and tradition that values innovation and creativity, and he is focused on providing the latest treatments for men who have any stage of prostate cancer. \"Yale Urology is one of the larger departments in the nation and we attract patients from regions far beyond New Haven. We're really dedicated to delivering the most innovative care in the most compassionate manner,\" he says. \"When a patient and concerned family members come in with a prostate cancer diagnosis, and I'm able to take care of it and see how he recovers, it is truly a privilege and a blessing.\"", "sitename": "Yale Medicine", "date": "2023-08-28", "cleaned_text": "- Yale UrologyYale Physicians Building800 Howard Avenue, Ste 3rd FloorNew Haven, CT 06519 - Yale UrologyOrchard Medical Center330 Orchard 164New Haven, CT 06511 - Yale UrologyGreenwich Hospital55 Holly Hill Lane, Ste Suite 240Greenwich, CT 06830 Isaac Y. Kim, MD, PhD, MBA [Learn more about telehealth](/patient-tools/telehealth) Biography Isaac Yi Kim, MD, PhD, MBA, chair of the Department of Urology at Yale School of Medicine, specializes in the treatment and management of prostate cancer with the goal of helping patients navigate and better understand their disease. Although he cares for all men with localized disease, his clinical and research focus is in men with high-risk disease, recurrence after radiation, and metastatic prostate cancer to lymph nodes, bones, lungs, and abdominal organs. Dr. Kim is an expert in minimally invasive robotic surgery and has performed more than 2,100 robot-assisted radical prostatectomies, which are surgeries to remove the entire prostate gland. In addition, he has established a same-day radical prostatectomy program by using the latest-generation da Vinci robot to remove a diseased prostate through a single, one-inch incision in the abdomen. This results in less pain\u2014and pain medication\u2014for the patient, who usually goes home the same day of the surgery. He was inspired to become a prostate surgeon during his medical training, when he decided he wanted to help men he saw struggling with complications such as impotence and incontinence, which often develop after prostate cancer surgery. Those post-surgery problems are less common with expert robotic surgeons, he says. \"I see what an impact and a difference the surgical robot has made in helping our patients and allaying their fears.\" As a professor at Yale School of Medicine, Dr. Kim is also a surgeon-scientist who is studying the mechanism of prostate cancer treatment resistance. He is the principal investigator in clinical trials focused on advanced and metastatic prostate cancer, providing surgery in men with Stage IV prostate cancer. He says the traditional paradigm shows that when cancer cells have escaped the organ of origin, it's too late to help. But his early data is showing that removing the prostate may enhance the effectiveness of chemotherapy and hormonal therapies for men with late-stage disease. Dr. Kim says working at Yale Medicine is rewarding because of the rich history and tradition that values innovation and creativity, and he is focused on providing the latest treatments for men who have any stage of prostate cancer. \"Yale Urology is one of the larger departments in the nation and we attract patients from regions far beyond New Haven. We're really dedicated to delivering the most innovative care in the most compassionate manner,\" he says. \"When a patient and concerned family members come in with a prostate cancer diagnosis, and I'm able to take care of it and see how he recovers, it is truly a privilege and a blessing.\" Titles - Professor of Urology - Professor, Urology - Chair, Urology - Chief, Urology - Co-Leader, Cancer Signaling Networks, Yale Cancer Center Education & Training - MBAUniversity of Pennsylvania Wharton Business School, Finance (2017) - Research FellowshipNational Institutes of Health (2005) - Clinical FellowshipUniversity of California, Irvine (2005) - ResidentBaylor College of Medicine (2003) - MDNorthwestern University, Feinberg School of Medicine (1997) - PhDNorthwestern University Graduate School, Tumor Cell Biology (1996) Additional Information - AB of Urology, Urology (2007) [Extended versus standard pelvic lymph node dissection yields no difference in 3-year biochemical recurrence rates](https://doi.org/10.1016/j.prnil.2022.12.005)Nagaya N, Chua K, Sterling J, Horie S, Kim I. Extended versus standard pelvic lymph node dissection yields no difference in 3-year biochemical recurrence rates Prostate International 2023, 11: 107-112. [DOI: 10.1016/j.prnil.2022.12.005](https://doi.org/10.1016/j.prnil.2022.12.005). - Choksi A, Hayden C, Rahman S, Lokeshwar S, Kim I. The disparities in clinical trials addressing urologic conditions among lower-income countries Frontiers In Urology 2023, 2: 1069265. [DOI: 10.3389/fruro.2022.1069265](https://doi.org/10.3389/fruro.2022.1069265). - Kim J, Kaldany A, Lichtbroun B, Singer E, Jang T, Ghodoussipour S, Kim M, Kim I. Single-Port Robotic Radical Prostatectomy: Short-Term Outcomes and SURGICAL PATHOLOGY AND OVERALL SURVIVAL AMONG PATIENTS WITH LOW-RISK PROSTATE CANCER](https://doi.org/10.1097/ju.0000000000002518.07)Lee G, Lee E, Leopold Z, Kim S, Leapman M, Kim I. PD03-07 ASSOCIATION BETWEEN ADVERSE SURGICAL PATHOLOGY AND OVERALL SURVIVAL AMONG PATIENTS WITH LOW-RISK PROSTATE CANCER of nonseminomatous germ cell tumors in pediatric patients and young adults - A stage group stratified analysis](http://www.ncbi.nlm.nih.gov/pubmed/35144865)Srivastava A, Patel H, Koehne E, Gupta G, Drachtman R, Pierorazio P, Bagrodia A, Elsamra S, Kim I, Ghodoussipour S, Singer E, Jang T, Patel H, Barone J. Survival of nonseminomatous germ cell tumors in pediatric patients and young adults - A stage group stratified analysis Urologic Oncology Seminars Retroperitoneal Lymphadenectomy for Nonseminomatous Testicular Cancer](http://www.ncbi.nlm.nih.gov/pubmed/34978466)Patel H, Srivastava A, Kim Patel H, Pierorazio P, Bagrodia A, Masterson T, Ghodoussipour S, Kim I, Singer E, Jang T. Association of Lymph Node Count and Survival after Primary Retroperitoneal Lymphadenectomy spectrometry aided by multivariate statistical analysis to predict prostate cancer treatment outcome](http://www.ncbi.nlm.nih.gov/pubmed/35642979)Ma Y, Zheng Z, Xu S, Attygalle A, Kim I, Du H. Untargeted urine metabolite profiling by mass spectrometry aided by multivariate statistical analysis to predict prostate cancer outcome Analyst 2022, 147: 3043-3054. E, Demkowicz P, Park H, An Y, Kann B, Yu J, Sprenkle P, Kim I, Leapman M. Facility-Level Variation in Use of Locoregional Therapy Urology Buck M, Ghiraldi E, Demkowicz P, Park H, An Y, Kann B, Yu J, Sprenkle P, Kim I, Leapman M. Facility-Level Variation in Use of Locoregional Therapy of Stage I and II Testicular Nonseminomatous Germ Cell Tumors (nsgct)](https://doi.org/10.1016/j.jamcollsurg.2021.08.622)Patel H, Srivastava A, Shinder B, Kim I, Singer E, Ghodoussipour S, Jang T. Factors Associated with Accurate Staging of Stage I and II Testicular Nonseminomatous Germ Cell Tumors (nsgct) Journal Of The Of Surgeons 2021, 233: e230. [DOI: 10.1016/j.jamcollsurg.2021.08.622](https://doi.org/10.1016/j.jamcollsurg.2021.08.622). [Quantifying Publication Rates and Time Publication for American Urological Association Podium Presentations](https://doi.org/10.1016/j.jamcollsurg.2021.07.643)Chua K, Mikail M, Patel H, Tabakin A, Doppalapudi S, Ghodoussipour S, Kim I, Jang T, Srivastava A, Singer E. Quantifying Publication Rates and Time to Publication for American Urological Association Podium Presentations Journal Of The American College Of Surgeons 2021, 233: s310-s311. [DOI: 10.1016/j.jamcollsurg.2021.07.643](https://doi.org/10.1016/j.jamcollsurg.2021.07.643). [Factors Associated with Palliative Care Utilization in Advanced and Metastatic Renal Cell Carcinoma (RCC)](https://doi.org/10.1016/j.jamcollsurg.2021.08.623)Patel H, Sterling J, Srivastava A, Saraiya B, Mayer T, Kim I, Ghodoussipour S, Jang T, Singer E. Factors Associated with Palliative Care (PC) Utilization in Advanced and Metastatic Renal Cell Carcinoma (RCC) Journal Of The American College Of Surgeons 2021, 233: e230-e231. [DOI: 10.1016/j.jamcollsurg.2021.08.623](https://doi.org/10.1016/j.jamcollsurg.2021.08.623). [Marginal improvement in survival among diagnosed with metastatic prostate cancer in the secondline antiandrogen therapy era](http://www.ncbi.nlm.nih.gov/pubmed/34713977)Kim I, Jang T, Kim S, Lee D, Kim D, Singer E, Ghodoussipour S, Stein M, Aron M, Dall'Era M, Kim I. Marginal improvement in survival among patients diagnosed with metastatic prostate cancer in the secondline antiandrogen to Publication for American Urological Association Podium Presentations](http://www.ncbi.nlm.nih.gov/pubmed/34694164)Chua K, Mikhail M, Patel H, Tabakin A, Doppalapudi S, Ghodoussipour S, Kim I, Jang T, Srivastava A, Singer E. Quantifying Publication Rates and Time to Publication for American Urological Association Podium in advanced and metastatic renal cell carcinoma.](https://doi.org/10.1200/jco.2020.39.28_suppl.146)Patel H, Sterling J, Srivastava A, Kim S, Saraiya B, Mayer T, Kim I, Ghodoussipour S, Jang T, Singer E. Factors associated with palliative care utilization in advanced and metastatic renal cell carcinoma. Of Clinical Oncology 2021, 39: 146-146. [DOI: 10.1200/jco.2020.39.28_suppl.146](https://doi.org/10.1200/jco.2020.39.28_suppl.146). [Abrogation of survival disparity and uninsured individuals after the USPSTF's 2012 prostate-specific antigen-based prostate cancer screening recommendation.](https://doi.org/10.1200/jco.2020.39.28_suppl.77)Kim I, Kim D, Kim S, Singer E, Jang T, Ghodoussipour S, Aron M, Kim I. Abrogation of survival disparity between insured and uninsured individuals after the USPSTF's 2012 prostate-specific antigen-based prostate cancer screening Oncology 2021, 39: 77-77. [DOI: 10.1200/jco.2020.39.28_suppl.77](https://doi.org/10.1200/jco.2020.39.28_suppl.77). Prostatectomy: An International, Multi-Surgeon Series](http://www.ncbi.nlm.nih.gov/pubmed/34181471)Kowalczyk K, Madi R, Eden C, Sooriakumaran P, Fransis Raskin Y, Joniau S, Johnson S, Jacobsohn K, Galfano A, Bocciardi A, Hwang J, Kim I, Hu J. Comparative Outcomes of Salvage Retzius-Sparing versus Standard Robotic Prostatectomy: An B, Jeong P, Byun Y, Kang H, Seo S, Kim W, Lee J, Ha Y, Lee Y, Kim I, Choi Y, Cha E, Moon S, Yun S, Kim W. Collagen type VI-1 and 2 repress the proliferation, migration and invasion of bladder cancer cells International Journal Of Oncology 2021, 59: 37. [PMID: 33982770](https://pubmed.ncbi.nlm.nih.gov/33982770), [DOI: 10.3892/ijo.2021.5217](https://doi.org/10.3892/ijo.2021.5217). in circulating tumor cells from castrationresistant prostate cancer](http://www.ncbi.nlm.nih.gov/pubmed/33977248)Nagaya N, Lee G, Lu Y, Ashizawa T, Nagata M, Kim I, Horie S. Transcription factor 4 expression in circulating tumor cells from castrationresistant prostate cancer IJU H, Kim W, Vaz R, Cruciani G, Kim I. Effects of MTX-23, a Novel PROTAC of Androgen Receptor Splice Receptor, carcinoma: Oncologic implications in the COVID-19 era and beyond.](https://doi.org/10.1200/jco.2021.39.6_suppl.283)Srivastava A, Patel H, Kim S, Shinder B, Sterling J, Tabakin A, Polotti C, Saraiya B, Mayer T, Kim I, Ghodoussipour S, Patel H, Jang T, Singer E. Delaying surgery for clinical T1b-T2bN0M0 renal cell carcinoma: Oncologic implications in the COVID-19 era and beyond. Journal Of Clinical Oncology 2021, 39: 283-283. [DOI: 10.1200/jco.2021.39.6_suppl.283](https://doi.org/10.1200/jco.2021.39.6_suppl.283). - Leopold Z, Dave Menon A, Patel H, Srivastava A, Kim I, Jang T, Singer E. Trends in the use of administrative databases in urologic oncology: 2000 - 2021, 39: 356-356. [DOI: 10.1200/jco.2021.39.6_suppl.356](https://doi.org/10.1200/jco.2021.39.6_suppl.356). - Mikhail Patel H, Tabakin A, Doppalapudi S, Ghodoussipour S, Kim I, Jang T, Srivastava A, Singer E. Quantifying publication rates and time to publication for urologic oncology podium presentations. [DOI: 10.1200/jco.2021.39.6_suppl.357](https://doi.org/10.1200/jco.2021.39.6_suppl.357). [Relationship communication and the course of psychological outcomes among couples coping with localised prostate cancer](http://www.ncbi.nlm.nih.gov/pubmed/33586282)Manne S, Kashy D, MyersVirtue S, Zaider T, Kissane D, Heckman C, Kim I, Penedo F, Lee D. Relationship communication and the course of psychological outcomes among couples coping with localised prostate cancer European Journal Of Menon A, Patel H, Srivastava A, Kim I, Jang T, Singer E. Trends in the use of administrative databases in urologic oncology: and Metabolites in Men after Supplementation with a -Tocopherol-Rich Vitamin E Mixture](http://www.ncbi.nlm.nih.gov/pubmed/33319628)Goodin S, Kim I, Lee M, Shih W, Orlick M, Zheng X, Yang C. Plasma, Prostate and Urine Levels of Tocopherols and Metabolites in Men after Supplementation with a -Tocopherol-Rich Vitamin E Mixture Nutrition J, Lee G, Kim I. RNA-seq profile of African American men with a clinically localized prostate cancer Prostate International radiotherapy is equivalent to early radiotherapy in high-risk prostate cancer after radical prostatectomy: A SEER-Medicare analysis on trends, survival outcomes, and complications](http://www.ncbi.nlm.nih.gov/pubmed/34386450)Kwon Y, Wang W, Srivastava A, Jang T, Singer E, Parikh R, Kim W, Kim I. Observation with or without late radiotherapy is equivalent to early radiotherapy in high-risk prostate cancer after radical prostatectomy: A SEER-Medicare analysis on trends, survival outcomes, and complications Kim I. CXC Chemokine/Receptor Axis Profile and Metastasis in Prostate Cancer Frontiers Raman scattering of patient urine and multivariate statistical analysis](http://www.ncbi.nlm.nih.gov/pubmed/32909380)Ma Y, Chi J, Zheng Z, Attygalle A, Kim I, Du H. Therapeutic prognosis of prostate cancer using surfaceenhanced Raman scattering of patient urine and multivariate statistical [DOI: 10.1002/jbio.202000275](https://doi.org/10.1002/jbio.202000275). [Abrogation of disparity and White individuals after the USPSTFs 2012 prostatespecific antigen-based prostate cancer screening recommendation](http://www.ncbi.nlm.nih.gov/pubmed/32888321)Kim I, Jang T, Kim S, Modi P, Singer E, Elsamra S, Kim I. Abrogation of survival disparity between Black and White individuals after the USPSTFs 2012 prostatespecific antigen-based prostate cancer 32888321](https://pubmed.ncbi.nlm.nih.gov/32888321), [DOI: 10.1002/cncr.33179](https://doi.org/10.1002/cncr.33179). [Association of lymph node and survival after primary retroperitoneal lymph node dissection (RPLND) for testicular nonseminomatous germ cell tumor (NSGCT).](https://doi.org/10.1200/jco.2020.38.15_suppl.e17052)Patel H, Srivastava A, Kim S, Singer E, Kim I, Jang T. Association of lymph node count and survival after primary retroperitoneal lymph node dissection (RPLND) for testicular nonseminomatous germ cell 38: e17052-e17052. [DOI: 10.1200/jco.2020.38.15_suppl.e17052](https://doi.org/10.1200/jco.2020.38.15_suppl.e17052). and IIa/b testicular nonseminomatous germ cell tumors (NSGCT) and implications on survival.](https://doi.org/10.1200/jco.2020.38.15_suppl.e17058)Srivastava A, Patel H, Kim S, Kim I, Singer E, Jang T. Accuracy of clinical staging in stage I and IIa/b testicular nonseminomatous germ cell tumors (NSGCT) and implications on individual trials are hoping to answer](http://www.ncbi.nlm.nih.gov/pubmed/32176456)Ranasinghe W, Chapin B, Kim I, Sooriakumaran P, Lawrentschuk N. The cytoreductive prostatectomy in metastatic prostate cancer: what the individual trials are hoping to 2020, 125: 792-800. statins on mortality among patients with highrisk prostate cancer](http://www.ncbi.nlm.nih.gov/pubmed/32035002)Tan X, E J, Lin Y, Rebbeck T, Lu S, Shang M, Kelly W, D'Amico A, Stein M, Zhang L, Jang T, Kim I, Demissie K, Ferrari A, LuYao G. Individual and joint effects of metformin and statins on mortality among patients with highrisk prostate Urology 2020, 135: 122. [PMID: 31895674](https://pubmed.ncbi.nlm.nih.gov/31895674), [DOI: 10.1016/j.urology.2019.07.052](https://doi.org/10.1016/j.urology.2019.07.052). - Piao X, Jeong P, Yan C, Kim Y, Byun Y, Xu Y, Kang H, Seo S, Kim W, Lee J, Kim I, Moon S, Choi Y, Cha E, Yun S, Kim W. A novel tumor suppressing gene, ARHGAP9, is an independent prognostic biomarker for J, Kim W, Kwon Y, Palapattu G, Mehra R, Kim W, Kim I. TCF4 induces enzalutamide resistance via neuroendocrine differentiation in - Lee Kim J, Kwon S, Stein M, Hong J, Nagaya N, Billakanti S, Kim M, Kim W, Kim I. Dihydrotestosterone Increases Cytotoxic Activity of Macrophages on Prostate Cancer in Locally Advanced Clear-Cell Renal-Cell Carcinoma Is Associated With a Poor Outcome](http://www.ncbi.nlm.nih.gov/pubmed/31204211)Na J, Nagaya N, Rha K, Han W, Kim I. DNA Damage Response Pathway Alteration in Locally Advanced Clear-Cell Renal-Cell Carcinoma Is Associated With a Poor Outcome 2019, 17: 299-305.e1. [PMID: 31204211](https://pubmed.ncbi.nlm.nih.gov/31204211), [DOI: 10.1016/j.clgc.2019.05.004](https://doi.org/10.1016/j.clgc.2019.05.004). [Similar incidence of DNA damage response pathway alterations between clinically localized and metastatic prostate cancer](http://www.ncbi.nlm.nih.gov/pubmed/31060606)Kim I, Kim S, Srivastava A, Saraiya B, Mayer T, Kim W, Kim I. Similar incidence of DNA damage response pathway alterations between clinically localized and metastatic prostate cancer therapy in men who present with a metastatic prostate cancer from special issue senior guest editor.](http://www.ncbi.nlm.nih.gov/pubmed/31139700)Kim I. Commentary on local therapy in men who present with a metastatic prostate cancer from special issue senior guest editor. American Journal Of Clinical And Experimental Urology 2019, 7: 61-63. [PMID: 31139700](https://pubmed.ncbi.nlm.nih.gov/31139700), [PMCID: PMC6526358](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6526358). - Lee G, Srivastava Kwon Y, Kim I. Immune reaction by cytoreductive prostatectomy. American Journal Of Clinical for Non-Muscle-Invasive Bladder Cancer](http://www.ncbi.nlm.nih.gov/pubmed/31088707)Xu Y, Kim Y, Jeong P, Piao X, Byun Y, Seo S, Kang H, Kim W, Lee J, Ryu D, Choi J, Kim I, Moon S, Choi Y, Yun S, Kim W. Urinary Cell-Free DNA IQGAP3/BMP4 Ratio as a Prognostic Marker for OF PATHOLOGIC NODE POSITIVE RENAL CELL CARCINOMA ON SURVIVAL IN PATIENTS WITHOUT METASTASIS: EVIDENCE IN SUPPORT OF EXPANDING THE DEFINITION OF STAGE IV KIDNEY CANCER](https://doi.org/10.1097/01.ju.0000555316.15591.47)Srivastava* A, Rivera-Nunez Z, Kim S, Sterling J, Farber N, Radadia K, Modi P, Goyal S, Parikh R, Mayer T, Saraiya B, Weiss R, Kim I, Elsamra S, Jang T, Singer E. MP14-20 IMPACT OF PATHOLOGIC NODE POSITIVE RENAL CELL CARCINOMA ON SURVIVAL IN PATIENTS WITHOUT METASTASIS: EVIDENCE IN SUPPORT OF EXPANDING THE DEFINITION OF STAGE IV KIDNEY CANCER Investigative Urology 2019, 201 [DOI: 10.1097/01.ju.0000555316.15591.47](https://doi.org/10.1097/01.ju.0000555316.15591.47). [MP60-20 LONG-TERM ONCOLOGIC OUTCOMES IN PATIENTS WITH METASTASIS TO THE PROSTATIC ANTERIOR FAT PAD LYMPH NODE](https://doi.org/10.1097/01.ju.0000556802.43534.0b)Chandra* A, Assassi N, Kwon Y, Farber N, Kim I. MP60-20 LONG-TERM ONCOLOGIC OUTCOMES IN PATIENTS WITH METASTASIS TO THE PROSTATIC ANTERIOR FAT PAD LYMPH NODE Investigative Urology 2019, 201 [DOI: 10.1097/01.ju.0000556802.43534.0b](https://doi.org/10.1097/01.ju.0000556802.43534.0b). [Reply to Effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer: Do we have certainties today?](http://www.ncbi.nlm.nih.gov/pubmed/30861093)Jang T, Kim I, Scardino P, Eastham J. Reply to Effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer: Do we have for prostate cancer and their spouses: A randomized clinical trial](http://www.ncbi.nlm.nih.gov/pubmed/30852854)Manne S, Kashy D, Zaider T, Kissane D, Lee D, Kim I, Heckman C, Penedo F, Murphy E, Virtue S. Couplefocused interventions for men with localized prostate cancer and their spouses: A randomized clinical trial British Journal Of Shinder B, Rivera-Nunez Z, Sterling J, Farber N, Radadia K, Kim I, Singer E, Jang T. Survival rates after retroperitoneal lymph node dissection (RPLND) for testicular [DOI: 10.1200/jco.2019.37.7_suppl.534](https://doi.org/10.1200/jco.2019.37.7_suppl.534). [Treatment disparities among patients in the National Cancer Database (NCDB) with clinical TIa and TIb renal masses.](https://doi.org/10.1200/jco.2019.37.7_suppl.648)Sterling J, Rivera-Nunez Z, Farber N, Modi P, Radadia K, Kim S, Sharad G, Rahul P, Weiss R, Kim I, Elsamra S, Jang T, Singer E. Treatment disparities among patients in the National Cancer Database (NCDB) with clinical TIa and TIb renal masses. Journal Of Clinical Oncology 2019, 37: 648-648. [DOI: 10.1200/jco.2019.37.7_suppl.648](https://doi.org/10.1200/jco.2019.37.7_suppl.648). [Factors linked with receiving a lymph node dissection during surgery for nonmetastatic renal cell carcinoma.](https://doi.org/10.1200/jco.2019.37.7_suppl.672)Radadia K, Rivera-Nunez Z, Kim S, Farber N, Sterling J, Modi P, Sharad G, Rahul P, Weiss R, Kim I, Elsamra S, Jang T, Singer E. Factors linked with receiving a lymph node dissection during surgery for nonmetastatic renal cell carcinoma. Journal Of Clinical Oncology 2019, 37: 672-672. [DOI: 10.1200/jco.2019.37.7_suppl.672](https://doi.org/10.1200/jco.2019.37.7_suppl.672). - Faiena I, Kim Jang expression ratios in urinary cell-free DNA for discriminating bladder cancer from hematuria](http://www.ncbi.nlm.nih.gov/pubmed/30446454)Xu Y, Kim Y, Jeong P, Piao X, Byun Y, Kang H, Kim W, Lee J, Kim I, Moon S, Choi Y, Yun S, Kim W. Diagnostic value of combined IQGAP3/BMP4 and IQGAP3/FAM107A expression ratios in urinary cell-free DNA for discriminating bladder cancer from hematuria Urologic cytoreductive radical prostatectomy in men with newly diagnosed metastatic prostate cancer](http://www.ncbi.nlm.nih.gov/pubmed/31485434)Yuh B, Kwon Y, Shinder B, Singer E, Jang T, Kim S, Stein M, Mayer T, Ferrari A, Lee N, Parikh R, Ruel N, Kim W, Horie S, Byun S, Ahlering T, Kim I. Results of Phase 1 study on cytoreductive radical prostatectomy in men with newly diagnosed metastatic prostate radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer](http://www.ncbi.nlm.nih.gov/pubmed/30252932)Jang T, Patel N, Faiena I, Radadia K, Moore D, Elsamra S, Singer E, Stein M, Eastham J, Scardino P, Lin Y, Kim I, LuYao G. Comparative effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate Lee D, Kim I, Heckman C, Penedo F, Kissane D, Virtue S. Interpersonal Processes and Intimacy Among Men With Localized Prostate Cancer and Their Partners Journal Of Family Psychology 2018, Shupe A, Lee G, Stein M, Kim I, Singer E. Role of the androgen signaling axis in genitourinary to Androgen Deprivation Therapy: a Pilot Study.](http://www.ncbi.nlm.nih.gov/pubmed/30714046)Tabakin A, Sadimin E, Tereshchenko I, Kareddula A, Stein M, Mayer T, Hirshfield K, Kim I, Tischfield J, DiPaola R, Singer E. Correlation of Prostate Cancer CHD1 Status with Response to Androgen Deprivation Therapy: a Pilot Study. 2018, 2 [PMID: 30714046](https://pubmed.ncbi.nlm.nih.gov/30714046), [PMCID: PMC6358174](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358174). [Multi-institution analysis of racial disparity among African-American men eligible for prostate cancer active surveillance](http://www.ncbi.nlm.nih.gov/pubmed/29765545)Dinizo M, Shih W, Kwon Y, Eun D, Reese A, Giusto L, Trabulsi E, Yuh B, Ruel N, Marchalik D, Hwang J, Kundu S, Eggener S, Kim I. Multi-institution analysis of racial disparity among African-American men eligible for prostate cancer active WITH RECEIPT OF OPEN VS MINIMALLY INVASIVE RETROPERITONEAL LYMPH NODE DISSECTION (RPLND) FOR TESTIS CANCER: ANALYZING THE NATIONAL CANCER DATABASE (NCDB) FROM 2010-2014](https://doi.org/10.1016/j.juro.2018.02.2780)Tabakin A, Kim S, Polotti C, Rivera-N\u00fa\u00f1ez Z, Sterling J, Modi P, Farber N, Radadia K, Parikh R, Goyal S, Weiss R, Kim I, Elsamra S, Singer E, Jang T. MP84-12 OUTCOMES AND FACTORS ASSOCIATED WITH RECEIPT OF OPEN VS MINIMALLY INVASIVE RETROPERITONEAL LYMPH NODE DISSECTION (RPLND) FOR TESTIS CANCER: ANALYZING THE NATIONAL CANCER PROPENSITY SCORE-WEIGHTED ANALYSIS](https://doi.org/10.1016/j.juro.2018.02.1135)Farber Rivera-Nunez Kim S, Radadia K, Modi P, Goyal S, Parikh R, Weiss R, Kim I, Elsamra S, Jang T, Singer E. MP36-01 OUTCOMES OF LYMPHADENECTOMY FOR NON-METASTATIC RENAL CELL CARCINOMA: FOR CANCER PATIENTS: EVIDENCE OF ONE-MONTH QUALITY OF LIFE IMPROVEMENTS](https://doi.org/10.1016/j.juro.2018.02.1382)Diefenbach M, Hudson S, Marziliano A, Fleszar S, Tagai E, Bator A, Chen D, Cox B, Hall S, Kim I, Kim S, Kutikov A, Miyamoto C, Potters L, Reese A, Vira M, Torre G, DeCoster C, Bhat R, Hui S, Miller S. PD29-07 PROGRESS, A WEB-BASED RESOURCE FOR PROSTATE CANCER PATIENTS: EVIDENCE OF ONE-MONTH QUALITY OF LIFE IMPROVEMENTS Investigative 10.1016/j.juro.2018.02.1382](https://doi.org/10.1016/j.juro.2018.02.1382). Kamaljot K, Williams S, Osann K, Joseph J, Lee D, Lee D, Davis J, Abaza R, Kaouk J, Patel V, Kim I, Porter J, Hu J. MP82-08 UNINTENDED CONSEQUENCES OF DECREASED PSA-BASED PROSTATE CANCER SCREENING Investigative 2018, Kaler Williams S, Osann K, Joseph J, Lee D, Abaza R, Kaouk J, Patel V, Kim I, Porter J, Hu J. 269 Unintended consequences of decreased PSA-based prostate cancer screening European Urology Open Science 2018, 17: [DOI: effect of postdiagnostic metformin and statin use on prostate cancer mortality among patients with high-risk prostate cancer.](https://doi.org/10.1200/jco.2018.36.6_suppl.202)Lu-Yao G, E J, Lin Y, Rebbeck T, Lu S, Kelly W, D'Amico A, Stein M, Zhang L, Kim I, Demissie K, Ferrari A, Tan X. Individual and joint effect of postdiagnostic metformin and statin use on prostate cancer mortality among patients with high-risk prostate cancer. Journal Of Clinical Oncology 2018, 36: 202-202. [DOI: 10.1200/jco.2018.36.6_suppl.202](https://doi.org/10.1200/jco.2018.36.6_suppl.202). - Kim W, Kim Y, Jeong P, Seo S, Kang H, Kim Y, Yun S, Lee S, Moon S, Choi Y, Lee G, Kim I, Kim W. Urinary cell-free nucleic acid IQGAP3: a new non-invasive diagnostic Extracts on Bladder Cancer Compared to Cisplatin: A Common Mechanism of Action via Centromere Protein M](http://www.ncbi.nlm.nih.gov/pubmed/29595070)Kim W, Seo S, Byun Y, Kang H, Kim Y, Lee S, Jeong P, Song H, Choe S, Kim D, Kim S, Ha Y, Moon S, Lee G, Kim I, Yun S, Kim W. The Anticancer Effects of Garlic Extracts on Bladder Cancer Compared to Cisplatin: A Common Mechanism of Action via Centromere Protein M The American Journal Of Chinese Medicine 2018, 46: 689-705. [PMID: 29595070](https://pubmed.ncbi.nlm.nih.gov/29595070), [DOI: 10.1142/s0192415x18500362](https://doi.org/10.1142/s0192415x18500362). [Predicting clinically on pre-operative patient profile and serum biomarkers](http://www.ncbi.nlm.nih.gov/pubmed/29312648)Faiena I, Kim S, Farber N, Kwon Y, Shinder B, Patel N, Salmasi A, Jang T, Singer E, Kim W, Kim I. Predicting clinically significant prostate cancer based on pre-operative patient profile for men with low-risk prostate cancer](http://www.ncbi.nlm.nih.gov/pubmed/29177226)Parikh R, Patel A, Kim S, Kim I, Goyal S. Comparative effectiveness of laparoscopic versus open prostatectomy for men with low-risk prostate cancer International Journal Transitional Cell Carcinoma 2017, 4637-4640. [DOI: 10.1007/978-3-662-46875-3_5930](https://doi.org/10.1007/978-3-662-46875-3_5930). [Garlic extract in bladder cancer prevention: from T24 bladder cancer cell xenograft model, tissue microarray, and gene network analysis](http://www.ncbi.nlm.nih.gov/pubmed/28498422)Kim W, Seo S, Byun Y, Kang H, Kim Y, Lee S, Jeong P, Seo Y, Choe S, Kim D, Kim S, Moon S, Choi Y, Lee G, Kim I, Yun S, Kim W. Garlic extract in bladder cancer prevention: Evidence from T24 bladder cancer cell xenograft model, tissue microarray, and gene network analysis Genomic Data Guide the Postoperative Management of Prostate PROSTATECTOMY IN MEN NEWLY DIAGNOSED WITH METASTATIC PROSTATE CANCER](https://doi.org/10.1016/j.juro.2017.02.1087)Yuh B, Kwon Y, Shinder B, Kim S, Lee N, Ruel N, Horie S, Byun S, Lee D, Dipaola R, Kim I. PD24-10 INTERIM ANALYSIS OF NCT02458716: FEASIBILITY OF CYTOREDUCTIVE PROSTATECTOMY IN MEN NEWLY DIAGNOSED 2017, 197: LONGITUDINAL PAIN SCORES AS A PROGNOSTIC FACTOR OF OVERALL SURVIVAL IN MEN WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER](https://doi.org/10.1016/j.juro.2017.02.1779)Wang W, Kwon Y, Su L, Kim I, Lu S. MP57-05 LONGITUDINAL PAIN SCORES AS A PROGNOSTIC FACTOR OF OVERALL SURVIVAL IN MEN WITH METASTATIC CANCER Investigative Urology 2017, 197: e765. [DOI: 10.1016/j.juro.2017.02.1779](https://doi.org/10.1016/j.juro.2017.02.1779). - Lee G, Han C, Kwon Y, Patel R, Modi P, Kwon S, Faiena I, Patel N, Ahn H, Kim W, Singer E, Kim I. MP60-08 INTRACRINE ANDROGEN BIOSYNTHESIS e792-e793. [DOI: 10.1016/j.juro.2017.02.1845](https://doi.org/10.1016/j.juro.2017.02.1845). - Lee G, Han C, Kwon Y, Patel R, Modi P, Kwon S, Faiena I, Patel N, Singer E, Ahn H, Kim W, Kim I. Intracrine androgen biosynthesis in renal cell carcinoma prostate cancer after robot-assisted radical prostatectomy](http://www.ncbi.nlm.nih.gov/pubmed/28230003)Hong J, Kwon Y, Kim I. Risk stratification for disease progression in pT3 prostate cancer after robot-assisted in men newly diagnosed with metastatic prostate cancer.](https://doi.org/10.1200/jco.2017.35.6_suppl.e578)Yuh B, Kwon Y, Shinder B, Kim S, Lee N, Ruel N, Kim I. Interim analysis of NCT02458716: Feasibility of cytoreductive prostatectomy in men newly diagnosed with metastatic prostate Clinical Goyal S, Kim I. Local Therapy Improves Overall Survival in Patients With Newly Diagnosed Metastatic Prostate Cancer Survival and Tumor Growth in Prostate Cancer](http://www.ncbi.nlm.nih.gov/pubmed/27307599)Bansal N, Bartucci M, Yusuff S, Davis S, Flaherty K, Huselid E, Patrizii M, Jones D, Cao L, Sydorenko N, Moon Y, Zhong H, Medina D, Kerrigan J, Stein M, Kim I, Davis T, DiPaola R, Bertino J, Sabaawy H. BMI-1 Targeting Interferes with Patient-Derived Tumor-Initiating Cell Survival and Tumor Growth in Prostate Cancer Clinical Cancer Research 2016, 22: 6176-6191. [PMID: 27307599](https://pubmed.ncbi.nlm.nih.gov/27307599), [PMCID: PMC5159329](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5159329), Kim I. Pharmacodynamics, pharmacokinetics and clinical efficacy of phosphodiesterase-5 inhibitors Expert Opinion On Drug Metabolism & Toxicology 2016, 183-192. [PMID: 27690667](https://pubmed.ncbi.nlm.nih.gov/27690667), Kim I, Parikh R. Local Therapy Improves Overall Survival in Patients with Newly Diagnosed Metastatic Prostate Cancer International Journal Of Radiation Oncology Biology Physics 2016, 96: s183-s184. [DOI: 10.1016/j.ijrobp.2016.06.459](https://doi.org/10.1016/j.ijrobp.2016.06.459). [Corrigendum: Personalized Medicine Approaches in Prostate Cancer Employing Patient Derived 3D Organoids and Humanized Mice](http://www.ncbi.nlm.nih.gov/pubmed/27583246)Bartucci M, Ferrari A, Kim I, Ploss A, Yarmush M, Sabaawy H. Corrigendum: Personalized Medicine Approaches in Prostate Cancer Employing Patient Derived 3D Organoids and Humanized Mice Frontiers In Cell And Developmental Biology 4: 74. [PMID: 27583246](https://pubmed.ncbi.nlm.nih.gov/27583246), [PMCID: PMC4999522](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4999522), [DOI: 10.3389/fcell.2016.00074](https://doi.org/10.3389/fcell.2016.00074). [Personalized Medicine Approaches Patient Derived 3D Organoids and Humanized Mice](http://www.ncbi.nlm.nih.gov/pubmed/27446916)Bartucci M, Ferrari A, Kim I, Ploss A, Yarmush M, Sabaawy H. Personalized Medicine Approaches in Prostate Cancer Employing Patient Derived 3D Organoids and Humanized Mice Frontiers In Cell And Developmental Biology 2016, 4: 64. [PMID: 27446916](https://pubmed.ncbi.nlm.nih.gov/27446916), [PMCID: PMC4917534](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4917534), [DOI: 10.3389/fcell.2016.00064](https://doi.org/10.3389/fcell.2016.00064). - Davis R, Farber N, Tabakin A, Kim I, Elsamra S. Open versus robotic cystectomy: Comparison of outcomes Investigative the Neurovascular Bundle](http://www.ncbi.nlm.nih.gov/pubmed/27072291)Patel R, Modi P, Elsamra S, Kim I. Long-Term Outcomes of Using Hyaluronic Acid-Carboxymethylcellulose Adhesion Barrier Film on the for Extracapsular Extension of Prostate Cancer in Community Practice](http://www.ncbi.nlm.nih.gov/pubmed/27188968)Davis R, Salmasi A, Koprowski C, Kim S, Kwon Y, Faiena I, Patel N, Elsamra S, Kim I. Accuracy of Multiparametric Magnetic Resonance Imaging for Extracapsular Extension of Prostate Cancer in Community Practice Clinical Genitourinary Cancer 2016, 14: e617-e622. [PMID: 27188968](https://pubmed.ncbi.nlm.nih.gov/27188968), [DOI: 10.1016/j.clgc.2016.04.010](https://doi.org/10.1016/j.clgc.2016.04.010). - Kwon Y, Kang S, Wang W, Farber N, Radadia K, Lee P, Kim J, Hong J, Kim I. MP37-08 MISATTRIBUTION ERRORS IN UROLOGIC PROCEDURES FROM THE Urology 2016, e499-e500. [DOI: 10.1016/j.juro.2016.02.1685](https://doi.org/10.1016/j.juro.2016.02.1685). LONGITUDINAL RECOVERY PATTERNS AND THE UNDEREXPLORED BENEFIT OF LONG-TERM PHOSPHODIESTERASE INHIBITOR USE AFTER RADICAL PROSTATECTOMY](https://doi.org/10.1016/j.juro.2016.02.2800)Kwon Y, Farber N, Yu J, Han C, Lee P, Kim J, Kim W, Kim I. PD50-10 LONGITUDINAL RECOVERY PATTERNS OF PENILE LENGTH AND THE UNDEREXPLORED BENEFIT OF LONG-TERM PHOSPHODIESTERASE INHIBITOR FOLLOWING RADICAL PROSTATECTOMY MEN WITH PSA GREATER THAN 10 AND HISTOLOGICALLY FAVORABLE-RISK PROSTATE CANCER](https://doi.org/10.1016/j.juro.2016.02.2096)Kwon Y, Yu J, Kim S, Han C, Farber N, Kim J, Byun S, Kim W, Jeon S, Kim I. PD03-08 PATHOLOGICAL OUTCOME FOLLOWING RADICAL PROSTATECTOMY IN MEN WITH PSA GREATER THAN 10 AND HISTOLOGICALLY FAVORABLE-RISK PROSTATE CANCER Investigative Urology 2016, 195: e59. OUTCOMES OF MEN LOCALLY ADVANCED (LAPCA) OR REGIONALLY ADVANCED PROSTATE CANCER (RAPCA) FOLLOWING CONSERVATIVE MANAGEMENT (CM)](https://doi.org/10.1016/j.juro.2016.02.2300)Modi P, Faiena I, Patel N, Shen S, Singer E, Moore D, DiPaola R, Lu-Yao G, Kim I, Jang T. MP09-13 OUTCOMES OF MEN WITH LOCALLY ADVANCED (LAPCA) OR REGIONALLY ADVANCED PROSTATE CANCER (RAPCA) FOLLOWING CONSERVATIVE CELL CARCINOMA: A XENOGRAFT STUDY](https://doi.org/10.1016/j.juro.2016.02.2645)Han C, Lee G, Patel R, Modi P, Kwon S, Faiena I, Patel N, Singer E, Kim I. MP92-12 ANTI-ANDROGEN THERAPY SUPPRESSES TUMOR GROWTH IN ANDROGEN RECEPTOR-POSITIVE (Org) to recreate clonal heterogeneity of PC foci and measure therapeutic response potential.](https://doi.org/10.1200/jco.2016.34.2_suppl.252)Ferrari A, DiPaola R, Bertino J, Kim I, Stein M, Sabaawy H, Bartucci M. Patient stem cell (SC)-derived prostate cancer (PC) organoids (Org) to recreate clonal heterogeneity of PC foci and measure therapeutic response potential. Journal Of Clinical Oncology 2016, 34: 252-252. [DOI: 10.1200/jco.2016.34.2_suppl.252](https://doi.org/10.1200/jco.2016.34.2_suppl.252). - Modi P, 21-28. [DOI: 10.1016/b978-0-12-800077-9.00003-7](https://doi.org/10.1016/b978-0-12-800077-9.00003-7). [Chapter 52 Androgen Deprivation Therapy: Appropriate Patients, Timing to Initiate ADT, and Complications](https://doi.org/10.1016/b978-0-12-800077-9.00052-9)Salmasi A, Patel N, Kim I. Chapter 52 Androgen Deprivation Therapy: Appropriate Patients, Timing to Initiate ADT, and Complications 2016, 481-489. [DOI: 10.1016/b978-0-12-800077-9.00052-9](https://doi.org/10.1016/b978-0-12-800077-9.00052-9). - Parihar J, Kim I. Chapter 57 for Castrate-Resistant Prostate Cancer 2016, 533-540. [DOI: 10.1016/b978-0-12-800077-9.00057-8](https://doi.org/10.1016/b978-0-12-800077-9.00057-8). [Pathological Outcome following Radical Prostatectomy in Men with Prostate Specific Antigen Greater than 10 ng/ml and Histologically Favorable Risk Prostate Cancer](http://www.ncbi.nlm.nih.gov/pubmed/26608903)Yu J, Kwon Y, Kim S, Han C, Farber N, Kim J, Byun S, Kim W, Jeon S, Kim I. Pathological Outcome following Radical Prostatectomy in Men with Prostate Specific Antigen Greater than 10 ng/ml and Histologically Favorable Risk Prostate different biological subtypes and responsiveness to therapy](https://doi.org/10.1158/1535-7163.targ-15-c36)Sabaawy H, Bartucci M, Stein M, Kim I, Bertino J, DiPaola R, Ferrari A. Abstract C36: Patient-derived organoids from high-risk prostate cancer identify different biological subtypes and responsiveness to therapy Molecular Cancer Therapeutics 2015, 14: c36-c36. [DOI: 10.1158/1535-7163.targ-15-c36](https://doi.org/10.1158/1535-7163.targ-15-c36). [Refining the American Urological Association and American Society for Radiation Oncology guideline for adjuvant radiotherapy after radical prostatectomy using the pathologic Gleason score](http://www.ncbi.nlm.nih.gov/pubmed/26620454)Song W, Kwon Y, Jeon S, Kim I. Refining the American Urological Association and American Society for Radiation Oncology guideline for adjuvant radiotherapy after radical prostatectomy using the pathologic Gleason Foran D, Ren J, Zhong H, Kim I, Qi X. Exploring automatic prostate histopathology image gleason grading via local structure modeling Annual International Conference Of The IEEE Engineering In Medicine And Biology Han C, Yu J, Kim S, Modi P, Davis R, Park J, Lee P, Ha Y, Kim W, Kim I. Neutrophil and Lymphocyte Counts as Clinical Markers for Stratifying Low-Risk mini-prostates from primary patient-derived tissues](https://doi.org/10.1158/1538-7445.am2015-223)Bartucci M, Patrizii M, Huselid E, Yussuf S, Bansal N, Flaherty K, Tolkunov D, Zhong H, Stein M, Bertino J, DiPaola R, Kim I, Sabaawy H. Abstract 223: Generation of single cell-derived normal, benign and cancer mini-prostates from primary patient-derived mm Hg: A Study of 751 Patients](http://www.ncbi.nlm.nih.gov/pubmed/25891967)Modi P, Kwon Y, Patel N, Dinizo M, Farber N, Zhao P, Salmasi A, Parihar J, Ginsberg S, Ha Y, Kim I. Safety of Robot-Assisted Radical Prostatectomy with Pneumoperitoneum of 20 mm Hg: A Study of Human Associated with Prostate Cancer Susceptibility and Aggressive Clinicopathological Characteristics](http://www.ncbi.nlm.nih.gov/pubmed/26130958)Kim E, Kim Y, Kang H, Yoon H, Kim W, Kim Y, Yun S, Moon S, Choi Y, Kim I, Lee S, Kim W. Lower Levels of Human MOB3B Are Associated with Prostate Cancer Susceptibility and Aggressive Clinicopathological Characteristics Journal Of Korean Medical With Open Radical Prostatectomy](http://www.ncbi.nlm.nih.gov/pubmed/26065923)Faiena I, Dombrovskiy V, Modi P, Patel N, Patel R, Salmasi A, Parihar J, Singer E, Kim I. Regional Cost Variations of Robot-Assisted Radical Prostatectomy Compared With Open Radical for treating metastatic castration-resistant prostate cancer](http://www.ncbi.nlm.nih.gov/pubmed/25936418)Han C, Patel R, Kim I. Pharmacokinetics, pharmacodynamics and clinical efficacy of abiraterone acetate for treating metastatic castration-resistant prostate cancer Expert Opinion On Drug Metabolism ASSOCIATED WITH PROGNOSIS IN LOCALIZED RENAL CELL CARCINOMA](https://doi.org/10.1016/j.juro.2015.02.1525)Modi P, Ha Y, Lee G, Ahn H, Kim W, Kim I. MP47-05 ANDROGEN RECEPTOR MRNA EXPRESSION IS ASSOCIATED WITH PROGNOSIS IN LOCALIZED RENAL CELL CARCINOMA Investigative Urology 2015, DURING ROBOT-ASSISTED RADICAL PROSTATECTOMY: LONG TERM OUTCOMES](https://doi.org/10.1016/j.juro.2015.02.697)Patel R, P, Kim I. PD18-12 USE OF HYALURONIC ACID-CARBOXYMETHYLCELLULOSE ADHESION BARRIER ON THE NEUROVASCULAR BUNDLE DURING ROBOT-ASSISTED [DOI: [MP53-04 SIGNIFICANT INTER-INSTITUTIONAL VARIATIONS IN RACIAL DISPARITIES AMONG AFRICAN-AMERICAN MEN ELIGIBLE FOR PROSTATE CANCER ACTIVE SURVEILLANCE](https://doi.org/10.1016/j.juro.2015.02.1698)Dinizo M, Shih W, Salmasi A, Faiena I, Modi P, Han M, Partin A, Eun D, Reese A, Llukani E, Giosto L, Wessel S, Trabulsi E, Lallas C, Yuh B, Wilson T, Marchalik D, Hwang J, Kundu S, Catalona W, Flum D, Eggener S, Negron E, Kim I. MP53-04 SIGNIFICANT INTER-INSTITUTIONAL VARIATIONS IN RACIAL DISPARITIES AMONG AFRICAN-AMERICAN MEN ELIGIBLE FOR PROSTATE CANCER ACTIVE SURVEILLANCE Investigative Urology 2015, 193: e636. [DOI: 10.1016/j.juro.2015.02.1698](https://doi.org/10.1016/j.juro.2015.02.1698). [PD36-06 EFFICACY OF ROLIPRAM LOADED NANOSPHERES IN LOCALIZED DELIVERY TO SITES OF NERVE INJURY FOR PREVENTION OF POST-PROSTATECTOMY ERECTILE DYSFUNCTION USING A RAT MODEL OF CAVERNOUS NERVE INJURY](https://doi.org/10.1016/j.juro.2015.02.2255)Patel N, Salmasi A, Dinizo M, Faiena I, Goyal R, Lee G, Hannan J, Bivalacqua T, Kohn J, Kim I. PD36-06 EFFICACY OF ROLIPRAM LOADED NANOSPHERES IN LOCALIZED DELIVERY TO SITES OF NERVE INJURY FOR PREVENTION OF POST-PROSTATECTOMY ERECTILE DYSFUNCTION USING A RAT MODEL OF CAVERNOUS NERVE INJURY Investigative Urology 2015, 193: e766-e767. [DOI: (RF-GM-CSF) OR RECOMBINANT FOWLPOX-TRICOM (RF-TRICOM) IN PATIENTS WITH BLADDER CARCINOMA PRIOR TO UNDERGOING CYSTECTOMY](https://doi.org/10.1016/j.juro.2015.02.2644)Weiss R, Stein M, Mayer T, Salmasi A, Kim I, DiPaola R, Lattime E. MP72-10 PHASE I STUDY OF INTRAVESICAL RECOMBINANT FOWLPOX-GM-CSF (RF-GM-CSF) OR RECOMBINANT FOWLPOX-TRICOM (RF-TRICOM) IN PATIENTS WITH BLADDER CARCINOMA PRIOR TO Investigative Urology 2015, 193: e924. [DOI: 10.1016/j.juro.2015.02.2644](https://doi.org/10.1016/j.juro.2015.02.2644). [Correspondence of physical activity and fruit/vegetable consumption among prostate cancer survivors and their spouses](http://www.ncbi.nlm.nih.gov/pubmed/25807856)Virtue S, Manne S, Kashy D, Heckman C, Zaider T, Kissane D, Kim I, Lee D, Olekson G. Correspondence of physical activity and fruit/vegetable consumption among prostate cancer survivors and their spouses European Journal Of Cancer Care mRNA in Human Renal Cell Carcinoma Cells is Associated with Poor Prognosis in Patients with Localized Renal Cell Carcinoma](http://www.ncbi.nlm.nih.gov/pubmed/25796113)Ha Y, Lee G, Modi P, Kwon Y, Ahn H, Kim W, Kim I. Increased Expression of Androgen Receptor mRNA in Human Renal Cell Carcinoma Cells is Associated with Poor Prognosis in Patients with Localized Renal Cell Carcinoma Investigative Urology 2015, 194: 1441-1448. [PMID: robot-assisted radical prostatectomy following active surveillance: a prospective study in a single center.](http://www.ncbi.nlm.nih.gov/pubmed/25664959)Ha Y, Yu J, Patel N, Hassanzadeh Salmasi A, Parihar J, Kwon T, Kim W, Kim I. Pathologic findings in patients who underwent robot-assisted radical prostatectomy following active surveillance: a prospective study in a single center. Minerva Nefrologica 2015, 67: 1-9. [PMID: in Koreans: A Retrospective Multicenter Study](http://www.ncbi.nlm.nih.gov/pubmed/25606565)Seo W, Kang P, Kim T, Moon K, Chung J, Lee D, Kim I, Min K, Chung J, Kim W, Kang D. Primary Androgen Deprivation Therapy for Prostate Cancer in Koreans: A Retrospective Multicenter Study The World Journal of S100A8 and S100A9 between Prostate Cancer and BPH](http://www.ncbi.nlm.nih.gov/pubmed/25348783)Yun S, Yan C, Jeong P, Kang H, Kim Y, Kim E, Lee O, Kim W, Moon S, Kim I, Choi Y, Kim W. Comparison of mRNA, Protein, and Urinary Nucleic Acid Levels of S100A8 and S100A9 between Prostate Cancer and BPH C, KIM I. Cytoreductive prostatectomy: Evidence in support of a new surgical paradigm (Review) International Journal Of is associated with poor prognosis in renal cell carcinoma](http://www.ncbi.nlm.nih.gov/pubmed/25227434)Ha Y, Lee G, Kim Y, Kwon S, Choi S, Kim T, Kwon T, Yun S, Kim I, Kim W. Decreased selenium-binding protein 1 mRNA expression is associated with poor prognosis in renal cell carcinoma World Journal Of Surgical Oncology 2014, 12: 288. [PMID: 25227434](https://pubmed.ncbi.nlm.nih.gov/25227434), [PMCID: 84: 372. [PMID: 24925832](https://pubmed.ncbi.nlm.nih.gov/24925832), [DOI: 10.1016/j.urology.2014.02.040](https://doi.org/10.1016/j.urology.2014.02.040). - Ha Y, Kim I. Enzalutamide: looking back at its preclinical discovery Expert Opinion On Drug Discovery 2014, 9: 837-845. on adjuvant radiotherapy after radical prostatectomy](http://www.ncbi.nlm.nih.gov/pubmed/24708639)Kang J, Ha Y, Kim S, Yu J, Patel N, Parihar J, Salmasi A, Kim W, Kim I. Concern for overtreatment using the AUA/ASTRO guideline on adjuvant radiotherapy ANTIGEN DENSITY ELIGIBILITY CRITERIA](https://doi.org/10.1016/j.juro.2014.02.2235)Ha Y, Patel N, Salmasi A, Singer E, Yu J, Kim J, Kim W, Kim I. MP69-16 ACTIVE SURVEILLANCE FOR PROSTATE CANCER: RETHINKING PROSTATE-SPECIFIC ANTIGEN PLUS RADIOTHERAPY FOR ADVANCED, NON-DISTANT METASTATIC PROSTATE CANCER](https://doi.org/10.1016/j.juro.2014.02.2428)Jang T, Patel N, Shen S, DiPaola R, Moore D, Kim I, Lu-Yao G. PD34-03 RADICAL PROSTATECTOMY WITH ADJUVANT RADIOTHERAPY VERSUS ANDROGEN DEPRIVATION THERAPY PLUS RADIOTHERAPY FOR ADVANCED, e896-e897. [MP78-17 FACTORS ASSOCIATED WITH INITIAL THERAPY FOR REGIONALLY ADVANCED PROSTATE CANCER IN THE UNITED STATES](https://doi.org/10.1016/j.juro.2014.02.2500)Jang T, Patel N, Shen S, Karellas M, DiPaola R, Moore D, Kim I, Lu-Yao G. MP78-17 FACTORS ASSOCIATED WITH INITIAL THERAPY FOR REGIONALLY ADVANCED PROSTATE CANCER IN THE UNITED STATES Investigative Urology 2014, 191: e927. [DOI: 10.1016/j.juro.2014.02.2500](https://doi.org/10.1016/j.juro.2014.02.2500). [MP43-11 DEVELOPMENT OF A NANOSPHERE BASED DELIVERY OF SILDENAFIL TO SITES OF NERVE INJURY FOR PREVENTION OF POST-PROSTATECTOMY ERECTILE DYSFUNCTION USING A RAT MODEL OF CAVERNOUS NERVE INJURY](https://doi.org/10.1016/j.juro.2014.02.1168)Patel N, Salmasi A, Dinizo M, Goyal R, Hannan J, Lee G, Kohn J, Bivalacqua T, Kim I. MP43-11 DEVELOPMENT OF A NANOSPHERE BASED DELIVERY OF SILDENAFIL TO SITES OF NERVE INJURY FOR PREVENTION OF POST-PROSTATECTOMY ERECTILE DYSFUNCTION USING A RAT MODEL OF CAVERNOUS NERVE INJURY Investigative Urology 2014, 191: e481. [DOI: 10.1016/j.juro.2014.02.1168](https://doi.org/10.1016/j.juro.2014.02.1168). - Salmasi A, Patel Lee Kim I. MP47-03 OFF-TARGET EFFECT OF SILDENAFIL following contemporary robot assisted radical prostatectomy technique](http://www.ncbi.nlm.nih.gov/pubmed/24693529)Parihar J, Ha Y, Kim I. Bladder neck contracture-incidence and management following contemporary robot assisted radical prostatectomy technique Prostate International [DOI: 10.12954/pi.13034](https://doi.org/10.12954/pi.13034). [Novel Combination Markers Survival in Patients with Muscle Invasive Bladder Cancer: USP18 and DGCR2](http://www.ncbi.nlm.nih.gov/pubmed/24616583)Kim Y, Kim W, Jeong P, Ha Y, Kang H, Yun S, Moon S, Choi Y, Kim I, Kim W. Novel Combination Markers for Predicting Survival in Patients with Muscle Invasive Bladder Cancer: USP18 and DGCR2 Journal Of of Progression in Patients with Non-Muscle-Invasive Urothelial Carcinoma, and Its Functional Role is Involved in the Aggressive Properties of Urothelial Carcinoma Cells](http://www.ncbi.nlm.nih.gov/pubmed/24562935)Lee G, Ha Y, Jung Y, Moon S, Kang H, Lee O, Joung J, Choi Y, Yun S, Kim W, Kim I. DHCR24 is an Independent Predictor of Progression in Patients with Non-Muscle-Invasive Urothelial Carcinoma, and Its Functional Role is Involved in the Aggressive Properties of Urothelial Carcinoma Cells Annals Of Surgical Oncology 2014, 21: 538-545. 24562935](https://pubmed.ncbi.nlm.nih.gov/24562935), [DOI: 10.1245/s10434-014-3560-6](https://doi.org/10.1245/s10434-014-3560-6). - Jin X, Yun S, Jeong P, Kim I, Kim W, Park S. Diagnosis of bladder cancer and prediction of survival by urinary deprivation via WNT5A-mediated BMP-6 induction](http://www.ncbi.nlm.nih.gov/pubmed/24518599)Lee G, Kang D, Ha Y, Jung Y, Chung J, Min K, Kim T, Moon K, Chung J, Lee D, Kim W, Kim I. Prostate cancer bone metastases acquire resistance to androgen deprivation via WNT5A-mediated BMP-6 in predicting the early response to induction BCG therapy in patients with non-muscle invasive bladder cancer](http://www.ncbi.nlm.nih.gov/pubmed/24411789)Kang H, Tchey D, Yan C, Kim W, Kim Y, Yun S, Lee S, Choi Y, Kim I, Kim W. The predictive value of polymorphisms in predicting the early response to induction BCG therapy in patients with non-muscle invasive bladder cancer Urologic Oncology Seminars 32: 458-465. [PMID: 24411789](https://pubmed.ncbi.nlm.nih.gov/24411789), [DOI: 10.1016/j.urolonc.2013.10.013](https://doi.org/10.1016/j.urolonc.2013.10.013). - Hong J, Kim Kim I. Transitional Cell Carcinoma 2014, 1-4. [DOI: 10.1007/978-3-642-27841-9_5930-2](https://doi.org/10.1007/978-3-642-27841-9_5930-2). - Han C, Parihar J, Kim I. Active surveillance in men with low-risk prostate cancer: current and future challenges. American Journal Of Clinical And Experimental Urology 2013, 1: 72-82. [PMID: 25374902](https://pubmed.ncbi.nlm.nih.gov/25374902), [PMCID: PMC4219278](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4219278). - Kang D, Chung J, Ha H, Min K, Yoon J, Kim W, Seo W, Kang P, Jung S, Kim I. Korean Prostate Cancer Patients Have Worse Disease Characteristics than their American Counterparts Asian Pacific Journal Of Cancer Prevention 2013, 14: 6913-6917. [PMID: 24377625](https://pubmed.ncbi.nlm.nih.gov/24377625), [DOI: 10.7314/apjcp.2013.14.11.6913](https://doi.org/10.7314/apjcp.2013.14.11.6913). [Diagnostic Role of in the Elderly Patients Who Experience Significant Co-Morbidity with a High Clinical Suspicion of Prostate Cancer](http://www.ncbi.nlm.nih.gov/pubmed/24339711)Kang H, Yang J, Kwon W, Lee Y, Kim W, Kim Y, Yun S, Lee S, Kim I, Kim W. Diagnostic Role of Prostate Resection in the Elderly Patients Who Experience Significant Co-Morbidity with a High Clinical Suspicion of Prostate Cancer Journal Of Korean Medical Science prostate cancer cells with tumor initiating properties in mouse and zebrafish xenografts by differential adhesion](http://www.ncbi.nlm.nih.gov/pubmed/24154958)Bansal N, Davis S, Tereshchenko I, BudakAlpdogan T, Zhong H, Stein M, Kim I, DiPaola R, Bertino J, Sabaawy H. Enrichment of human prostate cancer cells with tumor initiating properties in mouse and zebrafish xenografts by differential Outcome in Prostate Cancer Patients After Robot-Assisted Radical Prostatectomy](http://www.ncbi.nlm.nih.gov/pubmed/23987521)Woo S, Kang D, Ha Y, Salmasi A, Kim J, Lee D, Kim W, Kim I. Comprehensive Analysis of Sexual Function Outcome in Prostate Cancer Patients After Robot-Assisted Radical Prostatectomy and IL1](http://www.ncbi.nlm.nih.gov/pubmed/24185914)Kwon S, Lee G, Lee J, Iwakura Y, Kim W, Kim I. Mechanism of protumorigenic effect of BMP6: Neovascularization involving Sabaawy H. Therapeutic Role of Bmi-1 Inhibitors in Eliminating Prostate Tumor Stem Cells 2013 [DOI: 10.21236/ada598365](https://doi.org/10.21236/ada598365). [Decreased DBC1 Expression Is Associated With Poor Prognosis in Patients With Non-Muscle-Invasive Bladder Cancer](http://www.ncbi.nlm.nih.gov/pubmed/24044099)Shim U, Lee I, Kang H, Kim J, Kim W, Kim I, Ryu K, Choi Y, Moon S, Kim Y, Yun S, Lee S, Kim W. Decreased DBC1 Expression Is Associated With Poor Prognosis in Patients With Non-Muscle-Invasive Bladder Cancer Investigative And the Neurovascular Bundle and Prostatic Bed to Facilitate Earlier Recovery of Erectile Function After Robot-Assisted Prostatectomy: An Initial Experience](http://www.ncbi.nlm.nih.gov/pubmed/23879531)Joung J, Ha Y, Singer E, Ercolani M, Favaretto R, Lee D, Kim W, Lee K, Kim I. Use of a Hyaluronic Acid-Carboxymethylcellulose Adhesion Barrier on the Neurovascular Bundle and Prostatic Bed to Facilitate Earlier Recovery of Erectile Function After Robot-Assisted Prostatectomy: An Initial robot-assisted radical prostatectomy based on the expanded prostate cancer index composite survey](http://www.ncbi.nlm.nih.gov/pubmed/23917307)Kim J, Ha Y, Jeong S, Kim S, Kim W, Jang T, Kim I. Factors related to patient-perceived satisfaction after robot-assisted radical prostatectomy based on the expanded prostate cancer index composite survey Prostate Cancer And Prostatic 23876585](https://pubmed.ncbi.nlm.nih.gov/23876585), [DOI: 10.1016/j.urology.2013.03.082](https://doi.org/10.1016/j.urology.2013.03.082). [Bone morphogenetic protein6 induces castration resistance in prostate cancer cells through tumor infiltrating macrophages](http://www.ncbi.nlm.nih.gov/pubmed/23710822)Lee G, Jung Y, Ha Y, Kim J, Kim W, Kim I. Bone morphogenetic protein6 induces castration resistance in prostate cancer cells through tumor infiltrating macrophages Cancer Tumor Proliferation through IL-10-Dependent M2 Polarization of Tumor-Associated Macrophages](http://www.ncbi.nlm.nih.gov/pubmed/23633487)Lee J, Lee G, Woo S, Ha Y, Kwon S, Kim W, Kim I. BMP-6 in Renal Cell Carcinoma Promotes Tumor Proliferation through IL-10-Dependent M2 Polarization of Tumor-Associated Primary Radical Prostatectomy Compared with Radiation Therapy in Prostate Cancer Patients: Results of a Population-based, Propensity Score-Matched Analysis](http://www.ncbi.nlm.nih.gov/pubmed/23759328)Shao Y, Kim S, Moore D, Shih W, Lin Y, Stein M, Kim I, Lu-Yao G. Cancer-specific Survival After Metastasis Following Primary Radical Prostatectomy Compared with Radiation Therapy in Prostate Cancer Patients: Results of a Population-based, Propensity Androgen Receptor Expression in Prostate Cancer](http://www.ncbi.nlm.nih.gov/pubmed/23658864)Jung S, Oh S, Lee G, Chung J, Min K, Yoon J, Kim W, Ryu D, Kim I, Kang D. Clinical Significance of Wnt/-Catenin Signalling and Androgen Receptor Expression in Prostate Cancer The World Journal Of Sadimin E, Ha Y, Kim J, Skarecky D, Cha D, Wambi C, Ou Y, Yuh B, Park S, Llukani E, Albala D, Wilson T, Ahlering T, Badani K, Ahn H, Lee D, May M, Kim W, Lee D. 967 METASTASIS TO THE PROSTATIC ANTERIOR FAT PAD LYMPH NODES: STUDY Investigative Urology 2013, 189: [1865 S100A9 AND EGFR GENE SIGNATURES PREDICT DISEASE PROGRESSION IN BLADDER CANCER PATIENTS AFTER CHEMOTHERAPY](https://doi.org/10.1016/j.juro.2013.02.2284)Kim W, Yun S, Kim Y, Kim T, Seo J, Cho I, Ha Y, Kim I, Lee S, Kim W. 1865 S100A9 AND EGFR GENE SIGNATURES PREDICT DISEASE PROGRESSION IN BLADDER CANCER PATIENTS AFTER CHEMOTHERAPY Investigative Urology 2013, 189: e764-e765. [DOI: 10.1016/j.juro.2013.02.2284](https://doi.org/10.1016/j.juro.2013.02.2284). [226 INCREASED INCIDENCE OF PATHOLOGICALLY NON-ORGAN CONFINED PROSTATE CANCER IN AFRICAN-AMERICAN MEN ELIGIBLE FOR ACTIVE SURVEILLANCE](https://doi.org/10.1016/j.juro.2013.02.1606)Ha Y, Salmasi A, Kim J, Joung J, Lee D, Kim W, Kim I. 226 INCREASED INCIDENCE OF PATHOLOGICALLY NON-ORGAN CONFINED PROSTATE CANCER IN AFRICAN-AMERICAN MEN ELIGIBLE FOR ACTIVE SURVEILLANCE Investigative Urology 2013, 189: e93. [DOI: 10.1016/j.juro.2013.02.1606](https://doi.org/10.1016/j.juro.2013.02.1606). - Kim W, Kang H, Kim W, Lee S, Yun S, Kim Y, Kim T, Seo J, Cho I, Ha Y, Kim I. 2102 NATURAL HISTORY OF ASYMPTOMATIC RENAL STONES AND PREDICTION OF bladder cancer: Arraybased DNA methylation and expression profiling](http://www.ncbi.nlm.nih.gov/pubmed/23436614)Kim Y, Yoon H, Kim J, Kang H, Min B, Kim S, Ha Y, Kim I, Ryu K, Lee S, Kim W. HOXA9, ISL1 and ALDH1A3 methylation patterns as invasive bladder cancer: Arraybased DNA methylation and expression profiling 133: [PMID: 23436614](https://pubmed.ncbi.nlm.nih.gov/23436614), [DOI: 10.1002/ijc.28121](https://doi.org/10.1002/ijc.28121). Prostate Cancer in African-American Men Eligible for Active Surveillance](http://www.ncbi.nlm.nih.gov/pubmed/23465143)Ha Y, Salmasi A, Karellas M, Singer E, Kim J, Han M, Partin A, Kim W, Lee D, Kim I. Increased Incidence of Pathologically Nonorgan Confined Prostate Cancer in African-American Men Eligible for Prostatic Anterior Fat Pad Lymph Nodes: A Multi-Institutional Study](http://www.ncbi.nlm.nih.gov/pubmed/23485503)Kim I, Modi P, Sadimin E, Ha Y, Kim J, Skarecky D, Cha D, Wambi C, Ou Y, Yuh B, Park S, Llukani E, Albala D, Wilson T, Ahlering T, Badani K, Ahn H, Lee D, May M, Kim W, Lee D. Detailed Analysis of Patients with Metastasis to the Prostatic Anterior Fat Pad Lymph Nodes: Urinary Tract Symptoms and Predictive Factors for Symptom Changes: A Longitudinal Study](http://www.ncbi.nlm.nih.gov/pubmed/23434100)Kim J, Ha Y, Jeong S, Lee D, Kim W, Kim I. Impact of Robot-assisted Radical Prostatectomy on Lower Urinary Tract Symptoms and Predictive Factors for Symptom Changes: A Low-Volume Gleason Score 3+4 Prostate Cancers at Biopsy: Finding a New Group Eligible for Active Surveillance](http://www.ncbi.nlm.nih.gov/pubmed/23391718)Park H, Ha Y, Park S, Kim Y, Lee T, Kim J, Lee D, Kim W, Kim I. Incidence of Upgrading and Upstaging in Patients with Low-Volume Gleason Score 3+4 Prostate Cancers at Biopsy: Finding a New Group Eligible for Active I. Radium Ra 223 dichloride in castration-resistant prostate cancer. 2013, [DOI: 10.1358/dot.2013.49.8.1968670](https://doi.org/10.1358/dot.2013.49.8.1968670). R, Kim I. Enzalutamide for the treatment of castration-resistant prostate cancer. Drugs Of Today 2013, 49: 7-13. [PMID: 23362491](https://pubmed.ncbi.nlm.nih.gov/23362491), [DOI: 10.1358/dot.2013.49.1.1910724](https://doi.org/10.1358/dot.2013.49.1.1910724). - Ha Y, Chihara Y, Yoon H, Kim Y, Kim T, Woo S, Yun S, Kim I, Hirao Y, Kim W. Downregulation of Fumarate Hydratase Is Related to Tumorigenesis in S, JEONG P, KIM W, KIM T, LEE Y, SONG P, CHOI Y, KIM I, MOON S, KIM W. Cell-free microRNAs in urine as diagnostic and prognostic biomarkers of bladder cancer International associated with aggressive clinicopathological outcomes, whereas nuclear location of the protein is related to metastasis in prostate cancer](http://www.ncbi.nlm.nih.gov/pubmed/22890388)Yun S, Yoon H, Bae S, Lee O, Choi Y, Moon S, Kim I, Kim W. Transcriptional repression of RUNX2 is associated with aggressive clinicopathological outcomes, whereas nuclear location of the protein is related to metastasis in prostate cancer Prostate Cancer And patients with non-muscle-invasive bladder cancer: Potential role in the prediction of tumor progression](http://www.ncbi.nlm.nih.gov/pubmed/22884471)Jeong P, Min B, Ha Y, Song P, Kim I, Ryu K, Kim J, Yun S, Kim W. RUNX3 methylation in normal surrounding urothelium of patients with non-muscle-invasive bladder cancer: Potential role in the prediction of tumor progression European Journal Of Surgical Oncology 2012, 38: 1095-1100. [PMID: 22884471](https://pubmed.ncbi.nlm.nih.gov/22884471), [DOI: 10.1016/j.ejso.2012.07.116](https://doi.org/10.1016/j.ejso.2012.07.116). - Lee J, Lee G, Kwon S, Jeong J, Ha Y, Kim W, Kim I. CREBZF, a novel Smad8-binding protein Molecular [DOI: 10.1007/s11010-012-1353-4](https://doi.org/10.1007/s11010-012-1353-4). - Salmasi A, Han M, Kim I. Risk of more advanced cancer at surgery in African American men eligible for active surveillance. Journal Of Clinical Oncology 2012, Closure of Only the Midline 12-mm Port Site](http://www.ncbi.nlm.nih.gov/pubmed/22283233)Kang D, Woo S, Lee D, Kim I. Incidence of Port-Site Hernias After Robot-Assisted Radical Prostatectomy with the Fascial Closure of Only the Midline 12-mm (WHO G1 AND G2) BLADDER CANCER](https://doi.org/10.1016/j.juro.2012.02.460)HA Y, KIM Y, KIM J, Lee S, KIM I, Kim W, Seo J, Kim W, Chae Y, Yun S. 396 TUMORIGENIC AND PROGNOSTIC SIGNIFICANCE OF RASSF1A EXPRESSION IN NON-MUSCLE-INVASIVE LOW-GRADE NORMAL ADJACENT UROTHELIUM OF NON-MUSCLE INVASIVE BLADDER CANCER IN THE PATIENTS UNDERWENT TRANSURETHRAL RESECTION](https://doi.org/10.1016/j.juro.2012.02.634)Kim J, Kim W, Ha Y, Kim Y, Kim I, Lee S, Jang H, Kim W, Kim T, Yun S. 559 THE PROGNOSTIC SIGNIFICANCE OF RUNX3 METHYLATION IN NORMAL ADJACENT UROTHELIUM OF NON-MUSCLE INVASIVE BLADDER CANCER IN THE PATIENTS RASSF1A in Low-grade (WHO Grade 1 and Grade 2) Nonmuscle-invasive Bladder Cancer](http://www.ncbi.nlm.nih.gov/pubmed/22446336)Ha Y, Jeong P, Kim J, Kwon W, Kim I, Yun S, Kim G, Choi Y, Moon S, Kim W. Tumorigenic and Prognostic Significance of RASSF1A Expression in Low-grade (WHO Grade 1 and Grade 2) Marker in Recurrent Nonmuscle Invasive Bladder Cancer](http://www.ncbi.nlm.nih.gov/pubmed/22382007)Kim J, Chae Y, Ha Y, Kim I, Byun S, Yun S, Kim W. Ras Association Domain Family 1A: A Promising Prognostic Marker in Recurrent Nonmuscle Invasive Bladder 2012, 10: 114-120. [PMID: 22382007](https://pubmed.ncbi.nlm.nih.gov/22382007), [DOI: 10.1016/j.clgc.2011.12.003](https://doi.org/10.1016/j.clgc.2011.12.003). - Ha Y, Kim J, Yoon H, Jeong P, Kim T, Yun S, Lee S, Kim G, Choi Y, Moon S, Kim I, Kim W. Novel combination markers for predicting progression of nonmuscle invasive bladder cancer International Journal Of [PMID: 22025348](https://pubmed.ncbi.nlm.nih.gov/22025348), [DOI: 10.1002/ijc.27319](https://doi.org/10.1002/ijc.27319). [RUNX3 methylation disease progression in patients with nonmuscleinvasive bladder cancer](http://www.ncbi.nlm.nih.gov/pubmed/22311819)Yan C, Kim Y, Ha Y, Kim I, Kim Y, Yun S, Moon S, Bae S, Kim W. RUNX3 methylation as a predictor for disease progression in patients with nonmuscleinvasive bladder cancer Journal Of in patients who are candidates for active surveillance: impact of varying PSA levels.](http://www.ncbi.nlm.nih.gov/pubmed/21785442)Kang D, Jang T, Jeong J, Choi E, Johnson K, Lee D, Kim W, Kim I. Pathological findings following radical prostatectomy in patients who are candidates for active surveillance: impact of varying PSA levels. Asian Journal Prostate Cancer: Array-Based DNA Methylation and Expression Profiling](http://www.ncbi.nlm.nih.gov/pubmed/21571867)Kim Y, Yoon H, Kim S, Kim Y, Kim E, Kim I, Kim W. EFEMP1 as a Novel DNA Methylation Marker for Prostate Cancer: Array-Based DNA Methylation and Expression 17: 4523-4530. [PMID: 21571867](https://pubmed.ncbi.nlm.nih.gov/21571867), [DOI: 10.1158/1078-0432.ccr-10-2817](https://doi.org/10.1158/1078-0432.ccr-10-2817). - Woo S, Kim I. Editorial Comment for Rebuck et al. Journal requires PU.1/Smad1 interaction](http://www.ncbi.nlm.nih.gov/pubmed/21571370)Lee G, Jung Y, Lee J, Kim W, Kim I. Bone morphogenetic protein 6-induced interleukin-1 expression in macrophages - Jeong P, Ha Y, Cho I, Yun S, Yoo E, Kim I, Choi Y, Moon S, Kim W. Three-gene signature predicts disease progression of non-muscle invasive bladder cancer. with prostate cancer susceptibility and aggressive clinicopathological characteristics in the Korean population](http://www.ncbi.nlm.nih.gov/pubmed/21515665)Yun S, Ha Y, Chae Y, Kim J, Kim I, Kim W. The hOGG1 mutant genotype is associated with prostate cancer susceptibility and aggressive clinicopathological characteristics in the Korean population Annals BARRIER AROUND THE NEUROVASCULAR BUNDLES TO FACILITATE EARLIER RETURN OF POTENCY AFTER ROBOTIC PROSTATECTOMY: AN INITIAL EXPERIENCE](https://doi.org/10.1016/j.juro.2011.02.1005)Ercolani M, Johnson K, Su D, Kim I. 1305 USE OF A HYALURONIC ACID-CARBOXYMETHYLCELLULOSE ADHESION BARRIER AROUND THE NEUROVASCULAR BUNDLES TO FACILITATE EARLIER RETURN OF POTENCY AFTER ROBOTIC PROSTATECTOMY: AN INITIAL EXPERIENCE Investigative Urology 2011, 185: e522. [DOI: 10.1016/j.juro.2011.02.1005](https://doi.org/10.1016/j.juro.2011.02.1005). - Jeong J, Choi E, Kang D, Ercolani M, Lee D, Kim W, Kim I. Pathologic implications of prostatic anterior fat pad Urologic Oncology 31: 63-67. [PMID: 21396837](https://pubmed.ncbi.nlm.nih.gov/21396837), [DOI: 10.1016/j.urolonc.2010.09.003](https://doi.org/10.1016/j.urolonc.2010.09.003). - Lee G, Kwon S, Lee J, Jeon S, Jang K, Choi H, Lee H, Kim W, Lee D, Kim I. Macrophages induce neuroendocrine differentiation of prostate cancer cells via BMP6IL6 of life in patients with lower urinary tract symptoms](http://www.ncbi.nlm.nih.gov/pubmed/21342297)Choi E, Jeong J, Kang D, Johnson K, Ercolani M, Jang T, Lee D, Kim W, Kim I. Impact of robotassisted radical prostatectomy on healthrelated quality of life in patients with lower urinary tract symptoms International Journal Of Urology 2011, 18: 297-303. 21342297](https://pubmed.ncbi.nlm.nih.gov/21342297), [DOI: 10.1111/j.1442-2042.2011.02730.x](https://doi.org/10.1111/j.1442-2042.2011.02730.x). - Kim W, Kim S, Jeong P, Yun S, Cho I, Kim I, Moon S, Um H, Choi Y. A Four-Gene Signature Predicts Disease Progression in Muscle Invasive Bladder Cancer Molecular Medicine 2011, 17: 478-485. [PMID: 21308147](https://pubmed.ncbi.nlm.nih.gov/21308147), Yan C, Jeong P, Kim W, Yun S, Kim I, Moon S, Kim W. GSTM1 Tissue Genotype as a Recurrence Predictor in Non-muscle Invasive Bladder Cancer Journal Of Korean Medical sparing during robot-assisted radical prostatectomy](http://www.ncbi.nlm.nih.gov/pubmed/27637538)Jeong J, Choi E, Kang D, Lee D, Kim I. Impact of Partin nomogram on presurgical planning: intrafascial versus interfascial nerve sparing during robot-assisted radical Robotic Surgery 2011, 5: 121-125. [PMID: 27637538](https://pubmed.ncbi.nlm.nih.gov/27637538), [DOI: 10.1007/s11701-011-0247-x](https://doi.org/10.1007/s11701-011-0247-x). - Hong J, Kim I, Cell Carcinoma 2011, 3767-3769. [DOI: 10.1007/978-3-642-16483-5_5930](https://doi.org/10.1007/978-3-642-16483-5_5930). [Tissue hOGG1 Genotype Predicts Approach Using a Peptide Nucleic Acid Clamping Method](http://www.ncbi.nlm.nih.gov/pubmed/21184188)Ha Y, Yan C, Kim I, Yun S, Moon S, Kim W. Tissue hOGG1 Genotype Predicts Bladder Cancer Prognosis: A Novel Approach Using a Peptide Nucleic Acid Clamping Method Annals of Nonmuscle Invasive Bladder Cancer Recurrence and Progression](http://www.ncbi.nlm.nih.gov/pubmed/21168882)Yim M, Ha Y, Kim I, Yun S, Choi Y, Kim W. HMOX1 is an Important Prognostic Indicator of Nonmuscle Invasive Bladder Cancer Recurrence and Macrophages Requires Both SMAD and p38 Signaling Pathways*](http://www.ncbi.nlm.nih.gov/pubmed/20889504)Lee G, Kwon S, Lee J, Jeon S, Jang K, Choi H, Lee H, Kim W, Kim S, Kim I. Induction of Interleukin-6 Expression by Bone Morphogenetic Protein-6 in Macrophages Requires Both SMAD and p38 Signaling marker for muscle invasive bladder novel approach using peptide nucleic acid-mediated, real-time PCR clamping](http://www.ncbi.nlm.nih.gov/pubmed/20884250)Kim E, Yan C, Ha Y, Jeong P, Kim I, Moon S, Choi Y, Kim W. Analysis of hOGG1 genotype as a prognostic marker for muscle invasive bladder A novel peptide nucleic acid-mediated, real-time [DOI: 10.1016/j.urolonc.2010.07.008](https://doi.org/10.1016/j.urolonc.2010.07.008). [Clavien Classification the Initial Series of Robot-Assisted Radical Prostatectomy: The Cancer Institute of New Jersey/Robert Wood Johnson Medical School Experience](http://www.ncbi.nlm.nih.gov/pubmed/20673148)Jeong J, Choi E, Kim I. Clavien Classification of Complications After the Initial Series of Robot-Assisted Radical Prostatectomy: The Cancer Institute of New Jersey/Robert Wood Johnson Medical School Experience Journal 1457-1461. [PMID: quality of life following robot-assisted radical prostatectomy](http://www.ncbi.nlm.nih.gov/pubmed/27627949)Choi E, Jeong J, Kang D, Johnson K, Jang T, Kim I. Early assessment of patient satisfaction and health-related quality of life following robot-assisted radical prostatectomy Journal Of Robotic Surgery 2010, 4: 221-227. [PMID: 27627949](https://pubmed.ncbi.nlm.nih.gov/27627949), [DOI: 10.1007/s11701-010-0212-0](https://doi.org/10.1007/s11701-010-0212-0). - Jeong J, Kang D, Lee G, Kim I. Bone Morphogenetic Protein Signaling: Implications in Urology Investigative Kim I. Renal Hilar Control During Laparoscopic Partial Nephrectomy: To Clamp or Not to Clamp Radical Prostatectomy](http://www.ncbi.nlm.nih.gov/pubmed/20376897)Kim I, Hwang E, Mmeje C, Ercolani M, Lee D. Impact of Posterior Urethral Repair on Continence Following EXCISION DURING ROBOT-ASSISTED LAPAROSCOPIC RADICAL PROSTATECTOMY](https://doi.org/10.1016/j.juro.2010.02.353)Jeong J, Lamba S, Choi E, Kang D, Kim I. 291 STAGING IMPLICATIONS OF ANTERIOR PROSTATIC FAT PAD EXCISION DURING ROBOT-ASSISTED PATHOLOGICAL FINDINGS IN RADICAL PROSTATECTOMY SPECIMENS OF PATIENTS WHO ARE CANDIDATES FOR ACTIVE SURVEILLANCE PROTOCOLS](https://doi.org/10.1016/j.juro.2010.02.1809)Kang D, Jeong J, Choi E, Johnson K, Kim I. 1869 ANALYSIS OF PATHOLOGICAL FINDINGS IN RADICAL PROSTATECTOMY SPECIMENS OF PATIENTS WHO ARE CANDIDATES FOR ACTIVE SURVEILLANCE PROTOCOLS Investigative Urology 2010, 183: e726. [DOI: TUMOR-MACROPHARGE INTERACTION VIA BONE MORPHOGENETIC PROTEIN6-INTERLEUKIN6 LOOP](https://doi.org/10.1016/j.juro.2010.02.1134)Lee G, Kwon S, Lee J, Jeon S, Jang K, Choi H, Lee H, Kim W, Kim S, Choi E, Kim I. 1441 MECHANISM OF NEUROENDOCRINE DIFFERENTIATION IN PROSTATE CANCER: TUMOR-MACROPHARGE INTERACTION VIA BONE During Laparoscopic Nephroureterectomy\u2014A Novel and Simple Modification of the Pluck Technique](http://www.ncbi.nlm.nih.gov/pubmed/19913884)Mueller T, DaJusta D, Cha D, Kim I, Ankem M. Ureteral Fibrin Sealant Injection of the Distal Ureter During Laparoscopic Nephroureterectomy\u2014A Novel and Simple Modification Robot-Assisted Laparoscopic Radical Prostatectomies](http://www.ncbi.nlm.nih.gov/pubmed/19694530)Potdevin L, Ercolani M, Jeong J, Kim I. Functional and Oncologic Outcomes Comparing Interfascial and Intrafascial Nerve Sparing in PROSTATECTOMIES: FUNCTIONAL AND ONCOLOGICAL OUTCOMES AT THE CANCER INSTITUTE OF NJ/ROBERT WOOD JOHNSON MEDICAL SCHOOL](https://doi.org/10.1016/s0022-5347(09)61630-x)Potdevin L, Ercolani M, Kim I. COMPARING APPROACHES TO NERVE-SPARING IN ROBOTIC-ASSISTED RADICAL PROSTATECTOMIES: FUNCTIONAL AND ONCOLOGICAL OUTCOMES AT THE CANCER INSTITUTE OF NJ/ROBERT WOOD JOHNSON MEDICAL SCHOOL Investigative Urology 2009, 181: 578-579. nitric oxide synthase in macrophages](http://www.ncbi.nlm.nih.gov/pubmed/19740337)Kwon S, Lee G, Lee J, Kim W, Kim I. Bone morphogenetic protein6 induces the expression of inducible Hong Kim I. Transitional Cell Carcinoma 2009, 3040-3043. [DOI: 10.1007/978-3-540-47648-1_5930](https://doi.org/10.1007/978-3-540-47648-1_5930). - Jeon S, Kim I. Laparoscopic 2008, 22: 1943-1944. [DOI: 10.1089/end.2008.9773a](https://doi.org/10.1089/end.2008.9773a). [Evaluation of Flexible Cystoscope: A Randomized Controlled Trial](http://www.ncbi.nlm.nih.gov/pubmed/17919698)Krebs A, Borin J, Kim I, Jackson D, McDougall E, Clayman R. Evaluation of Practice Efficiency with a Novel Sheathed Flexible Cystoscope: A Subfamily of the Transforming Growth Factor- Superfamily, in Renal Cell Carcinoma](http://www.ncbi.nlm.nih.gov/pubmed/17644140)Kwak C, Park Y, Kim I, Moon K, Ku J. Expression of Bone Morphogenetic Proteins, the Subfamily of the Transforming Growth Factor- Superfamily, in Renal 17644140](https://pubmed.ncbi.nlm.nih.gov/17644140), [DOI: 10.1016/j.juro.2007.05.005](https://doi.org/10.1016/j.juro.2007.05.005). - Kim Eichel Edwards R, Uribe C, Chou D, Abdelshehid C, Ahlering M, White S, Woo E, McDougall E, Clayman R. Effects of Commonly Used Hemostatic Agents on the Porcine Collecting System Robotic Assisted Radical Prostatectomy at Minimum 12 Months Follow-Up](https://doi.org/10.1016/s0022-5347(18)31690-2)Mueller T, DaJusta D, Kim I, Hong J, Hwang J. 1489: the Patterns of Urinary Continence Following Robotic Assisted Radical Prostatectomy at Minimum 12 Follow-Up Investigative Urology 2007, 177: 491. [DOI: 10.1016/s0022-5347(18)31690-2](https://doi.org/10.1016/s0022-5347(18)31690-2). [Expression of estrogen receptors and in bladder cancer cell lines and human bladder tumor tissue](http://www.ncbi.nlm.nih.gov/pubmed/16700038)Shen S, Smith C, Hsieh J, Yu J, Kim I, Jian W, Sonpavde, Ayala G, Younes M, Lerner S. Expression of estrogen receptors and in bladder cancer cell lines and human bladder tumor tissue Cancer 2006, 106: 2610-2616. [PMID: 16700038](https://pubmed.ncbi.nlm.nih.gov/16700038), [DOI: 10.1002/cncr.21945](https://doi.org/10.1002/cncr.21945). - Kim I, Kim S. Role of bone morphogenetic proteins in transitional cell carcinoma cells Cancer Letters 2006, 241: 118-123. [PMID: 16500023](https://pubmed.ncbi.nlm.nih.gov/16500023), [DOI: 10.1016/j.canlet.2005.10.009](https://doi.org/10.1016/j.canlet.2005.10.009). CHOU D, PARK H, BASILLOTE J, LEE D, KIM I, EICHEL L, PROTSENKO D, WONG B, McDOUGALL E, CLAYMAN R. for Destruction of Experimental VX-2 Renal Tumors in Rabbits](https://doi.org/10.1016/s0022-5347(18)34889-4)Kim I, Eichel L, Chou D, Abdelshehid C, Ahlering M, and Radiofrequency Ablation for Destruction of Experimental VX-2 Renal Tumors in Rabbits Investigative Urology 2005, 173: 177. [DOI: 10.1016/s0022-5347(18)34889-4](https://doi.org/10.1016/s0022-5347(18)34889-4). - Kim I, Eichel L, Uribe C, Chou D, Abdelshehid C, Ahlering M, White S, McDougall E, Comparison Tisseel, Floseal, Coseal, Bioglue the Investigative Urology 2005, 173: 295. [DOI: 10.1016/s0022-5347(18)35244-3](https://doi.org/10.1016/s0022-5347(18)35244-3). - Kim I, Kim M, Kim S. Transforming Growth Factor-: Biology and Clinical Relevance 15715939](https://pubmed.ncbi.nlm.nih.gov/15715939), [DOI: 10.5483/bmbrep.2005.38.1.001](https://doi.org/10.5483/bmbrep.2005.38.1.001). [Restoration of Bone Morphogenetic Protein Receptor Type II Expression Leads to a Decreased Rate of Tumor Growth in Bladder Transitional Cell Carcinoma Cell Line TSU-Pr1](http://www.ncbi.nlm.nih.gov/pubmed/15492256)Kim I, Lee D, Lee D, Kim W, Kim M, Morton R, Lerner S, Kim S. Restoration of Bone Morphogenetic Protein Receptor Type II Expression Leads to a Decreased Rate of Tumor Growth in Bladder Transitional Cell Carcinoma Cell Line TSU-Pr1 Cancer Research 2004, 64: 7355-7360. [PMID: 15492256](https://pubmed.ncbi.nlm.nih.gov/15492256), [DOI: 10.1158/0008-5472.can-04-0154](https://doi.org/10.1158/0008-5472.can-04-0154). - Kim I, Lee D, Lee D, Ahn H, Kim M, Kim S, Morton R. Loss of expression of bone morphogenetic protein receptor type II in human prostate cancer cells Oncogene 2004, 23: 7651-7659. [PMID: 15354178](https://pubmed.ncbi.nlm.nih.gov/15354178), [DOI: its receptors: correlation with pathologic features and biochemical progression in patients undergoing radical prostatectomy](http://www.ncbi.nlm.nih.gov/pubmed/15183988)Shariat S, Menesses-Diaz A, Kim I, Muramoto M, Wheeler T, Slawin K. Tissue expression of transforming growth factor-1 and its receptors: correlation with pathologic features and biochemical progression in of Estrogen Receptor and in Bladder Cancer Cell Lines and Human Bladder Tumor Tissue](https://doi.org/10.1016/s0022-5347(18)37984-9)Shen S, Yu J, Kim I, Jian W, Matsumoto K, Kim M, Sonpavde G, Smith C, Ayala G, Younes M, Lerner S. 735: Differential Expression of Estrogen Receptor and in Bladder Cancer Cell Lines and Human Bladder Tumor Tissue Investigative Urology 2004, 171: 195. [DOI: 10.1016/s0022-5347(18)37984-9](https://doi.org/10.1016/s0022-5347(18)37984-9). [Decreased expression of bone morphogenetic protein (BMP) receptor type II correlates with insensitivity to BMP-6 in human renal cell carcinoma cells.](http://www.ncbi.nlm.nih.gov/pubmed/14676131)Kim I, Lee D, Lee D, Kim B, Kim H, Leach F, Linehan W, Morton R, Kim S. Decreased expression of bone morphogenetic protein (BMP) receptor type II correlates with insensitivity to BMP-6 in human renal cell carcinoma cells. Clinical Cancer Research 2003, 9: 6046-51. [PMID: androgen-independent human prostate cancer cell lines.](http://www.ncbi.nlm.nih.gov/pubmed/12235008)Kim I, Kim B, Seong D, Lee D, Seo J, Hong Y, Kim H, Morton R, Kim S. Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis in androgen-independent human prostate cancer Research [PMID: 12235008](https://pubmed.ncbi.nlm.nih.gov/12235008). Growth Factor- Signaling by Blocking Binding of the Smad Complex to Its Target Sequence*](http://www.ncbi.nlm.nih.gov/pubmed/12145312)Lee D, Kim B, Kim I, Cho E, Satterwhite D, Kim S. The Human Papilloma Virus E7 Oncoprotein Inhibits Transforming Growth Factor- Signaling by Blocking Binding of the Smad Complex to Its Target Sequence* Journal Of in androgen-responsive human prostate cancer cell line LNCaP through an androgen-independent pathway.](http://www.ncbi.nlm.nih.gov/pubmed/12097269)Kim I, Seong D, Kim B, Lee D, Remaley A, Leach F, Morton R, Kim S. Raloxifene, a selective estrogen receptor modulator, induces apoptosis in androgen-responsive human prostate cancer cell line LNCaP through an androgen-independent pathway. Cancer Research of BAD in TSU-PR1 Human Cancer Cells*](http://www.ncbi.nlm.nih.gov/pubmed/12084714)Kim H, Kim B, Kim I, Mamura M, Do Hwan Seong, Jang J, Kim S. Raloxifene, a Mixed Estrogen Agonist/Antagonist, Induces Apoptosis through Cleavage of BAD in TSU-PR1 Human Cancer Cells* [PMID: 12084714](https://pubmed.ncbi.nlm.nih.gov/12084714), [DOI: 10.1074/jbc.m202852200](https://doi.org/10.1074/jbc.m202852200). [Preoperative plasma levels of transforming growth factor 1 strongly predict clinical outcome in patients with bladder carcinoma](http://www.ncbi.nlm.nih.gov/pubmed/11753975)Shariat S, Kim J, Andrews B, Kattan M, Wheeler T, Kim I, Lerner S, Slawin K. Preoperative plasma levels of transforming growth factor 1 strongly predict clinical outcome in patients with bladder carcinoma Cancer 2001, 92: 2985-2992. [PMID: 11753975](https://pubmed.ncbi.nlm.nih.gov/11753975), [DOI: 10.1002/1097-0142(20011215)92:12<2985::aid-cncr10175>3.0.co;2-5](https://doi.org/10.1002/1097-0142(20011215)92:12<2985::aid-cncr10175>3.0.co;2-5). [Predictive value of expression of transforming growth factor1 and its receptors in transitional cell carcinoma of the urinary bladder](http://www.ncbi.nlm.nih.gov/pubmed/11745225)Kim J, Shariat S, Kim I, MenessesDiaz A, Tokunaga H, Wheeler T, Lerner S. Predictive value of expression of transforming growth factor1 and its receptors in transitional cell carcinoma of the urinary bladder Cancer 2001, 92: 1475-1483. [PMID: 11745225](https://pubmed.ncbi.nlm.nih.gov/11745225), growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy.](http://www.ncbi.nlm.nih.gov/pubmed/11387358)Shariat S, Shalev M, Menesses-Diaz A, Kim I, Kattan M, Wheeler T, Slawin K. Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy. Clinical Oncology 2001, 19: 2856-64. 10.1200/jco.2001.19.11.2856](https://doi.org/10.1200/jco.2001.19.11.2856). - KIM I, ELLIOTT D, HUSMANN D, BOONE T. AN UNUSUAL PRESENTING SYMPTOM OF SARCOIDOSIS: NEUROGENIC BLADDER 10.1016/s0022-5347(05)66561-5](https://doi.org/10.1016/s0022-5347(05)66561-5). - KIM I, ELLIOTT D, HUSMANN D, BOONE T. AN UNUSUAL PRESENTING SYMPTOM OF SARCOIDOSIS: NEUROGENIC BLADDER DYSFUNCTION Investigative Urology 2001, Kim I, Laparoscopic nephrectomy for renal cell carcinoma prostate of transgenic mice carrying the C3(1)TGF type II dominant negative receptor](http://www.ncbi.nlm.nih.gov/pubmed/10754527)Kundu S, Kim I, Yang T, Doglio L, Lang S, Zhang X, Buttyan R, Kim S, Chang J, Cai X, Wang Z, Lee C. Absence of proximal duct apoptosis in the ventral prostate of transgenic mice carrying the C3(1)TGF type II dominant negative receptor The Prostate 2000, 43: 118-124. [PMID: 10754527](https://pubmed.ncbi.nlm.nih.gov/10754527), [DOI: 10.1002/(sici)1097-0045(20000501)43:2<118::aid-pros6>3.0.co;2-v](https://doi.org/10.1002/(sici)1097-0045(20000501)43:2<118::aid-pros6>3.0.co;2-v). - J, LAPIN S. BACILLUS CALMETTE-GUERIN INDUCED PERITONITIS IN A PATIENT ON Investigative Urology 2000, 163: 237. [PMID: 10604359](https://pubmed.ncbi.nlm.nih.gov/10604359), [DOI: 10.1016/s0022-5347(05)68017-2](https://doi.org/10.1016/s0022-5347(05)68017-2). - OLIVERO J, LAPIN S. BACILLUS CALMETTE-GUERIN INDUCED PERITONITIS IN A PATIENT ON DIALYSIS Investigative Urology 2000, 163: 237. [DOI: 10.1097/00005392-200001000-00060](https://doi.org/10.1097/00005392-200001000-00060). [ABSENCE OF EXPRESSION OF TRANSFORMING GROWTH FACTOR-beta TYPE II RECEPTOR IS ASSOCIATED WITH AN AGGRESSIVE GROWTH PATTERN IN A MURINE RENAL CARCINOMA CELL LINE, RENCA](http://www.ncbi.nlm.nih.gov/pubmed/9783979)KUNDU S, KIM I, ZELNER D, JANULIS L, GOODWIN S, ENGEL J, LEE C. ABSENCE OF EXPRESSION OF TRANSFORMING GROWTH FACTOR-beta TYPE II RECEPTOR IS ASSOCIATED WITH AN AGGRESSIVE GROWTH PATTERN IN A MURINE RENAL CARCINOMA CELL LINE, OF TRANSFORMING GROWTH FACTOR-beta TYPE II RECEPTOR IS ASSOCIATED WITH AN AGGRESSIVE GROWTH PATTERN IN A MURINE RENAL CARCINOMA CELL LINE, RENCA](https://doi.org/10.1097/00005392-199811000-00077)KUNDU S, KIM I, ZELNER D, JANULIS L, GOODWIN S, ENGEL J, LEE C. ABSENCE OF EXPRESSION OF TRANSFORMING GROWTH FACTOR-beta TYPE II RECEPTOR IS ASSOCIATED WITH AN AGGRESSIVE GROWTH PATTERN IN A MURINE RENAL CARCINOMA CELL LINE, RENCA Investigative Urology associated with inhibition of protein kinase C and induction of p21waf1/cip1](http://www.ncbi.nlm.nih.gov/pubmed/9721069)Rohlff C, Blagosklonny M, Kyle E, Kesari A, Kim I, Zelner D, Hakim F, Trepel J, Bergan R. Prostate cancer cell growth inhibition by tamoxifen is associated with inhibition of protein kinase C and of expression of transforming growth factor-beta receptors is associated with poor prognosis in prostate cancer patients.](http://www.ncbi.nlm.nih.gov/pubmed/9676836)Kim I, Ahn H, Lang S, Oefelein M, Oyasu R, Kozlowski J, Lee C. Loss of expression of transforming growth factor-beta receptors is associated with poor prognosis in prostate cancer patients. Clinical Cancer Research 1998, 4: 1625-30. [PMID: 9676836](https://pubmed.ncbi.nlm.nih.gov/9676836). [The Conventional Transforming Growth Factor- (TGF-) Receptor Type I Is Not Required for TGF-1 Signaling in a Human Prostate Cancer Cell Line, LNCaP](http://www.ncbi.nlm.nih.gov/pubmed/9633523)Kim I, Zelner D, Lee C. The Conventional Transforming Growth Factor- (TGF-) Receptor Type I Is Not Required for TGF-1 Signaling in a Human Prostate Cancer Cell Line, LNCaP Experimental Cell Research 1998, 241: 151-160. [PMID: 9633523](https://pubmed.ncbi.nlm.nih.gov/9633523), [DOI: 10.1006/excr.1998.4034](https://doi.org/10.1006/excr.1998.4034). - Lee D, Yang S, Hong S, Chung B, Kim I. Telomerase: a potential marker of bladder transitional cell carcinoma in bladder washes. Clinical Cancer Research 1998, 4: 535-8. [PMID: 9533519](https://pubmed.ncbi.nlm.nih.gov/9533519). [Prostatic ductal system in rats: Tissuespecific expression regional variation in stromal distribution of transforming growth factor1](http://www.ncbi.nlm.nih.gov/pubmed/9294629)Nemeth J, Sensibar J, White R, Zelner D, Kim I, Lee C. Prostatic ductal system in rats: Tissuespecific expression and regional variation in stromal distribution of transforming growth factor1 The Prostate 1997, 33: 64-71. [PMID: 9294629](https://pubmed.ncbi.nlm.nih.gov/9294629), [DOI: 10.1002/(sici)1097-0045(19970915)33:1<64::aid-pros11>3.0.co;2-j](https://doi.org/10.1002/(sici)1097-0045(19970915)33:1<64::aid-pros11>3.0.co;2-j). - Yang S, Lee D, Hong S, Chung B, Kim I. Telomerase activity: a potential marker of bladder transitional cell carcinoma in bladder washes Yonsei Medical Journal 1997, 38: 155-159. [PMID: 9259615](https://pubmed.ncbi.nlm.nih.gov/9259615), [DOI: 10.3349/ymj.1997.38.3.155](https://doi.org/10.3349/ymj.1997.38.3.155). [Loss of expression of transforming growth factor beta type I and type II receptors correlates with tumor grade in human prostate cancer tissues.](http://www.ncbi.nlm.nih.gov/pubmed/9816295)Kim I, Ahn H, Zelner D, Shaw J, Lang S, Kato M, Oefelein M, Miyazono K, Nemeth J, Kozlowski J, Lee C. Loss of expression of transforming growth factor beta type I and type II receptors correlates with tumor grade in human prostate cancer tissues. Clinical Cancer Research 1996, 2: 1255-61. [PMID: 9816295](https://pubmed.ncbi.nlm.nih.gov/9816295). [Transforming growth factor-beta1 is a mediator of androgen-regulated growth arrest in an androgen-responsive prostatic cancer cell line, LNCaP.](http://www.ncbi.nlm.nih.gov/pubmed/8603613)Kim I, Kim J, Zelner D, Ahn H, Sensibar J, Lee C. Transforming growth factor-beta1 is a mediator of androgen-regulated growth arrest in an androgen-responsive prostatic Factor-1 (TGF-1) and the Level of Type II TGF- Receptor in LNCaP Cells by Dihydrotestosterone](http://www.ncbi.nlm.nih.gov/pubmed/8549651)Kim I, Zelner D, Sensibar J, Ahn H, Park L, Kim J, Lee C. Modulation of Sensitivity to Transforming Growth Factor-1 (TGF-1) and the Level of Type II TGF- Receptor in LNCaP Cells by Dihydrotestosterone [Expression and localization of transforming growth factor-beta receptors type I and type II in the rat ventral prostate during regression.](http://www.ncbi.nlm.nih.gov/pubmed/8838150)Kim I, Ahn H, Zelner D, Park L, Sensibar J, Lee C. Expression and localization of transforming growth factor-beta receptors type I and type II in the rat ventral prostate during transforming growth factor beta (TGF-beta) receptor type I gene correlates with insensitivity to TGF-beta 1 in human prostate cancer cells.](http://www.ncbi.nlm.nih.gov/pubmed/8548772)Kim I, Ahn H, Zelner D, Shaw J, Sensibar J, Kim J, Kato M, Lee C. Genetic change in transforming growth factor beta (TGF-beta) receptor type I gene correlates with insensitivity to TGF-beta 1 in human prostate cancer cells. Cancer Research 1996, 56: 44-8. [PMID: 8548772](https://pubmed.ncbi.nlm.nih.gov/8548772). [Regulation of proliferation and androgen-sensitive prostatic cancer cells, LNCaP, by dihydrotestosterone.](http://www.ncbi.nlm.nih.gov/pubmed/7530653)Lee Sutkowski D, Sensibar J, Zelner D, Kim I, Amsel I, Shaw N, Prins G, Kozlowski J. Regulation of proliferation and production of prostate-specific antigen in androgen-sensitive prostatic FloorNew Haven, CT 06519 - Yale UrologyOrchard Medical Center330 Orchard 164New Haven, CT 06511 - Yale UrologyGreenwich Hospital55 Holly Hill Lane, Ste Suite 240Greenwich, CT 06830 Biography Isaac Yi Kim, MD, PhD, MBA, chair of the Department of Urology at Yale School of Medicine, specializes in the treatment and management of prostate cancer with the goal of helping patients navigate and better understand their disease. Although he cares for all men with localized disease, his clinical and research focus is in men with high-risk disease, recurrence after radiation, and metastatic prostate cancer to lymph nodes, bones, lungs, and abdominal organs. Dr. Kim is an expert in minimally invasive robotic surgery and has performed more than 2,100 robot-assisted radical prostatectomies, which are surgeries to remove the entire prostate gland. In addition, he has established a same-day radical prostatectomy program by using the latest-generation da Vinci robot to remove a diseased prostate through a single, one-inch incision in the abdomen. This results in less pain\u2014and pain medication\u2014for the patient, who usually goes home the same day of the surgery. He was inspired to become a prostate surgeon during his medical training, when he decided he wanted to help men he saw struggling with complications such as impotence and incontinence, which often develop after prostate cancer surgery. Those post-surgery problems are less common with expert robotic surgeons, he says. \"I see what an impact and a difference the surgical robot has made in helping our patients and allaying their fears.\" As a professor at Yale School of Medicine, Dr. Kim is also a surgeon-scientist who is studying the mechanism of prostate cancer treatment resistance. He is the principal investigator in clinical trials focused on advanced and metastatic prostate cancer, providing surgery in men with Stage IV prostate cancer. He says the traditional paradigm shows that when cancer cells have escaped the organ of origin, it's too late to help. But his early data is showing that removing the prostate may enhance the effectiveness of chemotherapy and hormonal therapies for men with late-stage disease. Dr. Kim says working at Yale Medicine is rewarding because of the rich history and tradition that values innovation and creativity, and he is focused on providing the latest treatments for men who have any stage of prostate cancer. \"Yale Urology is one of the larger departments in the nation and we attract patients from regions far beyond New Haven. We're really dedicated to delivering the most innovative care in the most compassionate manner,\" he says. \"When a patient and concerned family members come in with a prostate cancer diagnosis, and I'm able to take care of it and see how he recovers, it is truly a privilege and a blessing.\" Titles - Professor of Urology - Professor, Urology - Chair, Urology - Chief, Urology - Co-Leader, Cancer Signaling Networks, Yale Cancer Center Education & Training - MBAUniversity of Pennsylvania Wharton Business School, Finance (2017) - Research FellowshipNational Institutes of Health (2005) - Clinical FellowshipUniversity of California, Irvine (2005) - ResidentBaylor College of Medicine (2003) - MDNorthwestern University, Feinberg School of Medicine (1997) - PhDNorthwestern University Graduate School, Tumor Cell Biology (1996) Additional Information - AB of Urology, Urology (2007) [Extended versus standard pelvic lymph node dissection yields no difference in 3-year biochemical recurrence rates](https://doi.org/10.1016/j.prnil.2022.12.005)Nagaya N, Chua K, Sterling J, Horie S, Kim I. Extended versus standard pelvic lymph node dissection yields no difference in 3-year biochemical recurrence rates Prostate International 2023, 11: 107-112. [DOI: 10.1016/j.prnil.2022.12.005](https://doi.org/10.1016/j.prnil.2022.12.005). - Choksi A, Hayden C, Rahman S, Lokeshwar S, Kim I. The disparities in clinical trials addressing urologic conditions among lower-income countries Frontiers In Urology 2023, 2: 1069265. [DOI: 10.3389/fruro.2022.1069265](https://doi.org/10.3389/fruro.2022.1069265). - Kim J, Kaldany A, Lichtbroun B, Singer E, Jang T, Ghodoussipour S, Kim M, Kim I. Single-Port Robotic Radical Prostatectomy: Short-Term Outcomes and SURGICAL PATHOLOGY AND OVERALL SURVIVAL AMONG PATIENTS WITH LOW-RISK PROSTATE CANCER](https://doi.org/10.1097/ju.0000000000002518.07)Lee G, Lee E, Leopold Z, Kim S, Leapman M, Kim I. PD03-07 ASSOCIATION BETWEEN ADVERSE SURGICAL PATHOLOGY AND OVERALL SURVIVAL AMONG PATIENTS WITH LOW-RISK PROSTATE CANCER of nonseminomatous germ cell tumors in pediatric patients and young adults - A stage group stratified analysis](http://www.ncbi.nlm.nih.gov/pubmed/35144865)Srivastava A, Patel H, Koehne E, Gupta G, Drachtman R, Pierorazio P, Bagrodia A, Elsamra S, Kim I, Ghodoussipour S, Singer E, Jang T, Patel H, Barone J. Survival of nonseminomatous germ cell tumors in pediatric patients and young adults - A stage group stratified analysis Urologic Oncology Seminars Retroperitoneal Lymphadenectomy for Nonseminomatous Testicular Cancer](http://www.ncbi.nlm.nih.gov/pubmed/34978466)Patel H, Srivastava A, Kim Patel H, Pierorazio P, Bagrodia A, Masterson T, Ghodoussipour S, Kim I, Singer E, Jang T. Association of Lymph Node Count and Survival after Primary Retroperitoneal Lymphadenectomy spectrometry aided by multivariate statistical analysis to predict prostate cancer treatment outcome](http://www.ncbi.nlm.nih.gov/pubmed/35642979)Ma Y, Zheng Z, Xu S, Attygalle A, Kim I, Du H. Untargeted urine metabolite profiling by mass spectrometry aided by multivariate statistical analysis to predict prostate cancer outcome Analyst 2022, 147: 3043-3054. E, Demkowicz P, Park H, An Y, Kann B, Yu J, Sprenkle P, Kim I, Leapman M. Facility-Level Variation in Use of Locoregional Therapy Urology Buck M, Ghiraldi E, Demkowicz P, Park H, An Y, Kann B, Yu J, Sprenkle P, Kim I, Leapman M. Facility-Level Variation in Use of Locoregional Therapy of Stage I and II Testicular Nonseminomatous Germ Cell Tumors (nsgct)](https://doi.org/10.1016/j.jamcollsurg.2021.08.622)Patel H, Srivastava A, Shinder B, Kim I, Singer E, Ghodoussipour S, Jang T. Factors Associated with Accurate Staging of Stage I and II Testicular Nonseminomatous Germ Cell Tumors (nsgct) Journal Of The Of Surgeons 2021, 233: e230. [DOI: 10.1016/j.jamcollsurg.2021.08.622](https://doi.org/10.1016/j.jamcollsurg.2021.08.622). [Quantifying Publication Rates and Time Publication for American Urological Association Podium Presentations](https://doi.org/10.1016/j.jamcollsurg.2021.07.643)Chua K, Mikail M, Patel H, Tabakin A, Doppalapudi S, Ghodoussipour S, Kim I, Jang T, Srivastava A, Singer E. Quantifying Publication Rates and Time to Publication for American Urological Association Podium Presentations Journal Of The American College Of Surgeons 2021, 233: s310-s311. [DOI: 10.1016/j.jamcollsurg.2021.07.643](https://doi.org/10.1016/j.jamcollsurg.2021.07.643). [Factors Associated with Palliative Care Utilization in Advanced and Metastatic Renal Cell Carcinoma (RCC)](https://doi.org/10.1016/j.jamcollsurg.2021.08.623)Patel H, Sterling J, Srivastava A, Saraiya B, Mayer T, Kim I, Ghodoussipour S, Jang T, Singer E. Factors Associated with Palliative Care (PC) Utilization in Advanced and Metastatic Renal Cell Carcinoma (RCC) Journal Of The American College Of Surgeons 2021, 233: e230-e231. [DOI: 10.1016/j.jamcollsurg.2021.08.623](https://doi.org/10.1016/j.jamcollsurg.2021.08.623). [Marginal improvement in survival among diagnosed with metastatic prostate cancer in the secondline antiandrogen therapy era](http://www.ncbi.nlm.nih.gov/pubmed/34713977)Kim I, Jang T, Kim S, Lee D, Kim D, Singer E, Ghodoussipour S, Stein M, Aron M, Dall'Era M, Kim I. Marginal improvement in survival among patients diagnosed with metastatic prostate cancer in the secondline antiandrogen to Publication for American Urological Association Podium Presentations](http://www.ncbi.nlm.nih.gov/pubmed/34694164)Chua K, Mikhail M, Patel H, Tabakin A, Doppalapudi S, Ghodoussipour S, Kim I, Jang T, Srivastava A, Singer E. Quantifying Publication Rates and Time to Publication for American Urological Association Podium in advanced and metastatic renal cell carcinoma.](https://doi.org/10.1200/jco.2020.39.28_suppl.146)Patel H, Sterling J, Srivastava A, Kim S, Saraiya B, Mayer T, Kim I, Ghodoussipour S, Jang T, Singer E. Factors associated with palliative care utilization in advanced and metastatic renal cell carcinoma. Of Clinical Oncology 2021, 39: 146-146. [DOI: 10.1200/jco.2020.39.28_suppl.146](https://doi.org/10.1200/jco.2020.39.28_suppl.146). [Abrogation of survival disparity and uninsured individuals after the USPSTF's 2012 prostate-specific antigen-based prostate cancer screening recommendation.](https://doi.org/10.1200/jco.2020.39.28_suppl.77)Kim I, Kim D, Kim S, Singer E, Jang T, Ghodoussipour S, Aron M, Kim I. Abrogation of survival disparity between insured and uninsured individuals after the USPSTF's 2012 prostate-specific antigen-based prostate cancer screening Oncology 2021, 39: 77-77. [DOI: 10.1200/jco.2020.39.28_suppl.77](https://doi.org/10.1200/jco.2020.39.28_suppl.77). Prostatectomy: An International, Multi-Surgeon Series](http://www.ncbi.nlm.nih.gov/pubmed/34181471)Kowalczyk K, Madi R, Eden C, Sooriakumaran P, Fransis Raskin Y, Joniau S, Johnson S, Jacobsohn K, Galfano A, Bocciardi A, Hwang J, Kim I, Hu J. Comparative Outcomes of Salvage Retzius-Sparing versus Standard Robotic Prostatectomy: An B, Jeong P, Byun Y, Kang H, Seo S, Kim W, Lee J, Ha Y, Lee Y, Kim I, Choi Y, Cha E, Moon S, Yun S, Kim W. Collagen type VI-1 and 2 repress the proliferation, migration and invasion of bladder cancer cells International Journal Of Oncology 2021, 59: 37. [PMID: 33982770](https://pubmed.ncbi.nlm.nih.gov/33982770), [DOI: 10.3892/ijo.2021.5217](https://doi.org/10.3892/ijo.2021.5217). in circulating tumor cells from castrationresistant prostate cancer](http://www.ncbi.nlm.nih.gov/pubmed/33977248)Nagaya N, Lee G, Lu Y, Ashizawa T, Nagata M, Kim I, Horie S. Transcription factor 4 expression in circulating tumor cells from castrationresistant prostate cancer IJU H, Kim W, Vaz R, Cruciani G, Kim I. Effects of MTX-23, a Novel PROTAC of Androgen Receptor Splice Receptor, carcinoma: Oncologic implications in the COVID-19 era and beyond.](https://doi.org/10.1200/jco.2021.39.6_suppl.283)Srivastava A, Patel H, Kim S, Shinder B, Sterling J, Tabakin A, Polotti C, Saraiya B, Mayer T, Kim I, Ghodoussipour S, Patel H, Jang T, Singer E. Delaying surgery for clinical T1b-T2bN0M0 renal cell carcinoma: Oncologic implications in the COVID-19 era and beyond. Journal Of Clinical Oncology 2021, 39: 283-283. [DOI: 10.1200/jco.2021.39.6_suppl.283](https://doi.org/10.1200/jco.2021.39.6_suppl.283). - Leopold Z, Dave Menon A, Patel H, Srivastava A, Kim I, Jang T, Singer E. Trends in the use of administrative databases in urologic oncology: 2000 - 2021, 39: 356-356. [DOI: 10.1200/jco.2021.39.6_suppl.356](https://doi.org/10.1200/jco.2021.39.6_suppl.356). - Mikhail Patel H, Tabakin A, Doppalapudi S, Ghodoussipour S, Kim I, Jang T, Srivastava A, Singer E. Quantifying publication rates and time to publication for urologic oncology podium presentations. [DOI: 10.1200/jco.2021.39.6_suppl.357](https://doi.org/10.1200/jco.2021.39.6_suppl.357). [Relationship communication and the course of psychological outcomes among couples coping with localised prostate cancer](http://www.ncbi.nlm.nih.gov/pubmed/33586282)Manne S, Kashy D, MyersVirtue S, Zaider T, Kissane D, Heckman C, Kim I, Penedo F, Lee D. Relationship communication and the course of psychological outcomes among couples coping with localised prostate cancer European Journal Of Menon A, Patel H, Srivastava A, Kim I, Jang T, Singer E. Trends in the use of administrative databases in urologic oncology: and Metabolites in Men after Supplementation with a -Tocopherol-Rich Vitamin E Mixture](http://www.ncbi.nlm.nih.gov/pubmed/33319628)Goodin S, Kim I, Lee M, Shih W, Orlick M, Zheng X, Yang C. Plasma, Prostate and Urine Levels of Tocopherols and Metabolites in Men after Supplementation with a -Tocopherol-Rich Vitamin E Mixture Nutrition J, Lee G, Kim I. RNA-seq profile of African American men with a clinically localized prostate cancer Prostate International radiotherapy is equivalent to early radiotherapy in high-risk prostate cancer after radical prostatectomy: A SEER-Medicare analysis on trends, survival outcomes, and complications](http://www.ncbi.nlm.nih.gov/pubmed/34386450)Kwon Y, Wang W, Srivastava A, Jang T, Singer E, Parikh R, Kim W, Kim I. Observation with or without late radiotherapy is equivalent to early radiotherapy in high-risk prostate cancer after radical prostatectomy: A SEER-Medicare analysis on trends, survival outcomes, and complications Kim I. CXC Chemokine/Receptor Axis Profile and Metastasis in Prostate Cancer Frontiers Raman scattering of patient urine and multivariate statistical analysis](http://www.ncbi.nlm.nih.gov/pubmed/32909380)Ma Y, Chi J, Zheng Z, Attygalle A, Kim I, Du H. Therapeutic prognosis of prostate cancer using surfaceenhanced Raman scattering of patient urine and multivariate statistical [DOI: 10.1002/jbio.202000275](https://doi.org/10.1002/jbio.202000275). [Abrogation of disparity and White individuals after the USPSTFs 2012 prostatespecific antigen-based prostate cancer screening recommendation](http://www.ncbi.nlm.nih.gov/pubmed/32888321)Kim I, Jang T, Kim S, Modi P, Singer E, Elsamra S, Kim I. Abrogation of survival disparity between Black and White individuals after the USPSTFs 2012 prostatespecific antigen-based prostate cancer 32888321](https://pubmed.ncbi.nlm.nih.gov/32888321), [DOI: 10.1002/cncr.33179](https://doi.org/10.1002/cncr.33179). [Association of lymph node and survival after primary retroperitoneal lymph node dissection (RPLND) for testicular nonseminomatous germ cell tumor (NSGCT).](https://doi.org/10.1200/jco.2020.38.15_suppl.e17052)Patel H, Srivastava A, Kim S, Singer E, Kim I, Jang T. Association of lymph node count and survival after primary retroperitoneal lymph node dissection (RPLND) for testicular nonseminomatous germ cell 38: e17052-e17052. [DOI: 10.1200/jco.2020.38.15_suppl.e17052](https://doi.org/10.1200/jco.2020.38.15_suppl.e17052). and IIa/b testicular nonseminomatous germ cell tumors (NSGCT) and implications on survival.](https://doi.org/10.1200/jco.2020.38.15_suppl.e17058)Srivastava A, Patel H, Kim S, Kim I, Singer E, Jang T. Accuracy of clinical staging in stage I and IIa/b testicular nonseminomatous germ cell tumors (NSGCT) and implications on individual trials are hoping to answer](http://www.ncbi.nlm.nih.gov/pubmed/32176456)Ranasinghe W, Chapin B, Kim I, Sooriakumaran P, Lawrentschuk N. The cytoreductive prostatectomy in metastatic prostate cancer: what the individual trials are hoping to 2020, 125: 792-800. statins on mortality among patients with highrisk prostate cancer](http://www.ncbi.nlm.nih.gov/pubmed/32035002)Tan X, E J, Lin Y, Rebbeck T, Lu S, Shang M, Kelly W, D'Amico A, Stein M, Zhang L, Jang T, Kim I, Demissie K, Ferrari A, LuYao G. Individual and joint effects of metformin and statins on mortality among patients with highrisk prostate Urology 2020, 135: 122. [PMID: 31895674](https://pubmed.ncbi.nlm.nih.gov/31895674), [DOI: 10.1016/j.urology.2019.07.052](https://doi.org/10.1016/j.urology.2019.07.052). - Piao X, Jeong P, Yan C, Kim Y, Byun Y, Xu Y, Kang H, Seo S, Kim W, Lee J, Kim I, Moon S, Choi Y, Cha E, Yun S, Kim W. A novel tumor suppressing gene, ARHGAP9, is an independent prognostic biomarker for J, Kim W, Kwon Y, Palapattu G, Mehra R, Kim W, Kim I. TCF4 induces enzalutamide resistance via neuroendocrine differentiation in - Lee Kim J, Kwon S, Stein M, Hong J, Nagaya N, Billakanti S, Kim M, Kim W, Kim I. Dihydrotestosterone Increases Cytotoxic Activity of Macrophages on Prostate Cancer in Locally Advanced Clear-Cell Renal-Cell Carcinoma Is Associated With a Poor Outcome](http://www.ncbi.nlm.nih.gov/pubmed/31204211)Na J, Nagaya N, Rha K, Han W, Kim I. DNA Damage Response Pathway Alteration in Locally Advanced Clear-Cell Renal-Cell Carcinoma Is Associated With a Poor Outcome 2019, 17: 299-305.e1. [PMID: 31204211](https://pubmed.ncbi.nlm.nih.gov/31204211), [DOI: 10.1016/j.clgc.2019.05.004](https://doi.org/10.1016/j.clgc.2019.05.004). [Similar incidence of DNA damage response pathway alterations between clinically localized and metastatic prostate cancer](http://www.ncbi.nlm.nih.gov/pubmed/31060606)Kim I, Kim S, Srivastava A, Saraiya B, Mayer T, Kim W, Kim I. Similar incidence of DNA damage response pathway alterations between clinically localized and metastatic prostate cancer therapy in men who present with a metastatic prostate cancer from special issue senior guest editor.](http://www.ncbi.nlm.nih.gov/pubmed/31139700)Kim I. Commentary on local therapy in men who present with a metastatic prostate cancer from special issue senior guest editor. American Journal Of Clinical And Experimental Urology 2019, 7: 61-63. [PMID: 31139700](https://pubmed.ncbi.nlm.nih.gov/31139700), [PMCID: PMC6526358](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6526358). - Lee G, Srivastava Kwon Y, Kim I. Immune reaction by cytoreductive prostatectomy. American Journal Of Clinical for Non-Muscle-Invasive Bladder Cancer](http://www.ncbi.nlm.nih.gov/pubmed/31088707)Xu Y, Kim Y, Jeong P, Piao X, Byun Y, Seo S, Kang H, Kim W, Lee J, Ryu D, Choi J, Kim I, Moon S, Choi Y, Yun S, Kim W. Urinary Cell-Free DNA IQGAP3/BMP4 Ratio as a Prognostic Marker for OF PATHOLOGIC NODE POSITIVE RENAL CELL CARCINOMA ON SURVIVAL IN PATIENTS WITHOUT METASTASIS: EVIDENCE IN SUPPORT OF EXPANDING THE DEFINITION OF STAGE IV KIDNEY CANCER](https://doi.org/10.1097/01.ju.0000555316.15591.47)Srivastava* A, Rivera-Nunez Z, Kim S, Sterling J, Farber N, Radadia K, Modi P, Goyal S, Parikh R, Mayer T, Saraiya B, Weiss R, Kim I, Elsamra S, Jang T, Singer E. MP14-20 IMPACT OF PATHOLOGIC NODE POSITIVE RENAL CELL CARCINOMA ON SURVIVAL IN PATIENTS WITHOUT METASTASIS: EVIDENCE IN SUPPORT OF EXPANDING THE DEFINITION OF STAGE IV KIDNEY CANCER Investigative Urology 2019, 201 [DOI: 10.1097/01.ju.0000555316.15591.47](https://doi.org/10.1097/01.ju.0000555316.15591.47). [MP60-20 LONG-TERM ONCOLOGIC OUTCOMES IN PATIENTS WITH METASTASIS TO THE PROSTATIC ANTERIOR FAT PAD LYMPH NODE](https://doi.org/10.1097/01.ju.0000556802.43534.0b)Chandra* A, Assassi N, Kwon Y, Farber N, Kim I. MP60-20 LONG-TERM ONCOLOGIC OUTCOMES IN PATIENTS WITH METASTASIS TO THE PROSTATIC ANTERIOR FAT PAD LYMPH NODE Investigative Urology 2019, 201 [DOI: 10.1097/01.ju.0000556802.43534.0b](https://doi.org/10.1097/01.ju.0000556802.43534.0b). [Reply to Effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer: Do we have certainties today?](http://www.ncbi.nlm.nih.gov/pubmed/30861093)Jang T, Kim I, Scardino P, Eastham J. Reply to Effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer: Do we have for prostate cancer and their spouses: A randomized clinical trial](http://www.ncbi.nlm.nih.gov/pubmed/30852854)Manne S, Kashy D, Zaider T, Kissane D, Lee D, Kim I, Heckman C, Penedo F, Murphy E, Virtue S. Couplefocused interventions for men with localized prostate cancer and their spouses: A randomized clinical trial British Journal Of Shinder B, Rivera-Nunez Z, Sterling J, Farber N, Radadia K, Kim I, Singer E, Jang T. Survival rates after retroperitoneal lymph node dissection (RPLND) for testicular [DOI: 10.1200/jco.2019.37.7_suppl.534](https://doi.org/10.1200/jco.2019.37.7_suppl.534). [Treatment disparities among patients in the National Cancer Database (NCDB) with clinical TIa and TIb renal masses.](https://doi.org/10.1200/jco.2019.37.7_suppl.648)Sterling J, Rivera-Nunez Z, Farber N, Modi P, Radadia K, Kim S, Sharad G, Rahul P, Weiss R, Kim I, Elsamra S, Jang T, Singer E. Treatment disparities among patients in the National Cancer Database (NCDB) with clinical TIa and TIb renal masses. Journal Of Clinical Oncology 2019, 37: 648-648. [DOI: 10.1200/jco.2019.37.7_suppl.648](https://doi.org/10.1200/jco.2019.37.7_suppl.648). [Factors linked with receiving a lymph node dissection during surgery for nonmetastatic renal cell carcinoma.](https://doi.org/10.1200/jco.2019.37.7_suppl.672)Radadia K, Rivera-Nunez Z, Kim S, Farber N, Sterling J, Modi P, Sharad G, Rahul P, Weiss R, Kim I, Elsamra S, Jang T, Singer E. Factors linked with receiving a lymph node dissection during surgery for nonmetastatic renal cell carcinoma. Journal Of Clinical Oncology 2019, 37: 672-672. [DOI: 10.1200/jco.2019.37.7_suppl.672](https://doi.org/10.1200/jco.2019.37.7_suppl.672). - Faiena I, Kim Jang expression ratios in urinary cell-free DNA for discriminating bladder cancer from hematuria](http://www.ncbi.nlm.nih.gov/pubmed/30446454)Xu Y, Kim Y, Jeong P, Piao X, Byun Y, Kang H, Kim W, Lee J, Kim I, Moon S, Choi Y, Yun S, Kim W. Diagnostic value of combined IQGAP3/BMP4 and IQGAP3/FAM107A expression ratios in urinary cell-free DNA for discriminating bladder cancer from hematuria Urologic cytoreductive radical prostatectomy in men with newly diagnosed metastatic prostate cancer](http://www.ncbi.nlm.nih.gov/pubmed/31485434)Yuh B, Kwon Y, Shinder B, Singer E, Jang T, Kim S, Stein M, Mayer T, Ferrari A, Lee N, Parikh R, Ruel N, Kim W, Horie S, Byun S, Ahlering T, Kim I. Results of Phase 1 study on cytoreductive radical prostatectomy in men with newly diagnosed metastatic prostate radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer](http://www.ncbi.nlm.nih.gov/pubmed/30252932)Jang T, Patel N, Faiena I, Radadia K, Moore D, Elsamra S, Singer E, Stein M, Eastham J, Scardino P, Lin Y, Kim I, LuYao G. Comparative effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate Lee D, Kim I, Heckman C, Penedo F, Kissane D, Virtue S. Interpersonal Processes and Intimacy Among Men With Localized Prostate Cancer and Their Partners Journal Of Family Psychology 2018, Shupe A, Lee G, Stein M, Kim I, Singer E. Role of the androgen signaling axis in genitourinary to Androgen Deprivation Therapy: a Pilot Study.](http://www.ncbi.nlm.nih.gov/pubmed/30714046)Tabakin A, Sadimin E, Tereshchenko I, Kareddula A, Stein M, Mayer T, Hirshfield K, Kim I, Tischfield J, DiPaola R, Singer E. Correlation of Prostate Cancer CHD1 Status with Response to Androgen Deprivation Therapy: a Pilot Study. 2018, 2 [PMID: 30714046](https://pubmed.ncbi.nlm.nih.gov/30714046), [PMCID: PMC6358174](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358174). [Multi-institution analysis of racial disparity among African-American men eligible for prostate cancer active surveillance](http://www.ncbi.nlm.nih.gov/pubmed/29765545)Dinizo M, Shih W, Kwon Y, Eun D, Reese A, Giusto L, Trabulsi E, Yuh B, Ruel N, Marchalik D, Hwang J, Kundu S, Eggener S, Kim I. Multi-institution analysis of racial disparity among African-American men eligible for prostate cancer active WITH RECEIPT OF OPEN VS MINIMALLY INVASIVE RETROPERITONEAL LYMPH NODE DISSECTION (RPLND) FOR TESTIS CANCER: ANALYZING THE NATIONAL CANCER DATABASE (NCDB) FROM 2010-2014](https://doi.org/10.1016/j.juro.2018.02.2780)Tabakin A, Kim S, Polotti C, Rivera-N\u00fa\u00f1ez Z, Sterling J, Modi P, Farber N, Radadia K, Parikh R, Goyal S, Weiss R, Kim I, Elsamra S, Singer E, Jang T. MP84-12 OUTCOMES AND FACTORS ASSOCIATED WITH RECEIPT OF OPEN VS MINIMALLY INVASIVE RETROPERITONEAL LYMPH NODE DISSECTION (RPLND) FOR TESTIS CANCER: ANALYZING THE NATIONAL CANCER PROPENSITY SCORE-WEIGHTED ANALYSIS](https://doi.org/10.1016/j.juro.2018.02.1135)Farber Rivera-Nunez Kim S, Radadia K, Modi P, Goyal S, Parikh R, Weiss R, Kim I, Elsamra S, Jang T, Singer E. MP36-01 OUTCOMES OF LYMPHADENECTOMY FOR NON-METASTATIC RENAL CELL CARCINOMA: FOR CANCER PATIENTS: EVIDENCE OF ONE-MONTH QUALITY OF LIFE IMPROVEMENTS](https://doi.org/10.1016/j.juro.2018.02.1382)Diefenbach M, Hudson S, Marziliano A, Fleszar S, Tagai E, Bator A, Chen D, Cox B, Hall S, Kim I, Kim S, Kutikov A, Miyamoto C, Potters L, Reese A, Vira M, Torre G, DeCoster C, Bhat R, Hui S, Miller S. PD29-07 PROGRESS, A WEB-BASED RESOURCE FOR PROSTATE CANCER PATIENTS: EVIDENCE OF ONE-MONTH QUALITY OF LIFE IMPROVEMENTS Investigative 10.1016/j.juro.2018.02.1382](https://doi.org/10.1016/j.juro.2018.02.1382). Kamaljot K, Williams S, Osann K, Joseph J, Lee D, Lee D, Davis J, Abaza R, Kaouk J, Patel V, Kim I, Porter J, Hu J. MP82-08 UNINTENDED CONSEQUENCES OF DECREASED PSA-BASED PROSTATE CANCER SCREENING Investigative 2018, Kaler Williams S, Osann K, Joseph J, Lee D, Abaza R, Kaouk J, Patel V, Kim I, Porter J, Hu J. 269 Unintended consequences of decreased PSA-based prostate cancer screening European Urology Open Science 2018, 17: [DOI: effect of postdiagnostic metformin and statin use on prostate cancer mortality among patients with high-risk prostate cancer.](https://doi.org/10.1200/jco.2018.36.6_suppl.202)Lu-Yao G, E J, Lin Y, Rebbeck T, Lu S, Kelly W, D'Amico A, Stein M, Zhang L, Kim I, Demissie K, Ferrari A, Tan X. Individual and joint effect of postdiagnostic metformin and statin use on prostate cancer mortality among patients with high-risk prostate cancer. Journal Of Clinical Oncology 2018, 36: 202-202. [DOI: 10.1200/jco.2018.36.6_suppl.202](https://doi.org/10.1200/jco.2018.36.6_suppl.202). - Kim W, Kim Y, Jeong P, Seo S, Kang H, Kim Y, Yun S, Lee S, Moon S, Choi Y, Lee G, Kim I, Kim W. Urinary cell-free nucleic acid IQGAP3: a new non-invasive diagnostic Extracts on Bladder Cancer Compared to Cisplatin: A Common Mechanism of Action via Centromere Protein M](http://www.ncbi.nlm.nih.gov/pubmed/29595070)Kim W, Seo S, Byun Y, Kang H, Kim Y, Lee S, Jeong P, Song H, Choe S, Kim D, Kim S, Ha Y, Moon S, Lee G, Kim I, Yun S, Kim W. The Anticancer Effects of Garlic Extracts on Bladder Cancer Compared to Cisplatin: A Common Mechanism of Action via Centromere Protein M The American Journal Of Chinese Medicine 2018, 46: 689-705. [PMID: 29595070](https://pubmed.ncbi.nlm.nih.gov/29595070), [DOI: 10.1142/s0192415x18500362](https://doi.org/10.1142/s0192415x18500362). [Predicting clinically on pre-operative patient profile and serum biomarkers](http://www.ncbi.nlm.nih.gov/pubmed/29312648)Faiena I, Kim S, Farber N, Kwon Y, Shinder B, Patel N, Salmasi A, Jang T, Singer E, Kim W, Kim I. Predicting clinically significant prostate cancer based on pre-operative patient profile for men with low-risk prostate cancer](http://www.ncbi.nlm.nih.gov/pubmed/29177226)Parikh R, Patel A, Kim S, Kim I, Goyal S. Comparative effectiveness of laparoscopic versus open prostatectomy for men with low-risk prostate cancer International Journal Transitional Cell Carcinoma 2017, 4637-4640. [DOI: 10.1007/978-3-662-46875-3_5930](https://doi.org/10.1007/978-3-662-46875-3_5930). [Garlic extract in bladder cancer prevention: from T24 bladder cancer cell xenograft model, tissue microarray, and gene network analysis](http://www.ncbi.nlm.nih.gov/pubmed/28498422)Kim W, Seo S, Byun Y, Kang H, Kim Y, Lee S, Jeong P, Seo Y, Choe S, Kim D, Kim S, Moon S, Choi Y, Lee G, Kim I, Yun S, Kim W. Garlic extract in bladder cancer prevention: Evidence from T24 bladder cancer cell xenograft model, tissue microarray, and gene network analysis Genomic Data Guide the Postoperative Management of Prostate PROSTATECTOMY IN MEN NEWLY DIAGNOSED WITH METASTATIC PROSTATE CANCER](https://doi.org/10.1016/j.juro.2017.02.1087)Yuh B, Kwon Y, Shinder B, Kim S, Lee N, Ruel N, Horie S, Byun S, Lee D, Dipaola R, Kim I. PD24-10 INTERIM ANALYSIS OF NCT02458716: FEASIBILITY OF CYTOREDUCTIVE PROSTATECTOMY IN MEN NEWLY DIAGNOSED 2017, 197: LONGITUDINAL PAIN SCORES AS A PROGNOSTIC FACTOR OF OVERALL SURVIVAL IN MEN WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER](https://doi.org/10.1016/j.juro.2017.02.1779)Wang W, Kwon Y, Su L, Kim I, Lu S. MP57-05 LONGITUDINAL PAIN SCORES AS A PROGNOSTIC FACTOR OF OVERALL SURVIVAL IN MEN WITH METASTATIC CANCER Investigative Urology 2017, 197: e765. [DOI: 10.1016/j.juro.2017.02.1779](https://doi.org/10.1016/j.juro.2017.02.1779). - Lee G, Han C, Kwon Y, Patel R, Modi P, Kwon S, Faiena I, Patel N, Ahn H, Kim W, Singer E, Kim I. MP60-08 INTRACRINE ANDROGEN BIOSYNTHESIS e792-e793. [DOI: 10.1016/j.juro.2017.02.1845](https://doi.org/10.1016/j.juro.2017.02.1845). - Lee G, Han C, Kwon Y, Patel R, Modi P, Kwon S, Faiena I, Patel N, Singer E, Ahn H, Kim W, Kim I. Intracrine androgen biosynthesis in renal cell carcinoma prostate cancer after robot-assisted radical prostatectomy](http://www.ncbi.nlm.nih.gov/pubmed/28230003)Hong J, Kwon Y, Kim I. Risk stratification for disease progression in pT3 prostate cancer after robot-assisted in men newly diagnosed with metastatic prostate cancer.](https://doi.org/10.1200/jco.2017.35.6_suppl.e578)Yuh B, Kwon Y, Shinder B, Kim S, Lee N, Ruel N, Kim I. Interim analysis of NCT02458716: Feasibility of cytoreductive prostatectomy in men newly diagnosed with metastatic prostate Clinical Goyal S, Kim I. Local Therapy Improves Overall Survival in Patients With Newly Diagnosed Metastatic Prostate Cancer Survival and Tumor Growth in Prostate Cancer](http://www.ncbi.nlm.nih.gov/pubmed/27307599)Bansal N, Bartucci M, Yusuff S, Davis S, Flaherty K, Huselid E, Patrizii M, Jones D, Cao L, Sydorenko N, Moon Y, Zhong H, Medina D, Kerrigan J, Stein M, Kim I, Davis T, DiPaola R, Bertino J, Sabaawy H. BMI-1 Targeting Interferes with Patient-Derived Tumor-Initiating Cell Survival and Tumor Growth in Prostate Cancer Clinical Cancer Research 2016, 22: 6176-6191. [PMID: 27307599](https://pubmed.ncbi.nlm.nih.gov/27307599), [PMCID: PMC5159329](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5159329), Kim I. Pharmacodynamics, pharmacokinetics and clinical efficacy of phosphodiesterase-5 inhibitors Expert Opinion On Drug Metabolism & Toxicology 2016, 183-192. [PMID: 27690667](https://pubmed.ncbi.nlm.nih.gov/27690667), Kim I, Parikh R. Local Therapy Improves Overall Survival in Patients with Newly Diagnosed Metastatic Prostate Cancer International Journal Of Radiation Oncology Biology Physics 2016, 96: s183-s184. [DOI: 10.1016/j.ijrobp.2016.06.459](https://doi.org/10.1016/j.ijrobp.2016.06.459). [Corrigendum: Personalized Medicine Approaches in Prostate Cancer Employing Patient Derived 3D Organoids and Humanized Mice](http://www.ncbi.nlm.nih.gov/pubmed/27583246)Bartucci M, Ferrari A, Kim I, Ploss A, Yarmush M, Sabaawy H. Corrigendum: Personalized Medicine Approaches in Prostate Cancer Employing Patient Derived 3D Organoids and Humanized Mice Frontiers In Cell And Developmental Biology 4: 74. [PMID: 27583246](https://pubmed.ncbi.nlm.nih.gov/27583246), [PMCID: PMC4999522](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4999522), [DOI: 10.3389/fcell.2016.00074](https://doi.org/10.3389/fcell.2016.00074). [Personalized Medicine Approaches Patient Derived 3D Organoids and Humanized Mice](http://www.ncbi.nlm.nih.gov/pubmed/27446916)Bartucci M, Ferrari A, Kim I, Ploss A, Yarmush M, Sabaawy H. Personalized Medicine Approaches in Prostate Cancer Employing Patient Derived 3D Organoids and Humanized Mice Frontiers In Cell And Developmental Biology 2016, 4: 64. [PMID: 27446916](https://pubmed.ncbi.nlm.nih.gov/27446916), [PMCID: PMC4917534](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4917534), [DOI: 10.3389/fcell.2016.00064](https://doi.org/10.3389/fcell.2016.00064). - Davis R, Farber N, Tabakin A, Kim I, Elsamra S. Open versus robotic cystectomy: Comparison of outcomes Investigative the Neurovascular Bundle](http://www.ncbi.nlm.nih.gov/pubmed/27072291)Patel R, Modi P, Elsamra S, Kim I. Long-Term Outcomes of Using Hyaluronic Acid-Carboxymethylcellulose Adhesion Barrier Film on the for Extracapsular Extension of Prostate Cancer in Community Practice](http://www.ncbi.nlm.nih.gov/pubmed/27188968)Davis R, Salmasi A, Koprowski C, Kim S, Kwon Y, Faiena I, Patel N, Elsamra S, Kim I. Accuracy of Multiparametric Magnetic Resonance Imaging for Extracapsular Extension of Prostate Cancer in Community Practice Clinical Genitourinary Cancer 2016, 14: e617-e622. [PMID: 27188968](https://pubmed.ncbi.nlm.nih.gov/27188968), [DOI: 10.1016/j.clgc.2016.04.010](https://doi.org/10.1016/j.clgc.2016.04.010). - Kwon Y, Kang S, Wang W, Farber N, Radadia K, Lee P, Kim J, Hong J, Kim I. MP37-08 MISATTRIBUTION ERRORS IN UROLOGIC PROCEDURES FROM THE Urology 2016, e499-e500. [DOI: 10.1016/j.juro.2016.02.1685](https://doi.org/10.1016/j.juro.2016.02.1685). LONGITUDINAL RECOVERY PATTERNS AND THE UNDEREXPLORED BENEFIT OF LONG-TERM PHOSPHODIESTERASE INHIBITOR USE AFTER RADICAL PROSTATECTOMY](https://doi.org/10.1016/j.juro.2016.02.2800)Kwon Y, Farber N, Yu J, Han C, Lee P, Kim J, Kim W, Kim I. PD50-10 LONGITUDINAL RECOVERY PATTERNS OF PENILE LENGTH AND THE UNDEREXPLORED BENEFIT OF LONG-TERM PHOSPHODIESTERASE INHIBITOR FOLLOWING RADICAL PROSTATECTOMY MEN WITH PSA GREATER THAN 10 AND HISTOLOGICALLY FAVORABLE-RISK PROSTATE CANCER](https://doi.org/10.1016/j.juro.2016.02.2096)Kwon Y, Yu J, Kim S, Han C, Farber N, Kim J, Byun S, Kim W, Jeon S, Kim I. PD03-08 PATHOLOGICAL OUTCOME FOLLOWING RADICAL PROSTATECTOMY IN MEN WITH PSA GREATER THAN 10 AND HISTOLOGICALLY FAVORABLE-RISK PROSTATE CANCER Investigative Urology 2016, 195: e59. OUTCOMES OF MEN LOCALLY ADVANCED (LAPCA) OR REGIONALLY ADVANCED PROSTATE CANCER (RAPCA) FOLLOWING CONSERVATIVE MANAGEMENT (CM)](https://doi.org/10.1016/j.juro.2016.02.2300)Modi P, Faiena I, Patel N, Shen S, Singer E, Moore D, DiPaola R, Lu-Yao G, Kim I, Jang T. MP09-13 OUTCOMES OF MEN WITH LOCALLY ADVANCED (LAPCA) OR REGIONALLY ADVANCED PROSTATE CANCER (RAPCA) FOLLOWING CONSERVATIVE CELL CARCINOMA: A XENOGRAFT STUDY](https://doi.org/10.1016/j.juro.2016.02.2645)Han C, Lee G, Patel R, Modi P, Kwon S, Faiena I, Patel N, Singer E, Kim I. MP92-12 ANTI-ANDROGEN THERAPY SUPPRESSES TUMOR GROWTH IN ANDROGEN RECEPTOR-POSITIVE (Org) to recreate clonal heterogeneity of PC foci and measure therapeutic response potential.](https://doi.org/10.1200/jco.2016.34.2_suppl.252)Ferrari A, DiPaola R, Bertino J, Kim I, Stein M, Sabaawy H, Bartucci M. Patient stem cell (SC)-derived prostate cancer (PC) organoids (Org) to recreate clonal heterogeneity of PC foci and measure therapeutic response potential. Journal Of Clinical Oncology 2016, 34: 252-252. [DOI: 10.1200/jco.2016.34.2_suppl.252](https://doi.org/10.1200/jco.2016.34.2_suppl.252). - Modi P, 21-28. [DOI: 10.1016/b978-0-12-800077-9.00003-7](https://doi.org/10.1016/b978-0-12-800077-9.00003-7). [Chapter 52 Androgen Deprivation Therapy: Appropriate Patients, Timing to Initiate ADT, and Complications](https://doi.org/10.1016/b978-0-12-800077-9.00052-9)Salmasi A, Patel N, Kim I. Chapter 52 Androgen Deprivation Therapy: Appropriate Patients, Timing to Initiate ADT, and Complications 2016, 481-489. [DOI: 10.1016/b978-0-12-800077-9.00052-9](https://doi.org/10.1016/b978-0-12-800077-9.00052-9). - Parihar J, Kim I. Chapter 57 for Castrate-Resistant Prostate Cancer 2016, 533-540. [DOI: 10.1016/b978-0-12-800077-9.00057-8](https://doi.org/10.1016/b978-0-12-800077-9.00057-8). [Pathological Outcome following Radical Prostatectomy in Men with Prostate Specific Antigen Greater than 10 ng/ml and Histologically Favorable Risk Prostate Cancer](http://www.ncbi.nlm.nih.gov/pubmed/26608903)Yu J, Kwon Y, Kim S, Han C, Farber N, Kim J, Byun S, Kim W, Jeon S, Kim I. Pathological Outcome following Radical Prostatectomy in Men with Prostate Specific Antigen Greater than 10 ng/ml and Histologically Favorable Risk Prostate different biological subtypes and responsiveness to therapy](https://doi.org/10.1158/1535-7163.targ-15-c36)Sabaawy H, Bartucci M, Stein M, Kim I, Bertino J, DiPaola R, Ferrari A. Abstract C36: Patient-derived organoids from high-risk prostate cancer identify different biological subtypes and responsiveness to therapy Molecular Cancer Therapeutics 2015, 14: c36-c36. [DOI: 10.1158/1535-7163.targ-15-c36](https://doi.org/10.1158/1535-7163.targ-15-c36). [Refining the American Urological Association and American Society for Radiation Oncology guideline for adjuvant radiotherapy after radical prostatectomy using the pathologic Gleason score](http://www.ncbi.nlm.nih.gov/pubmed/26620454)Song W, Kwon Y, Jeon S, Kim I. Refining the American Urological Association and American Society for Radiation Oncology guideline for adjuvant radiotherapy after radical prostatectomy using the pathologic Gleason Foran D, Ren J, Zhong H, Kim I, Qi X. Exploring automatic prostate histopathology image gleason grading via local structure modeling Annual International Conference Of The IEEE Engineering In Medicine And Biology Han C, Yu J, Kim S, Modi P, Davis R, Park J, Lee P, Ha Y, Kim W, Kim I. Neutrophil and Lymphocyte Counts as Clinical Markers for Stratifying Low-Risk mini-prostates from primary patient-derived tissues](https://doi.org/10.1158/1538-7445.am2015-223)Bartucci M, Patrizii M, Huselid E, Yussuf S, Bansal N, Flaherty K, Tolkunov D, Zhong H, Stein M, Bertino J, DiPaola R, Kim I, Sabaawy H. Abstract 223: Generation of single cell-derived normal, benign and cancer mini-prostates from primary patient-derived mm Hg: A Study of 751 Patients](http://www.ncbi.nlm.nih.gov/pubmed/25891967)Modi P, Kwon Y, Patel N, Dinizo M, Farber N, Zhao P, Salmasi A, Parihar J, Ginsberg S, Ha Y, Kim I. Safety of Robot-Assisted Radical Prostatectomy with Pneumoperitoneum of 20 mm Hg: A Study of Human Associated with Prostate Cancer Susceptibility and Aggressive Clinicopathological Characteristics](http://www.ncbi.nlm.nih.gov/pubmed/26130958)Kim E, Kim Y, Kang H, Yoon H, Kim W, Kim Y, Yun S, Moon S, Choi Y, Kim I, Lee S, Kim W. Lower Levels of Human MOB3B Are Associated with Prostate Cancer Susceptibility and Aggressive Clinicopathological Characteristics Journal Of Korean Medical With Open Radical Prostatectomy](http://www.ncbi.nlm.nih.gov/pubmed/26065923)Faiena I, Dombrovskiy V, Modi P, Patel N, Patel R, Salmasi A, Parihar J, Singer E, Kim I. Regional Cost Variations of Robot-Assisted Radical Prostatectomy Compared With Open Radical for treating metastatic castration-resistant prostate cancer](http://www.ncbi.nlm.nih.gov/pubmed/25936418)Han C, Patel R, Kim I. Pharmacokinetics, pharmacodynamics and clinical efficacy of abiraterone acetate for treating metastatic castration-resistant prostate cancer Expert Opinion On Drug Metabolism ASSOCIATED WITH PROGNOSIS IN LOCALIZED RENAL CELL CARCINOMA](https://doi.org/10.1016/j.juro.2015.02.1525)Modi P, Ha Y, Lee G, Ahn H, Kim W, Kim I. MP47-05 ANDROGEN RECEPTOR MRNA EXPRESSION IS ASSOCIATED WITH PROGNOSIS IN LOCALIZED RENAL CELL CARCINOMA Investigative Urology 2015, DURING ROBOT-ASSISTED RADICAL PROSTATECTOMY: LONG TERM OUTCOMES](https://doi.org/10.1016/j.juro.2015.02.697)Patel R, P, Kim I. PD18-12 USE OF HYALURONIC ACID-CARBOXYMETHYLCELLULOSE ADHESION BARRIER ON THE NEUROVASCULAR BUNDLE DURING ROBOT-ASSISTED [DOI: [MP53-04 SIGNIFICANT INTER-INSTITUTIONAL VARIATIONS IN RACIAL DISPARITIES AMONG AFRICAN-AMERICAN MEN ELIGIBLE FOR PROSTATE CANCER ACTIVE SURVEILLANCE](https://doi.org/10.1016/j.juro.2015.02.1698)Dinizo M, Shih W, Salmasi A, Faiena I, Modi P, Han M, Partin A, Eun D, Reese A, Llukani E, Giosto L, Wessel S, Trabulsi E, Lallas C, Yuh B, Wilson T, Marchalik D, Hwang J, Kundu S, Catalona W, Flum D, Eggener S, Negron E, Kim I. MP53-04 SIGNIFICANT INTER-INSTITUTIONAL VARIATIONS IN RACIAL DISPARITIES AMONG AFRICAN-AMERICAN MEN ELIGIBLE FOR PROSTATE CANCER ACTIVE SURVEILLANCE Investigative Urology 2015, 193: e636. [DOI: 10.1016/j.juro.2015.02.1698](https://doi.org/10.1016/j.juro.2015.02.1698). [PD36-06 EFFICACY OF ROLIPRAM LOADED NANOSPHERES IN LOCALIZED DELIVERY TO SITES OF NERVE INJURY FOR PREVENTION OF POST-PROSTATECTOMY ERECTILE DYSFUNCTION USING A RAT MODEL OF CAVERNOUS NERVE INJURY](https://doi.org/10.1016/j.juro.2015.02.2255)Patel N, Salmasi A, Dinizo M, Faiena I, Goyal R, Lee G, Hannan J, Bivalacqua T, Kohn J, Kim I. PD36-06 EFFICACY OF ROLIPRAM LOADED NANOSPHERES IN LOCALIZED DELIVERY TO SITES OF NERVE INJURY FOR PREVENTION OF POST-PROSTATECTOMY ERECTILE DYSFUNCTION USING A RAT MODEL OF CAVERNOUS NERVE INJURY Investigative Urology 2015, 193: e766-e767. [DOI: (RF-GM-CSF) OR RECOMBINANT FOWLPOX-TRICOM (RF-TRICOM) IN PATIENTS WITH BLADDER CARCINOMA PRIOR TO UNDERGOING CYSTECTOMY](https://doi.org/10.1016/j.juro.2015.02.2644)Weiss R, Stein M, Mayer T, Salmasi A, Kim I, DiPaola R, Lattime E. MP72-10 PHASE I STUDY OF INTRAVESICAL RECOMBINANT FOWLPOX-GM-CSF (RF-GM-CSF) OR RECOMBINANT FOWLPOX-TRICOM (RF-TRICOM) IN PATIENTS WITH BLADDER CARCINOMA PRIOR TO Investigative Urology 2015, 193: e924. [DOI: 10.1016/j.juro.2015.02.2644](https://doi.org/10.1016/j.juro.2015.02.2644). [Correspondence of physical activity and fruit/vegetable consumption among prostate cancer survivors and their spouses](http://www.ncbi.nlm.nih.gov/pubmed/25807856)Virtue S, Manne S, Kashy D, Heckman C, Zaider T, Kissane D, Kim I, Lee D, Olekson G. Correspondence of physical activity and fruit/vegetable consumption among prostate cancer survivors and their spouses European Journal Of Cancer Care mRNA in Human Renal Cell Carcinoma Cells is Associated with Poor Prognosis in Patients with Localized Renal Cell Carcinoma](http://www.ncbi.nlm.nih.gov/pubmed/25796113)Ha Y, Lee G, Modi P, Kwon Y, Ahn H, Kim W, Kim I. Increased Expression of Androgen Receptor mRNA in Human Renal Cell Carcinoma Cells is Associated with Poor Prognosis in Patients with Localized Renal Cell Carcinoma Investigative Urology 2015, 194: 1441-1448. [PMID: robot-assisted radical prostatectomy following active surveillance: a prospective study in a single center.](http://www.ncbi.nlm.nih.gov/pubmed/25664959)Ha Y, Yu J, Patel N, Hassanzadeh Salmasi A, Parihar J, Kwon T, Kim W, Kim I. Pathologic findings in patients who underwent robot-assisted radical prostatectomy following active surveillance: a prospective study in a single center. Minerva Nefrologica 2015, 67: 1-9. [PMID: in Koreans: A Retrospective Multicenter Study](http://www.ncbi.nlm.nih.gov/pubmed/25606565)Seo W, Kang P, Kim T, Moon K, Chung J, Lee D, Kim I, Min K, Chung J, Kim W, Kang D. Primary Androgen Deprivation Therapy for Prostate Cancer in Koreans: A Retrospective Multicenter Study The World Journal of S100A8 and S100A9 between Prostate Cancer and BPH](http://www.ncbi.nlm.nih.gov/pubmed/25348783)Yun S, Yan C, Jeong P, Kang H, Kim Y, Kim E, Lee O, Kim W, Moon S, Kim I, Choi Y, Kim W. Comparison of mRNA, Protein, and Urinary Nucleic Acid Levels of S100A8 and S100A9 between Prostate Cancer and BPH C, KIM I. Cytoreductive prostatectomy: Evidence in support of a new surgical paradigm (Review) International Journal Of is associated with poor prognosis in renal cell carcinoma](http://www.ncbi.nlm.nih.gov/pubmed/25227434)Ha Y, Lee G, Kim Y, Kwon S, Choi S, Kim T, Kwon T, Yun S, Kim I, Kim W. Decreased selenium-binding protein 1 mRNA expression is associated with poor prognosis in renal cell carcinoma World Journal Of Surgical Oncology 2014, 12: 288. [PMID: 25227434](https://pubmed.ncbi.nlm.nih.gov/25227434), [PMCID: 84: 372. [PMID: 24925832](https://pubmed.ncbi.nlm.nih.gov/24925832), [DOI: 10.1016/j.urology.2014.02.040](https://doi.org/10.1016/j.urology.2014.02.040). - Ha Y, Kim I. Enzalutamide: looking back at its preclinical discovery Expert Opinion On Drug Discovery 2014, 9: 837-845. on adjuvant radiotherapy after radical prostatectomy](http://www.ncbi.nlm.nih.gov/pubmed/24708639)Kang J, Ha Y, Kim S, Yu J, Patel N, Parihar J, Salmasi A, Kim W, Kim I. Concern for overtreatment using the AUA/ASTRO guideline on adjuvant radiotherapy ANTIGEN DENSITY ELIGIBILITY CRITERIA](https://doi.org/10.1016/j.juro.2014.02.2235)Ha Y, Patel N, Salmasi A, Singer E, Yu J, Kim J, Kim W, Kim I. MP69-16 ACTIVE SURVEILLANCE FOR PROSTATE CANCER: RETHINKING PROSTATE-SPECIFIC ANTIGEN PLUS RADIOTHERAPY FOR ADVANCED, NON-DISTANT METASTATIC PROSTATE CANCER](https://doi.org/10.1016/j.juro.2014.02.2428)Jang T, Patel N, Shen S, DiPaola R, Moore D, Kim I, Lu-Yao G. PD34-03 RADICAL PROSTATECTOMY WITH ADJUVANT RADIOTHERAPY VERSUS ANDROGEN DEPRIVATION THERAPY PLUS RADIOTHERAPY FOR ADVANCED, e896-e897. [MP78-17 FACTORS ASSOCIATED WITH INITIAL THERAPY FOR REGIONALLY ADVANCED PROSTATE CANCER IN THE UNITED STATES](https://doi.org/10.1016/j.juro.2014.02.2500)Jang T, Patel N, Shen S, Karellas M, DiPaola R, Moore D, Kim I, Lu-Yao G. MP78-17 FACTORS ASSOCIATED WITH INITIAL THERAPY FOR REGIONALLY ADVANCED PROSTATE CANCER IN THE UNITED STATES Investigative Urology 2014, 191: e927. [DOI: 10.1016/j.juro.2014.02.2500](https://doi.org/10.1016/j.juro.2014.02.2500). [MP43-11 DEVELOPMENT OF A NANOSPHERE BASED DELIVERY OF SILDENAFIL TO SITES OF NERVE INJURY FOR PREVENTION OF POST-PROSTATECTOMY ERECTILE DYSFUNCTION USING A RAT MODEL OF CAVERNOUS NERVE INJURY](https://doi.org/10.1016/j.juro.2014.02.1168)Patel N, Salmasi A, Dinizo M, Goyal R, Hannan J, Lee G, Kohn J, Bivalacqua T, Kim I. MP43-11 DEVELOPMENT OF A NANOSPHERE BASED DELIVERY OF SILDENAFIL TO SITES OF NERVE INJURY FOR PREVENTION OF POST-PROSTATECTOMY ERECTILE DYSFUNCTION USING A RAT MODEL OF CAVERNOUS NERVE INJURY Investigative Urology 2014, 191: e481. [DOI: 10.1016/j.juro.2014.02.1168](https://doi.org/10.1016/j.juro.2014.02.1168). - Salmasi A, Patel Lee Kim I. MP47-03 OFF-TARGET EFFECT OF SILDENAFIL following contemporary robot assisted radical prostatectomy technique](http://www.ncbi.nlm.nih.gov/pubmed/24693529)Parihar J, Ha Y, Kim I. Bladder neck contracture-incidence and management following contemporary robot assisted radical prostatectomy technique Prostate International [DOI: 10.12954/pi.13034](https://doi.org/10.12954/pi.13034). [Novel Combination Markers Survival in Patients with Muscle Invasive Bladder Cancer: USP18 and DGCR2](http://www.ncbi.nlm.nih.gov/pubmed/24616583)Kim Y, Kim W, Jeong P, Ha Y, Kang H, Yun S, Moon S, Choi Y, Kim I, Kim W. Novel Combination Markers for Predicting Survival in Patients with Muscle Invasive Bladder Cancer: USP18 and DGCR2 Journal Of of Progression in Patients with Non-Muscle-Invasive Urothelial Carcinoma, and Its Functional Role is Involved in the Aggressive Properties of Urothelial Carcinoma Cells](http://www.ncbi.nlm.nih.gov/pubmed/24562935)Lee G, Ha Y, Jung Y, Moon S, Kang H, Lee O, Joung J, Choi Y, Yun S, Kim W, Kim I. DHCR24 is an Independent Predictor of Progression in Patients with Non-Muscle-Invasive Urothelial Carcinoma, and Its Functional Role is Involved in the Aggressive Properties of Urothelial Carcinoma Cells Annals Of Surgical Oncology 2014, 21: 538-545. 24562935](https://pubmed.ncbi.nlm.nih.gov/24562935), [DOI: 10.1245/s10434-014-3560-6](https://doi.org/10.1245/s10434-014-3560-6). - Jin X, Yun S, Jeong P, Kim I, Kim W, Park S. Diagnosis of bladder cancer and prediction of survival by urinary deprivation via WNT5A-mediated BMP-6 induction](http://www.ncbi.nlm.nih.gov/pubmed/24518599)Lee G, Kang D, Ha Y, Jung Y, Chung J, Min K, Kim T, Moon K, Chung J, Lee D, Kim W, Kim I. Prostate cancer bone metastases acquire resistance to androgen deprivation via WNT5A-mediated BMP-6 in predicting the early response to induction BCG therapy in patients with non-muscle invasive bladder cancer](http://www.ncbi.nlm.nih.gov/pubmed/24411789)Kang H, Tchey D, Yan C, Kim W, Kim Y, Yun S, Lee S, Choi Y, Kim I, Kim W. The predictive value of polymorphisms in predicting the early response to induction BCG therapy in patients with non-muscle invasive bladder cancer Urologic Oncology Seminars 32: 458-465. [PMID: 24411789](https://pubmed.ncbi.nlm.nih.gov/24411789), [DOI: 10.1016/j.urolonc.2013.10.013](https://doi.org/10.1016/j.urolonc.2013.10.013). - Hong J, Kim Kim I. Transitional Cell Carcinoma 2014, 1-4. [DOI: 10.1007/978-3-642-27841-9_5930-2](https://doi.org/10.1007/978-3-642-27841-9_5930-2). - Han C, Parihar J, Kim I. Active surveillance in men with low-risk prostate cancer: current and future challenges. American Journal Of Clinical And Experimental Urology 2013, 1: 72-82. [PMID: 25374902](https://pubmed.ncbi.nlm.nih.gov/25374902), [PMCID: PMC4219278](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4219278). - Kang D, Chung J, Ha H, Min K, Yoon J, Kim W, Seo W, Kang P, Jung S, Kim I. Korean Prostate Cancer Patients Have Worse Disease Characteristics than their American Counterparts Asian Pacific Journal Of Cancer Prevention 2013, 14: 6913-6917. [PMID: 24377625](https://pubmed.ncbi.nlm.nih.gov/24377625), [DOI: 10.7314/apjcp.2013.14.11.6913](https://doi.org/10.7314/apjcp.2013.14.11.6913). [Diagnostic Role of in the Elderly Patients Who Experience Significant Co-Morbidity with a High Clinical Suspicion of Prostate Cancer](http://www.ncbi.nlm.nih.gov/pubmed/24339711)Kang H, Yang J, Kwon W, Lee Y, Kim W, Kim Y, Yun S, Lee S, Kim I, Kim W. Diagnostic Role of Prostate Resection in the Elderly Patients Who Experience Significant Co-Morbidity with a High Clinical Suspicion of Prostate Cancer Journal Of Korean Medical Science prostate cancer cells with tumor initiating properties in mouse and zebrafish xenografts by differential adhesion](http://www.ncbi.nlm.nih.gov/pubmed/24154958)Bansal N, Davis S, Tereshchenko I, BudakAlpdogan T, Zhong H, Stein M, Kim I, DiPaola R, Bertino J, Sabaawy H. Enrichment of human prostate cancer cells with tumor initiating properties in mouse and zebrafish xenografts by differential Outcome in Prostate Cancer Patients After Robot-Assisted Radical Prostatectomy](http://www.ncbi.nlm.nih.gov/pubmed/23987521)Woo S, Kang D, Ha Y, Salmasi A, Kim J, Lee D, Kim W, Kim I. Comprehensive Analysis of Sexual Function Outcome in Prostate Cancer Patients After Robot-Assisted Radical Prostatectomy and IL1](http://www.ncbi.nlm.nih.gov/pubmed/24185914)Kwon S, Lee G, Lee J, Iwakura Y, Kim W, Kim I. Mechanism of protumorigenic effect of BMP6: Neovascularization involving Sabaawy H. Therapeutic Role of Bmi-1 Inhibitors in Eliminating Prostate Tumor Stem Cells 2013 [DOI: 10.21236/ada598365](https://doi.org/10.21236/ada598365). [Decreased DBC1 Expression Is Associated With Poor Prognosis in Patients With Non-Muscle-Invasive Bladder Cancer](http://www.ncbi.nlm.nih.gov/pubmed/24044099)Shim U, Lee I, Kang H, Kim J, Kim W, Kim I, Ryu K, Choi Y, Moon S, Kim Y, Yun S, Lee S, Kim W. Decreased DBC1 Expression Is Associated With Poor Prognosis in Patients With Non-Muscle-Invasive Bladder Cancer Investigative And the Neurovascular Bundle and Prostatic Bed to Facilitate Earlier Recovery of Erectile Function After Robot-Assisted Prostatectomy: An Initial Experience](http://www.ncbi.nlm.nih.gov/pubmed/23879531)Joung J, Ha Y, Singer E, Ercolani M, Favaretto R, Lee D, Kim W, Lee K, Kim I. Use of a Hyaluronic Acid-Carboxymethylcellulose Adhesion Barrier on the Neurovascular Bundle and Prostatic Bed to Facilitate Earlier Recovery of Erectile Function After Robot-Assisted Prostatectomy: An Initial robot-assisted radical prostatectomy based on the expanded prostate cancer index composite survey](http://www.ncbi.nlm.nih.gov/pubmed/23917307)Kim J, Ha Y, Jeong S, Kim S, Kim W, Jang T, Kim I. Factors related to patient-perceived satisfaction after robot-assisted radical prostatectomy based on the expanded prostate cancer index composite survey Prostate Cancer And Prostatic 23876585](https://pubmed.ncbi.nlm.nih.gov/23876585), [DOI: 10.1016/j.urology.2013.03.082](https://doi.org/10.1016/j.urology.2013.03.082). [Bone morphogenetic protein6 induces castration resistance in prostate cancer cells through tumor infiltrating macrophages](http://www.ncbi.nlm.nih.gov/pubmed/23710822)Lee G, Jung Y, Ha Y, Kim J, Kim W, Kim I. Bone morphogenetic protein6 induces castration resistance in prostate cancer cells through tumor infiltrating macrophages Cancer Tumor Proliferation through IL-10-Dependent M2 Polarization of Tumor-Associated Macrophages](http://www.ncbi.nlm.nih.gov/pubmed/23633487)Lee J, Lee G, Woo S, Ha Y, Kwon S, Kim W, Kim I. BMP-6 in Renal Cell Carcinoma Promotes Tumor Proliferation through IL-10-Dependent M2 Polarization of Tumor-Associated Primary Radical Prostatectomy Compared with Radiation Therapy in Prostate Cancer Patients: Results of a Population-based, Propensity Score-Matched Analysis](http://www.ncbi.nlm.nih.gov/pubmed/23759328)Shao Y, Kim S, Moore D, Shih W, Lin Y, Stein M, Kim I, Lu-Yao G. Cancer-specific Survival After Metastasis Following Primary Radical Prostatectomy Compared with Radiation Therapy in Prostate Cancer Patients: Results of a Population-based, Propensity Androgen Receptor Expression in Prostate Cancer](http://www.ncbi.nlm.nih.gov/pubmed/23658864)Jung S, Oh S, Lee G, Chung J, Min K, Yoon J, Kim W, Ryu D, Kim I, Kang D. Clinical Significance of Wnt/-Catenin Signalling and Androgen Receptor Expression in Prostate Cancer The World Journal Of Sadimin E, Ha Y, Kim J, Skarecky D, Cha D, Wambi C, Ou Y, Yuh B, Park S, Llukani E, Albala D, Wilson T, Ahlering T, Badani K, Ahn H, Lee D, May M, Kim W, Lee D. 967 METASTASIS TO THE PROSTATIC ANTERIOR FAT PAD LYMPH NODES: STUDY Investigative Urology 2013, 189: [1865 S100A9 AND EGFR GENE SIGNATURES PREDICT DISEASE PROGRESSION IN BLADDER CANCER PATIENTS AFTER CHEMOTHERAPY](https://doi.org/10.1016/j.juro.2013.02.2284)Kim W, Yun S, Kim Y, Kim T, Seo J, Cho I, Ha Y, Kim I, Lee S, Kim W. 1865 S100A9 AND EGFR GENE SIGNATURES PREDICT DISEASE PROGRESSION IN BLADDER CANCER PATIENTS AFTER CHEMOTHERAPY Investigative Urology 2013, 189: e764-e765. [DOI: 10.1016/j.juro.2013.02.2284](https://doi.org/10.1016/j.juro.2013.02.2284). [226 INCREASED INCIDENCE OF PATHOLOGICALLY NON-ORGAN CONFINED PROSTATE CANCER IN AFRICAN-AMERICAN MEN ELIGIBLE FOR ACTIVE SURVEILLANCE](https://doi.org/10.1016/j.juro.2013.02.1606)Ha Y, Salmasi A, Kim J, Joung J, Lee D, Kim W, Kim I. 226 INCREASED INCIDENCE OF PATHOLOGICALLY NON-ORGAN CONFINED PROSTATE CANCER IN AFRICAN-AMERICAN MEN ELIGIBLE FOR ACTIVE SURVEILLANCE Investigative Urology 2013, 189: e93. [DOI: 10.1016/j.juro.2013.02.1606](https://doi.org/10.1016/j.juro.2013.02.1606). - Kim W, Kang H, Kim W, Lee S, Yun S, Kim Y, Kim T, Seo J, Cho I, Ha Y, Kim I. 2102 NATURAL HISTORY OF ASYMPTOMATIC RENAL STONES AND PREDICTION OF bladder cancer: Arraybased DNA methylation and expression profiling](http://www.ncbi.nlm.nih.gov/pubmed/23436614)Kim Y, Yoon H, Kim J, Kang H, Min B, Kim S, Ha Y, Kim I, Ryu K, Lee S, Kim W. HOXA9, ISL1 and ALDH1A3 methylation patterns as invasive bladder cancer: Arraybased DNA methylation and expression profiling 133: [PMID: 23436614](https://pubmed.ncbi.nlm.nih.gov/23436614), [DOI: 10.1002/ijc.28121](https://doi.org/10.1002/ijc.28121). Prostate Cancer in African-American Men Eligible for Active Surveillance](http://www.ncbi.nlm.nih.gov/pubmed/23465143)Ha Y, Salmasi A, Karellas M, Singer E, Kim J, Han M, Partin A, Kim W, Lee D, Kim I. Increased Incidence of Pathologically Nonorgan Confined Prostate Cancer in African-American Men Eligible for Prostatic Anterior Fat Pad Lymph Nodes: A Multi-Institutional Study](http://www.ncbi.nlm.nih.gov/pubmed/23485503)Kim I, Modi P, Sadimin E, Ha Y, Kim J, Skarecky D, Cha D, Wambi C, Ou Y, Yuh B, Park S, Llukani E, Albala D, Wilson T, Ahlering T, Badani K, Ahn H, Lee D, May M, Kim W, Lee D. Detailed Analysis of Patients with Metastasis to the Prostatic Anterior Fat Pad Lymph Nodes: Urinary Tract Symptoms and Predictive Factors for Symptom Changes: A Longitudinal Study](http://www.ncbi.nlm.nih.gov/pubmed/23434100)Kim J, Ha Y, Jeong S, Lee D, Kim W, Kim I. Impact of Robot-assisted Radical Prostatectomy on Lower Urinary Tract Symptoms and Predictive Factors for Symptom Changes: A Low-Volume Gleason Score 3+4 Prostate Cancers at Biopsy: Finding a New Group Eligible for Active Surveillance](http://www.ncbi.nlm.nih.gov/pubmed/23391718)Park H, Ha Y, Park S, Kim Y, Lee T, Kim J, Lee D, Kim W, Kim I. Incidence of Upgrading and Upstaging in Patients with Low-Volume Gleason Score 3+4 Prostate Cancers at Biopsy: Finding a New Group Eligible for Active I. Radium Ra 223 dichloride in castration-resistant prostate cancer. 2013, [DOI: 10.1358/dot.2013.49.8.1968670](https://doi.org/10.1358/dot.2013.49.8.1968670). R, Kim I. Enzalutamide for the treatment of castration-resistant prostate cancer. Drugs Of Today 2013, 49: 7-13. [PMID: 23362491](https://pubmed.ncbi.nlm.nih.gov/23362491), [DOI: 10.1358/dot.2013.49.1.1910724](https://doi.org/10.1358/dot.2013.49.1.1910724). - Ha Y, Chihara Y, Yoon H, Kim Y, Kim T, Woo S, Yun S, Kim I, Hirao Y, Kim W. Downregulation of Fumarate Hydratase Is Related to Tumorigenesis in S, JEONG P, KIM W, KIM T, LEE Y, SONG P, CHOI Y, KIM I, MOON S, KIM W. Cell-free microRNAs in urine as diagnostic and prognostic biomarkers of bladder cancer International associated with aggressive clinicopathological outcomes, whereas nuclear location of the protein is related to metastasis in prostate cancer](http://www.ncbi.nlm.nih.gov/pubmed/22890388)Yun S, Yoon H, Bae S, Lee O, Choi Y, Moon S, Kim I, Kim W. Transcriptional repression of RUNX2 is associated with aggressive clinicopathological outcomes, whereas nuclear location of the protein is related to metastasis in prostate cancer Prostate Cancer And patients with non-muscle-invasive bladder cancer: Potential role in the prediction of tumor progression](http://www.ncbi.nlm.nih.gov/pubmed/22884471)Jeong P, Min B, Ha Y, Song P, Kim I, Ryu K, Kim J, Yun S, Kim W. RUNX3 methylation in normal surrounding urothelium of patients with non-muscle-invasive bladder cancer: Potential role in the prediction of tumor progression European Journal Of Surgical Oncology 2012, 38: 1095-1100. [PMID: 22884471](https://pubmed.ncbi.nlm.nih.gov/22884471), [DOI: 10.1016/j.ejso.2012.07.116](https://doi.org/10.1016/j.ejso.2012.07.116). - Lee J, Lee G, Kwon S, Jeong J, Ha Y, Kim W, Kim I. CREBZF, a novel Smad8-binding protein Molecular [DOI: 10.1007/s11010-012-1353-4](https://doi.org/10.1007/s11010-012-1353-4). - Salmasi A, Han M, Kim I. Risk of more advanced cancer at surgery in African American men eligible for active surveillance. Journal Of Clinical Oncology 2012, Closure of Only the Midline 12-mm Port Site](http://www.ncbi.nlm.nih.gov/pubmed/22283233)Kang D, Woo S, Lee D, Kim I. Incidence of Port-Site Hernias After Robot-Assisted Radical Prostatectomy with the Fascial Closure of Only the Midline 12-mm (WHO G1 AND G2) BLADDER CANCER](https://doi.org/10.1016/j.juro.2012.02.460)HA Y, KIM Y, KIM J, Lee S, KIM I, Kim W, Seo J, Kim W, Chae Y, Yun S. 396 TUMORIGENIC AND PROGNOSTIC SIGNIFICANCE OF RASSF1A EXPRESSION IN NON-MUSCLE-INVASIVE LOW-GRADE NORMAL ADJACENT UROTHELIUM OF NON-MUSCLE INVASIVE BLADDER CANCER IN THE PATIENTS UNDERWENT TRANSURETHRAL RESECTION](https://doi.org/10.1016/j.juro.2012.02.634)Kim J, Kim W, Ha Y, Kim Y, Kim I, Lee S, Jang H, Kim W, Kim T, Yun S. 559 THE PROGNOSTIC SIGNIFICANCE OF RUNX3 METHYLATION IN NORMAL ADJACENT UROTHELIUM OF NON-MUSCLE INVASIVE BLADDER CANCER IN THE PATIENTS RASSF1A in Low-grade (WHO Grade 1 and Grade 2) Nonmuscle-invasive Bladder Cancer](http://www.ncbi.nlm.nih.gov/pubmed/22446336)Ha Y, Jeong P, Kim J, Kwon W, Kim I, Yun S, Kim G, Choi Y, Moon S, Kim W. Tumorigenic and Prognostic Significance of RASSF1A Expression in Low-grade (WHO Grade 1 and Grade 2) Marker in Recurrent Nonmuscle Invasive Bladder Cancer](http://www.ncbi.nlm.nih.gov/pubmed/22382007)Kim J, Chae Y, Ha Y, Kim I, Byun S, Yun S, Kim W. Ras Association Domain Family 1A: A Promising Prognostic Marker in Recurrent Nonmuscle Invasive Bladder 2012, 10: 114-120. [PMID: 22382007](https://pubmed.ncbi.nlm.nih.gov/22382007), [DOI: 10.1016/j.clgc.2011.12.003](https://doi.org/10.1016/j.clgc.2011.12.003). - Ha Y, Kim J, Yoon H, Jeong P, Kim T, Yun S, Lee S, Kim G, Choi Y, Moon S, Kim I, Kim W. Novel combination markers for predicting progression of nonmuscle invasive bladder cancer International Journal Of [PMID: 22025348](https://pubmed.ncbi.nlm.nih.gov/22025348), [DOI: 10.1002/ijc.27319](https://doi.org/10.1002/ijc.27319). [RUNX3 methylation disease progression in patients with nonmuscleinvasive bladder cancer](http://www.ncbi.nlm.nih.gov/pubmed/22311819)Yan C, Kim Y, Ha Y, Kim I, Kim Y, Yun S, Moon S, Bae S, Kim W. RUNX3 methylation as a predictor for disease progression in patients with nonmuscleinvasive bladder cancer Journal Of in patients who are candidates for active surveillance: impact of varying PSA levels.](http://www.ncbi.nlm.nih.gov/pubmed/21785442)Kang D, Jang T, Jeong J, Choi E, Johnson K, Lee D, Kim W, Kim I. Pathological findings following radical prostatectomy in patients who are candidates for active surveillance: impact of varying PSA levels. Asian Journal Prostate Cancer: Array-Based DNA Methylation and Expression Profiling](http://www.ncbi.nlm.nih.gov/pubmed/21571867)Kim Y, Yoon H, Kim S, Kim Y, Kim E, Kim I, Kim W. EFEMP1 as a Novel DNA Methylation Marker for Prostate Cancer: Array-Based DNA Methylation and Expression 17: 4523-4530. [PMID: 21571867](https://pubmed.ncbi.nlm.nih.gov/21571867), [DOI: 10.1158/1078-0432.ccr-10-2817](https://doi.org/10.1158/1078-0432.ccr-10-2817). - Woo S, Kim I. Editorial Comment for Rebuck et al. Journal requires PU.1/Smad1 interaction](http://www.ncbi.nlm.nih.gov/pubmed/21571370)Lee G, Jung Y, Lee J, Kim W, Kim I. Bone morphogenetic protein 6-induced interleukin-1 expression in macrophages - Jeong P, Ha Y, Cho I, Yun S, Yoo E, Kim I, Choi Y, Moon S, Kim W. Three-gene signature predicts disease progression of non-muscle invasive bladder cancer. with prostate cancer susceptibility and aggressive clinicopathological characteristics in the Korean population](http://www.ncbi.nlm.nih.gov/pubmed/21515665)Yun S, Ha Y, Chae Y, Kim J, Kim I, Kim W. The hOGG1 mutant genotype is associated with prostate cancer susceptibility and aggressive clinicopathological characteristics in the Korean population Annals BARRIER AROUND THE NEUROVASCULAR BUNDLES TO FACILITATE EARLIER RETURN OF POTENCY AFTER ROBOTIC PROSTATECTOMY: AN INITIAL EXPERIENCE](https://doi.org/10.1016/j.juro.2011.02.1005)Ercolani M, Johnson K, Su D, Kim I. 1305 USE OF A HYALURONIC ACID-CARBOXYMETHYLCELLULOSE ADHESION BARRIER AROUND THE NEUROVASCULAR BUNDLES TO FACILITATE EARLIER RETURN OF POTENCY AFTER ROBOTIC PROSTATECTOMY: AN INITIAL EXPERIENCE Investigative Urology 2011, 185: e522. [DOI: 10.1016/j.juro.2011.02.1005](https://doi.org/10.1016/j.juro.2011.02.1005). - Jeong J, Choi E, Kang D, Ercolani M, Lee D, Kim W, Kim I. Pathologic implications of prostatic anterior fat pad Urologic Oncology 31: 63-67. [PMID: 21396837](https://pubmed.ncbi.nlm.nih.gov/21396837), [DOI: 10.1016/j.urolonc.2010.09.003](https://doi.org/10.1016/j.urolonc.2010.09.003). - Lee G, Kwon S, Lee J, Jeon S, Jang K, Choi H, Lee H, Kim W, Lee D, Kim I. Macrophages induce neuroendocrine differentiation of prostate cancer cells via BMP6IL6 of life in patients with lower urinary tract symptoms](http://www.ncbi.nlm.nih.gov/pubmed/21342297)Choi E, Jeong J, Kang D, Johnson K, Ercolani M, Jang T, Lee D, Kim W, Kim I. Impact of robotassisted radical prostatectomy on healthrelated quality of life in patients with lower urinary tract symptoms International Journal Of Urology 2011, 18: 297-303. 21342297](https://pubmed.ncbi.nlm.nih.gov/21342297), [DOI: 10.1111/j.1442-2042.2011.02730.x](https://doi.org/10.1111/j.1442-2042.2011.02730.x). - Kim W, Kim S, Jeong P, Yun S, Cho I, Kim I, Moon S, Um H, Choi Y. A Four-Gene Signature Predicts Disease Progression in Muscle Invasive Bladder Cancer Molecular Medicine 2011, 17: 478-485. [PMID: 21308147](https://pubmed.ncbi.nlm.nih.gov/21308147), Yan C, Jeong P, Kim W, Yun S, Kim I, Moon S, Kim W. GSTM1 Tissue Genotype as a Recurrence Predictor in Non-muscle Invasive Bladder Cancer Journal Of Korean Medical sparing during robot-assisted radical prostatectomy](http://www.ncbi.nlm.nih.gov/pubmed/27637538)Jeong J, Choi E, Kang D, Lee D, Kim I. Impact of Partin nomogram on presurgical planning: intrafascial versus interfascial nerve sparing during robot-assisted radical Robotic Surgery 2011, 5: 121-125. [PMID: 27637538](https://pubmed.ncbi.nlm.nih.gov/27637538), [DOI: 10.1007/s11701-011-0247-x](https://doi.org/10.1007/s11701-011-0247-x). - Hong J, Kim I, Cell Carcinoma 2011, 3767-3769. [DOI: 10.1007/978-3-642-16483-5_5930](https://doi.org/10.1007/978-3-642-16483-5_5930). [Tissue hOGG1 Genotype Predicts Approach Using a Peptide Nucleic Acid Clamping Method](http://www.ncbi.nlm.nih.gov/pubmed/21184188)Ha Y, Yan C, Kim I, Yun S, Moon S, Kim W. Tissue hOGG1 Genotype Predicts Bladder Cancer Prognosis: A Novel Approach Using a Peptide Nucleic Acid Clamping Method Annals of Nonmuscle Invasive Bladder Cancer Recurrence and Progression](http://www.ncbi.nlm.nih.gov/pubmed/21168882)Yim M, Ha Y, Kim I, Yun S, Choi Y, Kim W. HMOX1 is an Important Prognostic Indicator of Nonmuscle Invasive Bladder Cancer Recurrence and Macrophages Requires Both SMAD and p38 Signaling Pathways*](http://www.ncbi.nlm.nih.gov/pubmed/20889504)Lee G, Kwon S, Lee J, Jeon S, Jang K, Choi H, Lee H, Kim W, Kim S, Kim I. Induction of Interleukin-6 Expression by Bone Morphogenetic Protein-6 in Macrophages Requires Both SMAD and p38 Signaling marker for muscle invasive bladder novel approach using peptide nucleic acid-mediated, real-time PCR clamping](http://www.ncbi.nlm.nih.gov/pubmed/20884250)Kim E, Yan C, Ha Y, Jeong P, Kim I, Moon S, Choi Y, Kim W. Analysis of hOGG1 genotype as a prognostic marker for muscle invasive bladder A novel peptide nucleic acid-mediated, real-time [DOI: 10.1016/j.urolonc.2010.07.008](https://doi.org/10.1016/j.urolonc.2010.07.008). [Clavien Classification the Initial Series of Robot-Assisted Radical Prostatectomy: The Cancer Institute of New Jersey/Robert Wood Johnson Medical School Experience](http://www.ncbi.nlm.nih.gov/pubmed/20673148)Jeong J, Choi E, Kim I. Clavien Classification of Complications After the Initial Series of Robot-Assisted Radical Prostatectomy: The Cancer Institute of New Jersey/Robert Wood Johnson Medical School Experience Journal 1457-1461. [PMID: quality of life following robot-assisted radical prostatectomy](http://www.ncbi.nlm.nih.gov/pubmed/27627949)Choi E, Jeong J, Kang D, Johnson K, Jang T, Kim I. Early assessment of patient satisfaction and health-related quality of life following robot-assisted radical prostatectomy Journal Of Robotic Surgery 2010, 4: 221-227. [PMID: 27627949](https://pubmed.ncbi.nlm.nih.gov/27627949), [DOI: 10.1007/s11701-010-0212-0](https://doi.org/10.1007/s11701-010-0212-0). - Jeong J, Kang D, Lee G, Kim I. Bone Morphogenetic Protein Signaling: Implications in Urology Investigative Kim I. Renal Hilar Control During Laparoscopic Partial Nephrectomy: To Clamp or Not to Clamp Radical Prostatectomy](http://www.ncbi.nlm.nih.gov/pubmed/20376897)Kim I, Hwang E, Mmeje C, Ercolani M, Lee D. Impact of Posterior Urethral Repair on Continence Following EXCISION DURING ROBOT-ASSISTED LAPAROSCOPIC RADICAL PROSTATECTOMY](https://doi.org/10.1016/j.juro.2010.02.353)Jeong J, Lamba S, Choi E, Kang D, Kim I. 291 STAGING IMPLICATIONS OF ANTERIOR PROSTATIC FAT PAD EXCISION DURING ROBOT-ASSISTED PATHOLOGICAL FINDINGS IN RADICAL PROSTATECTOMY SPECIMENS OF PATIENTS WHO ARE CANDIDATES FOR ACTIVE SURVEILLANCE PROTOCOLS](https://doi.org/10.1016/j.juro.2010.02.1809)Kang D, Jeong J, Choi E, Johnson K, Kim I. 1869 ANALYSIS OF PATHOLOGICAL FINDINGS IN RADICAL PROSTATECTOMY SPECIMENS OF PATIENTS WHO ARE CANDIDATES FOR ACTIVE SURVEILLANCE PROTOCOLS Investigative Urology 2010, 183: e726. [DOI: TUMOR-MACROPHARGE INTERACTION VIA BONE MORPHOGENETIC PROTEIN6-INTERLEUKIN6 LOOP](https://doi.org/10.1016/j.juro.2010.02.1134)Lee G, Kwon S, Lee J, Jeon S, Jang K, Choi H, Lee H, Kim W, Kim S, Choi E, Kim I. 1441 MECHANISM OF NEUROENDOCRINE DIFFERENTIATION IN PROSTATE CANCER: TUMOR-MACROPHARGE INTERACTION VIA BONE During Laparoscopic Nephroureterectomy\u2014A Novel and Simple Modification of the Pluck Technique](http://www.ncbi.nlm.nih.gov/pubmed/19913884)Mueller T, DaJusta D, Cha D, Kim I, Ankem M. Ureteral Fibrin Sealant Injection of the Distal Ureter During Laparoscopic Nephroureterectomy\u2014A Novel and Simple Modification Robot-Assisted Laparoscopic Radical Prostatectomies](http://www.ncbi.nlm.nih.gov/pubmed/19694530)Potdevin L, Ercolani M, Jeong J, Kim I. Functional and Oncologic Outcomes Comparing Interfascial and Intrafascial Nerve Sparing in PROSTATECTOMIES: FUNCTIONAL AND ONCOLOGICAL OUTCOMES AT THE CANCER INSTITUTE OF NJ/ROBERT WOOD JOHNSON MEDICAL SCHOOL](https://doi.org/10.1016/s0022-5347(09)61630-x)Potdevin L, Ercolani M, Kim I. COMPARING APPROACHES TO NERVE-SPARING IN ROBOTIC-ASSISTED RADICAL PROSTATECTOMIES: FUNCTIONAL AND ONCOLOGICAL OUTCOMES AT THE CANCER INSTITUTE OF NJ/ROBERT WOOD JOHNSON MEDICAL SCHOOL Investigative Urology 2009, 181: 578-579. nitric oxide synthase in macrophages](http://www.ncbi.nlm.nih.gov/pubmed/19740337)Kwon S, Lee G, Lee J, Kim W, Kim I. Bone morphogenetic protein6 induces the expression of inducible Hong Kim I. Transitional Cell Carcinoma 2009, 3040-3043. [DOI: 10.1007/978-3-540-47648-1_5930](https://doi.org/10.1007/978-3-540-47648-1_5930). - Jeon S, Kim I. Laparoscopic 2008, 22: 1943-1944. [DOI: 10.1089/end.2008.9773a](https://doi.org/10.1089/end.2008.9773a). [Evaluation of Flexible Cystoscope: A Randomized Controlled Trial](http://www.ncbi.nlm.nih.gov/pubmed/17919698)Krebs A, Borin J, Kim I, Jackson D, McDougall E, Clayman R. Evaluation of Practice Efficiency with a Novel Sheathed Flexible Cystoscope: A Subfamily of the Transforming Growth Factor- Superfamily, in Renal Cell Carcinoma](http://www.ncbi.nlm.nih.gov/pubmed/17644140)Kwak C, Park Y, Kim I, Moon K, Ku J. Expression of Bone Morphogenetic Proteins, the Subfamily of the Transforming Growth Factor- Superfamily, in Renal 17644140](https://pubmed.ncbi.nlm.nih.gov/17644140), [DOI: 10.1016/j.juro.2007.05.005](https://doi.org/10.1016/j.juro.2007.05.005). - Kim Eichel Edwards R, Uribe C, Chou D, Abdelshehid C, Ahlering M, White S, Woo E, McDougall E, Clayman R. Effects of Commonly Used Hemostatic Agents on the Porcine Collecting System Robotic Assisted Radical Prostatectomy at Minimum 12 Months Follow-Up](https://doi.org/10.1016/s0022-5347(18)31690-2)Mueller T, DaJusta D, Kim I, Hong J, Hwang J. 1489: the Patterns of Urinary Continence Following Robotic Assisted Radical Prostatectomy at Minimum 12 Follow-Up Investigative Urology 2007, 177: 491. [DOI: 10.1016/s0022-5347(18)31690-2](https://doi.org/10.1016/s0022-5347(18)31690-2). [Expression of estrogen receptors and in bladder cancer cell lines and human bladder tumor tissue](http://www.ncbi.nlm.nih.gov/pubmed/16700038)Shen S, Smith C, Hsieh J, Yu J, Kim I, Jian W, Sonpavde, Ayala G, Younes M, Lerner S. Expression of estrogen receptors and in bladder cancer cell lines and human bladder tumor tissue Cancer 2006, 106: 2610-2616. [PMID: 16700038](https://pubmed.ncbi.nlm.nih.gov/16700038), [DOI: 10.1002/cncr.21945](https://doi.org/10.1002/cncr.21945). - Kim I, Kim S. Role of bone morphogenetic proteins in transitional cell carcinoma cells Cancer Letters 2006, 241: 118-123. [PMID: 16500023](https://pubmed.ncbi.nlm.nih.gov/16500023), [DOI: 10.1016/j.canlet.2005.10.009](https://doi.org/10.1016/j.canlet.2005.10.009). CHOU D, PARK H, BASILLOTE J, LEE D, KIM I, EICHEL L, PROTSENKO D, WONG B, McDOUGALL E, CLAYMAN R. for Destruction of Experimental VX-2 Renal Tumors in Rabbits](https://doi.org/10.1016/s0022-5347(18)34889-4)Kim I, Eichel L, Chou D, Abdelshehid C, Ahlering M, and Radiofrequency Ablation for Destruction of Experimental VX-2 Renal Tumors in Rabbits Investigative Urology 2005, 173: 177. [DOI: 10.1016/s0022-5347(18)34889-4](https://doi.org/10.1016/s0022-5347(18)34889-4). - Kim I, Eichel L, Uribe C, Chou D, Abdelshehid C, Ahlering M, White S, McDougall E, Comparison Tisseel, Floseal, Coseal, Bioglue the Investigative Urology 2005, 173: 295. [DOI: 10.1016/s0022-5347(18)35244-3](https://doi.org/10.1016/s0022-5347(18)35244-3). - Kim I, Kim M, Kim S. Transforming Growth Factor-: Biology and Clinical Relevance 15715939](https://pubmed.ncbi.nlm.nih.gov/15715939), [DOI: 10.5483/bmbrep.2005.38.1.001](https://doi.org/10.5483/bmbrep.2005.38.1.001). [Restoration of Bone Morphogenetic Protein Receptor Type II Expression Leads to a Decreased Rate of Tumor Growth in Bladder Transitional Cell Carcinoma Cell Line TSU-Pr1](http://www.ncbi.nlm.nih.gov/pubmed/15492256)Kim I, Lee D, Lee D, Kim W, Kim M, Morton R, Lerner S, Kim S. Restoration of Bone Morphogenetic Protein Receptor Type II Expression Leads to a Decreased Rate of Tumor Growth in Bladder Transitional Cell Carcinoma Cell Line TSU-Pr1 Cancer Research 2004, 64: 7355-7360. [PMID: 15492256](https://pubmed.ncbi.nlm.nih.gov/15492256), [DOI: 10.1158/0008-5472.can-04-0154](https://doi.org/10.1158/0008-5472.can-04-0154). - Kim I, Lee D, Lee D, Ahn H, Kim M, Kim S, Morton R. Loss of expression of bone morphogenetic protein receptor type II in human prostate cancer cells Oncogene 2004, 23: 7651-7659. [PMID: 15354178](https://pubmed.ncbi.nlm.nih.gov/15354178), [DOI: its receptors: correlation with pathologic features and biochemical progression in patients undergoing radical prostatectomy](http://www.ncbi.nlm.nih.gov/pubmed/15183988)Shariat S, Menesses-Diaz A, Kim I, Muramoto M, Wheeler T, Slawin K. Tissue expression of transforming growth factor-1 and its receptors: correlation with pathologic features and biochemical progression in of Estrogen Receptor and in Bladder Cancer Cell Lines and Human Bladder Tumor Tissue](https://doi.org/10.1016/s0022-5347(18)37984-9)Shen S, Yu J, Kim I, Jian W, Matsumoto K, Kim M, Sonpavde G, Smith C, Ayala G, Younes M, Lerner S. 735: Differential Expression of Estrogen Receptor and in Bladder Cancer Cell Lines and Human Bladder Tumor Tissue Investigative Urology 2004, 171: 195. [DOI: 10.1016/s0022-5347(18)37984-9](https://doi.org/10.1016/s0022-5347(18)37984-9). [Decreased expression of bone morphogenetic protein (BMP) receptor type II correlates with insensitivity to BMP-6 in human renal cell carcinoma cells.](http://www.ncbi.nlm.nih.gov/pubmed/14676131)Kim I, Lee D, Lee D, Kim B, Kim H, Leach F, Linehan W, Morton R, Kim S. Decreased expression of bone morphogenetic protein (BMP) receptor type II correlates with insensitivity to BMP-6 in human renal cell carcinoma cells. Clinical Cancer Research 2003, 9: 6046-51. [PMID: androgen-independent human prostate cancer cell lines.](http://www.ncbi.nlm.nih.gov/pubmed/12235008)Kim I, Kim B, Seong D, Lee D, Seo J, Hong Y, Kim H, Morton R, Kim S. Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis in androgen-independent human prostate cancer Research [PMID: 12235008](https://pubmed.ncbi.nlm.nih.gov/12235008). Growth Factor- Signaling by Blocking Binding of the Smad Complex to Its Target Sequence*](http://www.ncbi.nlm.nih.gov/pubmed/12145312)Lee D, Kim B, Kim I, Cho E, Satterwhite D, Kim S. The Human Papilloma Virus E7 Oncoprotein Inhibits Transforming Growth Factor- Signaling by Blocking Binding of the Smad Complex to Its Target Sequence* Journal Of in androgen-responsive human prostate cancer cell line LNCaP through an androgen-independent pathway.](http://www.ncbi.nlm.nih.gov/pubmed/12097269)Kim I, Seong D, Kim B, Lee D, Remaley A, Leach F, Morton R, Kim S. Raloxifene, a selective estrogen receptor modulator, induces apoptosis in androgen-responsive human prostate cancer cell line LNCaP through an androgen-independent pathway. Cancer Research of BAD in TSU-PR1 Human Cancer Cells*](http://www.ncbi.nlm.nih.gov/pubmed/12084714)Kim H, Kim B, Kim I, Mamura M, Do Hwan Seong, Jang J, Kim S. Raloxifene, a Mixed Estrogen Agonist/Antagonist, Induces Apoptosis through Cleavage of BAD in TSU-PR1 Human Cancer Cells* [PMID: 12084714](https://pubmed.ncbi.nlm.nih.gov/12084714), [DOI: 10.1074/jbc.m202852200](https://doi.org/10.1074/jbc.m202852200). [Preoperative plasma levels of transforming growth factor 1 strongly predict clinical outcome in patients with bladder carcinoma](http://www.ncbi.nlm.nih.gov/pubmed/11753975)Shariat S, Kim J, Andrews B, Kattan M, Wheeler T, Kim I, Lerner S, Slawin K. Preoperative plasma levels of transforming growth factor 1 strongly predict clinical outcome in patients with bladder carcinoma Cancer 2001, 92: 2985-2992. [PMID: 11753975](https://pubmed.ncbi.nlm.nih.gov/11753975), [DOI: 10.1002/1097-0142(20011215)92:12<2985::aid-cncr10175>3.0.co;2-5](https://doi.org/10.1002/1097-0142(20011215)92:12<2985::aid-cncr10175>3.0.co;2-5). [Predictive value of expression of transforming growth factor1 and its receptors in transitional cell carcinoma of the urinary bladder](http://www.ncbi.nlm.nih.gov/pubmed/11745225)Kim J, Shariat S, Kim I, MenessesDiaz A, Tokunaga H, Wheeler T, Lerner S. Predictive value of expression of transforming growth factor1 and its receptors in transitional cell carcinoma of the urinary bladder Cancer 2001, 92: 1475-1483. [PMID: 11745225](https://pubmed.ncbi.nlm.nih.gov/11745225), growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy.](http://www.ncbi.nlm.nih.gov/pubmed/11387358)Shariat S, Shalev M, Menesses-Diaz A, Kim I, Kattan M, Wheeler T, Slawin K. Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy. Clinical Oncology 2001, 19: 2856-64. 10.1200/jco.2001.19.11.2856](https://doi.org/10.1200/jco.2001.19.11.2856). - KIM I, ELLIOTT D, HUSMANN D, BOONE T. AN UNUSUAL PRESENTING SYMPTOM OF SARCOIDOSIS: NEUROGENIC BLADDER 10.1016/s0022-5347(05)66561-5](https://doi.org/10.1016/s0022-5347(05)66561-5). - KIM I, ELLIOTT D, HUSMANN D, BOONE T. AN UNUSUAL PRESENTING SYMPTOM OF SARCOIDOSIS: NEUROGENIC BLADDER DYSFUNCTION Investigative Urology 2001, Kim I, Laparoscopic nephrectomy for renal cell carcinoma prostate of transgenic mice carrying the C3(1)TGF type II dominant negative receptor](http://www.ncbi.nlm.nih.gov/pubmed/10754527)Kundu S, Kim I, Yang T, Doglio L, Lang S, Zhang X, Buttyan R, Kim S, Chang J, Cai X, Wang Z, Lee C. Absence of proximal duct apoptosis in the ventral prostate of transgenic mice carrying the C3(1)TGF type II dominant negative receptor The Prostate 2000, 43: 118-124. [PMID: 10754527](https://pubmed.ncbi.nlm.nih.gov/10754527), [DOI: 10.1002/(sici)1097-0045(20000501)43:2<118::aid-pros6>3.0.co;2-v](https://doi.org/10.1002/(sici)1097-0045(20000501)43:2<118::aid-pros6>3.0.co;2-v). - J, LAPIN S. BACILLUS CALMETTE-GUERIN INDUCED PERITONITIS IN A PATIENT ON Investigative Urology 2000, 163: 237. [PMID: 10604359](https://pubmed.ncbi.nlm.nih.gov/10604359), [DOI: 10.1016/s0022-5347(05)68017-2](https://doi.org/10.1016/s0022-5347(05)68017-2). - OLIVERO J, LAPIN S. BACILLUS CALMETTE-GUERIN INDUCED PERITONITIS IN A PATIENT ON DIALYSIS Investigative Urology 2000, 163: 237. [DOI: 10.1097/00005392-200001000-00060](https://doi.org/10.1097/00005392-200001000-00060). [ABSENCE OF EXPRESSION OF TRANSFORMING GROWTH FACTOR-beta TYPE II RECEPTOR IS ASSOCIATED WITH AN AGGRESSIVE GROWTH PATTERN IN A MURINE RENAL CARCINOMA CELL LINE, RENCA](http://www.ncbi.nlm.nih.gov/pubmed/9783979)KUNDU S, KIM I, ZELNER D, JANULIS L, GOODWIN S, ENGEL J, LEE C. ABSENCE OF EXPRESSION OF TRANSFORMING GROWTH FACTOR-beta TYPE II RECEPTOR IS ASSOCIATED WITH AN AGGRESSIVE GROWTH PATTERN IN A MURINE RENAL CARCINOMA CELL LINE, OF TRANSFORMING GROWTH FACTOR-beta TYPE II RECEPTOR IS ASSOCIATED WITH AN AGGRESSIVE GROWTH PATTERN IN A MURINE RENAL CARCINOMA CELL LINE, RENCA](https://doi.org/10.1097/00005392-199811000-00077)KUNDU S, KIM I, ZELNER D, JANULIS L, GOODWIN S, ENGEL J, LEE C. ABSENCE OF EXPRESSION OF TRANSFORMING GROWTH FACTOR-beta TYPE II RECEPTOR IS ASSOCIATED WITH AN AGGRESSIVE GROWTH PATTERN IN A MURINE RENAL CARCINOMA CELL LINE, RENCA Investigative Urology associated with inhibition of protein kinase C and induction of p21waf1/cip1](http://www.ncbi.nlm.nih.gov/pubmed/9721069)Rohlff C, Blagosklonny M, Kyle E, Kesari A, Kim I, Zelner D, Hakim F, Trepel J, Bergan R. Prostate cancer cell growth inhibition by tamoxifen is associated with inhibition of protein kinase C and of expression of transforming growth factor-beta receptors is associated with poor prognosis in prostate cancer patients.](http://www.ncbi.nlm.nih.gov/pubmed/9676836)Kim I, Ahn H, Lang S, Oefelein M, Oyasu R, Kozlowski J, Lee C. Loss of expression of transforming growth factor-beta receptors is associated with poor prognosis in prostate cancer patients. Clinical Cancer Research 1998, 4: 1625-30. [PMID: 9676836](https://pubmed.ncbi.nlm.nih.gov/9676836). [The Conventional Transforming Growth Factor- (TGF-) Receptor Type I Is Not Required for TGF-1 Signaling in a Human Prostate Cancer Cell Line, LNCaP](http://www.ncbi.nlm.nih.gov/pubmed/9633523)Kim I, Zelner D, Lee C. The Conventional Transforming Growth Factor- (TGF-) Receptor Type I Is Not Required for TGF-1 Signaling in a Human Prostate Cancer Cell Line, LNCaP Experimental Cell Research 1998, 241: 151-160. [PMID: 9633523](https://pubmed.ncbi.nlm.nih.gov/9633523), [DOI: 10.1006/excr.1998.4034](https://doi.org/10.1006/excr.1998.4034). - Lee D, Yang S, Hong S, Chung B, Kim I. Telomerase: a potential marker of bladder transitional cell carcinoma in bladder washes. Clinical Cancer Research 1998, 4: 535-8. [PMID: 9533519](https://pubmed.ncbi.nlm.nih.gov/9533519). [Prostatic ductal system in rats: Tissuespecific expression regional variation in stromal distribution of transforming growth factor1](http://www.ncbi.nlm.nih.gov/pubmed/9294629)Nemeth J, Sensibar J, White R, Zelner D, Kim I, Lee C. Prostatic ductal system in rats: Tissuespecific expression and regional variation in stromal distribution of transforming growth factor1 The Prostate 1997, 33: 64-71. [PMID: 9294629](https://pubmed.ncbi.nlm.nih.gov/9294629), [DOI: 10.1002/(sici)1097-0045(19970915)33:1<64::aid-pros11>3.0.co;2-j](https://doi.org/10.1002/(sici)1097-0045(19970915)33:1<64::aid-pros11>3.0.co;2-j). - Yang S, Lee D, Hong S, Chung B, Kim I. Telomerase activity: a potential marker of bladder transitional cell carcinoma in bladder washes Yonsei Medical Journal 1997, 38: 155-159. [PMID: 9259615](https://pubmed.ncbi.nlm.nih.gov/9259615), [DOI: 10.3349/ymj.1997.38.3.155](https://doi.org/10.3349/ymj.1997.38.3.155). [Loss of expression of transforming growth factor beta type I and type II receptors correlates with tumor grade in human prostate cancer tissues.](http://www.ncbi.nlm.nih.gov/pubmed/9816295)Kim I, Ahn H, Zelner D, Shaw J, Lang S, Kato M, Oefelein M, Miyazono K, Nemeth J, Kozlowski J, Lee C. Loss of expression of transforming growth factor beta type I and type II receptors correlates with tumor grade in human prostate cancer tissues. Clinical Cancer Research 1996, 2: 1255-61. [PMID: 9816295](https://pubmed.ncbi.nlm.nih.gov/9816295). [Transforming growth factor-beta1 is a mediator of androgen-regulated growth arrest in an androgen-responsive prostatic cancer cell line, LNCaP.](http://www.ncbi.nlm.nih.gov/pubmed/8603613)Kim I, Kim J, Zelner D, Ahn H, Sensibar J, Lee C. Transforming growth factor-beta1 is a mediator of androgen-regulated growth arrest in an androgen-responsive prostatic Factor-1 (TGF-1) and the Level of Type II TGF- Receptor in LNCaP Cells by Dihydrotestosterone](http://www.ncbi.nlm.nih.gov/pubmed/8549651)Kim I, Zelner D, Sensibar J, Ahn H, Park L, Kim J, Lee C. Modulation of Sensitivity to Transforming Growth Factor-1 (TGF-1) and the Level of Type II TGF- Receptor in LNCaP Cells by Dihydrotestosterone [Expression and localization of transforming growth factor-beta receptors type I and type II in the rat ventral prostate during regression.](http://www.ncbi.nlm.nih.gov/pubmed/8838150)Kim I, Ahn H, Zelner D, Park L, Sensibar J, Lee C. Expression and localization of transforming growth factor-beta receptors type I and type II in the rat ventral prostate during transforming growth factor beta (TGF-beta) receptor type I gene correlates with insensitivity to TGF-beta 1 in human prostate cancer cells.](http://www.ncbi.nlm.nih.gov/pubmed/8548772)Kim I, Ahn H, Zelner D, Shaw J, Sensibar J, Kim J, Kato M, Lee C. Genetic change in transforming growth factor beta (TGF-beta) receptor type I gene correlates with insensitivity to TGF-beta 1 in human prostate cancer cells. Cancer Research 1996, 56: 44-8. [PMID: 8548772](https://pubmed.ncbi.nlm.nih.gov/8548772). [Regulation of proliferation and androgen-sensitive prostatic cancer cells, LNCaP, by dihydrotestosterone.](http://www.ncbi.nlm.nih.gov/pubmed/7530653)Lee Sutkowski D, Sensibar J, Zelner D, Kim I, Amsel I, Shaw N, Prins G, Kozlowski J. Regulation of proliferation and production of prostate-specific antigen in androgen-sensitive prostatic FloorNew Haven, CT 06519 - Yale UrologyOrchard Medical Center330 Orchard 164New Haven, CT 06511 - Yale UrologyGreenwich Hospital55 Holly 240Greenwich, CT 06830 - Yale UrologyYale Physicians Building800 Howard FloorNew Haven, CT 06519 - Yale UrologyOrchard Medical Center330 Orchard 164New Haven, CT 06511 - Yale UrologyGreenwich "}